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Chronic widespread pain is characteristic of fibromyalgia, a condition which also includes 
features such as cognitive dysfunction, sleep problems, fatigue and mood disorders. The 
lack of objective measures of the disorder has proved challenging in terms of diagnostic 
criteria, and thus timely diagnosis and access to effective management. Although there is a 
perception that the aetiology of the condition is not known and that there is no effective 
treatment, this is not the case. Over the past decades understanding of the pathophysiology 
and aetiology of the condition has improved and management that results in improved 
symptoms for many patients, has been identified. This thesis addresses important 
components in relation to improving outcome for patients with chronic widespread pain and 
fibromyalgia.  
The thesis focuses on three areas (over seven published manuscripts): effective 
management for persons with chronic widespread pain and fibromyalgia; investigating 
excess mortality in people with chronic widespread pain; Identifying and managing 
fibromyalgia when it occurs in the context of inflammatory arthritis. It includes seven 
manuscripts. 
The results of the manuscripts show that there is good evidence for the non-pharmacologic 
therapies of exercise and a cognitive behaviour informed approach to managing people with 
chronic widespread pain/fibromyalgia, that the excess mortality in such patients could be 
addressed by focussing on lifestyle factors (diet and exercise). When fibromyalgia occurs in 
the context of axial spondyloarthritis, such patients do (as a group) respond to biologic 
therapy but that specific aspects of their conditions (high somatic symptom burden) predict 
non-response and the likely need for additional (non-pharmacologic approaches) to 
management.  
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Chapter 1 Introduction 
 
Chronic widespread pain (CWP) is the characteristic feature of fibromyalgia, a condition 
which also includes fatigue, poor quality sleep and cognitive dysfunction.  The population 
prevalence of chronic widespread pain has been estimated, in a meta-analysis and using 
high quality studies, at 11.8% 95% CI (10.3%-13.3%) (Mansfield et al, 2016) while that of 
fibromyalgia has been estimated at 1.78% (1.65, 1.92) (Heidari et al, 2017). The prevalence 
of both increases with age, reaching a peak around the seventh decade and decreasing 
thereafter (Wolfe et al, 1995). Chronic widespread pain is more common in females than 
males (as is pain generally). Originally fibromyalgia was considered to occur almost 
exclusively in females, with early studies suggesting a female:male ratio of around 9:1 
(Yunus et al, 2001). However, these early studies were of consulters and based on clinical 
diagnoses; when considering more recent classification criteria (such as the 2011 “research 
criteria” (Wolfe et al, 2011)) and use in population studies, the proportion of females is ≤ 
60% (Wolfe et al, 2018).   
 
Risk factors for the development of chronic widespread pain and fibromyalgia include 
physical trauma and psychological stressors (Jones et al, 2011). In adult populations, high 
levels of psychological distress, poor sleep and aspects of illness attitudes and behaviour 
are predictive of new onset of chronic widespread pain (Benjamin et al, 2000; Gupta et al, 
2007) although the first onset of chronic widespread pain is rare in mid-life. Indeed poor 
sleep is a predictor of ongoing-CWP (Mundal et al, 2014) while restorative sleep is associated 
with resolution of symptoms (Davies et al, 2008). It has been demonstrated, in longitudinal 
studies, that although persons with chronic widespread pain may not have symptoms at each 
follow-up they remain at high risk for continuing to experience symptoms (Landmark et al, 
2019). Further, also in longitudinal studies, it is unusual for a person who has reported 
chronic widespread pain to be pain-free subsequently and vice-versa (Papageorgiou et al, 
2002).  
 
Although it is often claimed that the aetiology of these conditions is “unknown” – we do 
understand a considerable amount about risk factors for the conditions, effective ways to 
manage symptoms and indeed the underlying pathophysiology. There is good evidence that 
they involve altered central nervous system processing leading to central sensitisation and 
a heightened awareness of sensory inputs (Sluka and Clauw et al, 2016). These inputs may 
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be from physically traumatic events (such as a motor vehicle accident) but also 
psychologically traumatic events or adverse experiences (such as death of a spouse). In 
combination with this, descending “inhibitory” pathways appear to be less effective; indeed 
many of the pharmacological therapies which are licensed for use (although none are 
licensed in the United Kingdom or European Union) are targeted at inhibiting the function 
of the former and enhancing the function of the latter.  One aspect on which neurobiology 
and epidemiology completely agree, and which has informed criteria development, is that 
chronic widespread pain and fibromyalgia are part of a continuum rather than discrete 
entities.  
The first scientific focus of the thesis will consider the evidence for effective management 
of fibromyalgia and specifically for pharmacological and non-pharmacological therapies 
using work undertaken as part of the European League Against Rheumatism (EULAR) revised 
recommendations for the management of fibromyalgia. The data which inform these 
recommendations comes exclusively from randomised controlled trials, and the thesis will 
also include a manuscript considering how generalisable results are from such designs, 
taking advantage of a trial which had detailed information on eligible non-participants.  
The second focus of the thesis will consider observations that persons with chronic 
widespread pain may be at risk of premature death using data from the largest-ever study 
with such data available together with all other currently published data, and if so what 
may be the mechanism for such premature mortality. It will also provide data on the possible 
role of the use of opioids, which are predominantly used for the treatment of pain, in 
premature deaths. Although their routine prescription in patients with chronic pain is not 
supported by the available evidence, including in patients with fibromyalgia, their use 
generally has become more common and the adverse effects have become more evident 
including an increased risk of death, particularly from non-disease related causes (Volkow 
et al, 2018). 
Although fibromyalgia is itself common, it seems to occur more commonly than would be 
expected in people with inflammatory arthritis, with a recent meta-analysis reporting 
pooled prevalence of 13%, 18% and 21%  in axSpA, PsA and RA respectively (Duffield et al, 
2018). This may be because they share a common aetiology and/or that aspects of these 
diseases (e.g. inflammation) act as peripheral nociceptive drivers facilitating central 
sensitisation. It can be difficult to distinguish the conditions – since for example, widespread 
pain is a common symptom of inflammatory arthritis. There is concern also that having 
fibromyalgia may distort inflammatory disease specific markers and people therefore may 
receive inappropriate therapy for their inflammatory arthritis. This is particularly true for 
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axial spondyloarthritis where back pain as a result of inflammation in the spine is a key 
feature, but this symptom (referred to as axial pain) is also a key feature of fibromyalgia 
and indeed its presence was a requirement to meet the 1990 ACR criteria for fibromyalgia. 
Therefore, the third focus of the thesis will be fibromyalgia occurring in patients with axial 
spondyloarthritis. How common does co-morbid fibromyalgia occur in people with axSpA, 
how can these people be identified, how does this affect disease markers, and does it affect 
response to biologic therapy? 
The publications are produced in Chapter 2 (Manuscripts) and are organised as follows 
according to the themes discussed above. 
Effective management for fibromyalgia  
2.1 Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris 
K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-
Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of 
fibromyalgia. Ann Rheum Dis. 2017 Feb;76(2):318-328. 
 
2.2 Jones GT, Jones EA, Beasley MJ, Macfarlane GJ. Investigating generalizability of results 
from a randomized controlled trial of the management of chronic widespread pain: the 
MUSICIAN study. Pain. 2017;158(1):96-102.  
Mortality experience of persons with chronic widespread pain  
2.3 Macfarlane GJ, Barnish MS, Jones GT. Persons with chronic widespread pain experience 
excess mortality: longitudinal results from UK Biobank and meta-analysis. Ann Rheum 
Dis. 2017;76(11):1815-1822. 
 
2.4 Macfarlane GJ, Beasley M, Jones GT, Stannard C. The epidemiology of regular opioid 
use and its association with mortality: prospective cohort study of 466 486 UK Biobank 
participants. eClinicalMedicine 2020 (in press) 
Chronic widespread pain and fibromyalgia in the context of inflammatory arthritis (axial 
spondyloarthritis) 
2.5 Macfarlane GJ, Barnish MS, Pathan E, Martin KR, Haywood KL, Siebert S, Packham J, 
Atzeni F, Jones GT. Co-Occurrence and Characteristics of Patients With Axial 
Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National 
Register. Arthritis Rheumatol. 2017;69(11):2144-2150. 
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2.6 Macfarlane GJ, MacDonald RIR, Pathan E, Siebert S, Gaffney K, Choy E, Packham  J, 
Martin KR, Haywood K, Sengupta R, Atzeni F, Jones GT. Influence of co-morbid 
fibromyalgia on disease activity measures and response to tumour necrosis factor  
inhibitors in axial spondyloarthritis: results from a UK national register. Rheumatology 
(Oxford). 2018;57(11):1982-1990.  
 
2.7 Macfarlane GJ, Pathan E, Siebert S, Packham J, Gaffney K, Choy E, Sengupta R, Atzeni 
F, Martin KR, Jones GT, Dean LE. AxSpA patients who also meet criteria for fibromyalgia: 
identifying distinct patient clusters using data from a UK national register (BSRBR-AS). 
BMC Rheumatol. 2019;3:19.  
 
Chapter 3 (Discussion) then considers the results in the context of the wider scientific 
literature, specifically what the group of papers add to current knowledge and the clinical 
implications of such.   
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Objective: The original EULAR recommendations for managing fibromyalgia assessed 
evidence up to 2005. The paucity of studies meant that most recommendations were “expert 
opinion”.  
Methods: A multidisciplinary group from 12 countries assessed evidence with a focus on 
systematic reviews and meta-analyses concerned with pharmacological/non-
pharmacological management for fibromyalgia. A review, in May 2015, identified eligible 
publications and key outcomes assessed were pain, fatigue, sleep and daily functioning. The 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was 
used for making recommendations. 
Results: 2979 titles were identified: from these 275 full papers were selected for review, 
and 107 reviews (and/or meta-analyses) evaluated as eligible. Based on meta-analyses, the 
only “strong for” therapy-based recommendation in the guidelines was exercise. Based on 
expert opinion, a graduated approach, following four main stages is suggested underpinned 
by shared decision-making with patients. Initial management should involve patient 
education and focus on non-pharmacological therapies. In case of non-response, further 
therapies (all of which were evaluated as “weak for” based on meta-analyses) should be 
tailored to the specific needs of the individual and may involve psychological therapies (for 
mood disorders and unhelpful coping strategies), pharmacotherapy (for severe pain or sleep 
disturbance) and/or a multimodal rehabilitation programme (for severe disability)  
Conclusion: These recommendations are underpinned by high-quality reviews and meta-
analyses. The size of effect for most treatments is relatively modest. We propose research 
priorities clarifying who will benefit from specific interventions, their effect in combination, 
and organisation of health care systems to optimise outcome. 
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Introduction 
Fibromyalgia is common with a prevalence of 2% in the general population [1,2]. However, 
its diagnosis and management remain a challenge for patients and healthcare professionals. 
It often takes more than 2 years for a diagnosis to be made with an average of 3.7 
consultations with different physicians [3]. Referral to specialists and investigations results 
in high healthcare utilisation, for up to 10 years prior to diagnosis, when compared with 
persons who do not have fibromyalgia [4]. Although pain is the dominant symptom in 
fibromyalgia, other symptoms such as fatigue, non-refreshed sleep, mood disturbance and 
cognitive impairment are common, but not universal, have an important influence on quality 
of life, and emphasize that it is a heterogeneous and complex condition [5,6]. 
The original EULAR recommendations for the management of fibromyalgia assessed evidence 
up to and including 2005 [7]. Given the paucity of information and poor quality of the studies 
available, it was recommended that the guidelines be revised after a period of 4 years. 
However, no subsequent revision took place and thus a decade later we revisit the 
recommendations with the aim of making them more evidence based. In the time since the 
original recommendations there have been a considerable number of individual trials 
examining pharmacological and non-pharmacological interventions and, moreover, there 
have been systematic reviews conducted for nearly all of the commonly used management 
strategies. Our aim therefore was, using the systematic reviews conducted and taking into 
account their quality, to make evidence-based recommendations for the use of individual 
pharmacological and non-pharmacological approaches, and how these could be combined. 




Working group membership 
The working group included 18 members from 12 European countries: clinicians 
(representing rheumatology, internal medicine, pain medicine and epidemiology), non-
clinical scientists (occupational health, epidemiology), patient representatives, and the 
allied health professions (nursing). 
 
Eligibility, search strategy and quality assessment 
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We focused on systematic reviews (with or without meta-analysis) concerned with the 
management of fibromyalgia. Details of eligibility, review and quality assessment is 
provided in supplementary text available on-line.  
Evaluating evidence 
We retained pain as one of the key outcomes of interest, from the original guidelines, but 
also included fatigue, sleep and daily functioning. The committee considered the following 
in making a recommendation: number of trials; number of patients; outcomes assessed; 
quality of reviews and the trials included within the reviews; effect size (and 95% CI); 
adverse events; cost. We used the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) system for making recommendations [8]. This is a 4-point scale: 
strong for/weak for/ weak against/ strong against; or allowing a recommendation “use only 
for research”.  The strength of recommendation is based on the balance between desirable 
and undesirable effects (considering values and preferences), confidence in the magnitude 
of effects and resource use.  A strong recommendation implies that, if presented with the 
evidence, all or almost all informed persons would make the recommendation for or against 
the therapy, while a weak recommendation would imply that most people would, although 
a substantial minority would not [9]. 
Two sub-groups considered the evidence for pharmacological and non-pharmacological 
therapies and proposed a recommendation. At a face-to-face meeting, after presentation 
of the evidence and the preliminary recommendation, discussion resulted in a “final 
recommendation”. In addition to the evidence on efficacy/effectiveness, the committee 
also took into account safety. All participants then voted on their level of agreement with 
the recommendation on a scale from 0 “completely disagree” to 10 “completely agree”. 





In total, 2979 titles were identified.  From these, 571 abstracts and then 275 full papers 
were selected for review, and 107 reviews evaluated as eligible for consideration in making 
recommendations for management (Figure 1). 
Information on the reviews informing these recommendations on pharmacological therapy 
and on non-pharmacological and complementary and alternative medicines/therapies is 
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collated in Supplementary Tables A and B respectively while information from one review, 
for each medicine/therapy, selected based on recency and quality is provided in Tables 1 
and 2 respectively.  
 
Evaluation of pharmacological medicines 
Amitriptyline: Five reviews included up to 13 trials and a maximum of 919 subjects. Hauser 
et al [10] reported that patients receiving amitriptyline were more likely to achieve 30% 
pain reduction (RR 1.60, 95% CI (1.15,2.24)), equivalent to a “number needed to treat” 
(NNT) of 3.54 95% CI (2.74, 5.01). There was a moderate effect on sleep (SMD -0.56, 95% CI 
-0.78,-0.34)1 and small effect on fatigue (-0.44; -0.71, -0.16). There was no difference in 
discontinuation rates compared to patients receiving placebo. Nishishinya et al [11] in their 
high-quality review concluded that 25mg/day improved pain, sleep and fatigue at 6-8 weeks 
of treatment but not at 12 weeks while 50 mg/day did not demonstrate efficacy  
Amitriptyline Evaluation: Weak for, at low dose (100% agreement) 
Anticonvulsants: Nine reviews of pregabalin included up to 7 studies and a maximum of 3344 
patients. A recent Cochrane review [22] reported patients receiving active treatment were 
more likely to have 30% pain reduction RR 1.37 95% CI (1.22, 1.53) with a “number needed 
to benefit” (NNTB) over placebo of 9 95% CI (7, 13). There was a very small effect on fatigue 
(-0.17; -0.25, -0.09) and small effect on sleep (-0.35; -0.43, -0.27) but no effect on disability 
(-0.01; -0.11, 0.09).  A single, moderate quality, study of gabapentin in 150 subjects (e.g. 
in [101) showed a significant effect on 30% pain reduction (RR 1.65 95% CI 1.10, 2.48), a 
small effect on sleep (-0.71; -1.08, -0.24) and a large effect on disability (-0.94; -1.32, -
0.56). Anticonvulsant Evaluation: Pregabalin - Weak for (94% agreement); Gabapentin – 
Research only (100% agreement) 
Cyclobenzaprine: A single systematic review of 5 studies involving 312 patients reported 
that of those taking cyclobenzaprine 85% experienced side effects and only 71% completed 
the studies. They were more likely to report themselves as “improved” (NNT 4.8 95% CI (3.0, 
11.0)). Only two studies reported an “intention-to-treat” (ITT) analysis. Sleep, but not pain,  
showed a significant, very small, improvement relative to baseline at the longest outcome 
considered (12 weeks: SMD 0.34) and patients on placebo showed  similar improvement (SMD 
0.52) [23]. Cyclobenzaprine Evaluation: Weak for (75% agreement) 
 
1 All effect sizes are expressed as SMD with 95% CI unless otherwise stated.  
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Growth hormone: A single systematic review of 2 studies involving 74 patients reported an 
effect size on pain of 1.36 (0.01, 1.34)[14]. The improvement in functional deficit was not 
statistically significant (1.24; −0.36, 2.84).  There are concerns on safety (sleep apnœa, 
carpal tunnel syndrome).  The drug is not approved for FM or related disorders in Europe. 
Growth hormone Evaluation: Strong against (94% agreement) 
Monoamine Oxidase Inhibitors (MAOIs): Four reviews identified up to 3 studies and 241 
patients. Hauser et al [24] reported a moderate effect on pain across the studies (-0.54; -
1.02, - 0.07), but the single studies which evaluated fatigue and sleep showed no effect. 
There were no differences in dropouts or adverse events compared with placebo. There was 
no comparison between compounds. Life-threatening interactions have been documented. 
MAOIs Evaluation: Weak against (81% agreement) 
NSAIDs: A single review [19] identified two small trials with no evidence of improved 
outcome compared to placebo. One low quality review was not considered NSAIDs 
Evaluation: Weak against (100% agreement) 
Serotonin-Noradrenalin re-uptake inhibitors (SNRIs): Eight systematic reviews were 
identified which presented data separately for duloxetine.  The largest review of 2249 
subjects [30] reported duloxetine, short term (up to 12 wks)and long-term (up to 28 wks), 
was more effective than placebo at reducing pain (RR > 30% pain RR 1.38, 95% CI 1.22, 1.56) 
although there was no significant effect at 20-30 mg/day and no difference between doses 
of 60 and 120 mg/day. NNTB, based on 60mg/day up to 12 weeks, was 6 95% CI (3, 12). A 
previous review reported small effects on sleep (-0.24; -0.37,-0.12) and disability (-0.33; -
0.43,-0.24) but no effect on fatigue [28]. Seven systematic reviews were identified of 
milnacipran, a recent one of which evaluated 5 trials [28]. Patients taking milnacipran were 
more likely, at the end of treatment, to have  30% pain reduction (RR 1.38, 95% CI 1.25, 
1.51) but there was only a small benefit on fatigue (-0.14; -0.19, -0.08), disability (-0.16; -
0.23,-0.10) and no effect on sleep. Duloxetine and Milnacipran Evaluation: Weak for (100% 
agreement) 
Selective Serotonin Reuptake Inhibitors (SSRIs): Seven systematic reviews included up to 11 
trials and a maximum of 521 subjects. Given that reviews have not focussed on specific 
drugs or comparisons, drugs within this class were considered together. A recent review, of 
medium quality included 7 trials and reported a moderate effect on pain (-0.40; -0.73,-
0.07), sleep (-0.31; -0.60,-0.02) and no effect on fatigue (-0.17; -0.46, 0.11)[34]. SSRI 
Evaluation: Weak against (94% agreement) 
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Sodium Oxybate: A single systematic review of 5 studies including 1535 patients reported 
small effects sizes on pain (0.44; 0.31, 0.58], sleep problems  (0.47; 0.28, 0.66)  and fatigue 
[0.48; 0.35, 0.60). EMA and FDA refused the approval for FM because of safety concerns 
[14]. The drug is only approved for narcolepsy. Sodium Oxybate evaluation: Strong against 
(94% agreement) 
Tramadol, a weak opioid with mild SNRI activity, was considered by two reviews. Roskell et 
al [20] identified a single study of tramadol with paracetamol. Those in the active arm were 
more likely to have 30% improvement in pain (RR 1.77 95% CI 1.26, 2.48).  Tramadol 
Evaluation: Weak for (100% agreement) 
The literature search did not identify any reviews on corticosteroids, strong opioids, 
cannabinoids, and anti-psychotics. The committee made a “Strong against” evaluation (100% 
agreement) regarding the use of strong opioids and corticosteroids in patients with 
fibromyalgia, on the basis of lack of evidence of efficacy and high risk of side 
effects/addiction reported in individual trials.  
 
Evaluation of non-pharmacological therapies; complementary and alternative medicines 
and therapies 
Acupuncture: Eight reviews included up to 16 trials and 1081 participants.  One high quality 
review included nine trials, with 395 patients and demonstrated that acupuncture, added 
to standard therapy resulted in a 30% (21%, 39%) improvement in pain [68].  Electric 
acupuncture was also associated with improvements in pain (22%; 4%, 41%) and fatigue (11%; 
2%, 20%).  Some adverse events were reported, but these were commonly mild and 
transient.  There is little understanding of the active component of acupuncture, and the 
evidence supporting the use of real versus sham acupuncture was less consistent.  
Acupuncture evaluation: Weak for (93% agreement). 
Biofeedback: Two reviews included up to seven trials and 307 participants.  Glombiewski et 
al [90] reviewed seven studies, comprising 321 participants.  Treatment sessions varied from 
6-22; with control therapy comprising sham biofeedback, attention control, medication, and 
treatment as usual.  Biofeedback was effective in reducing pain intensity (Hedges’ g = 0.79; 
0.22, 1.36) although all trials were poor quality.  There was no evidence of effectiveness in 
terms of fatigue or sleep and sub-group analysis suggested that any effect was limited to 
electromyographic (0.86; 0.11, 1.62) rather than electroencephalographic biofeedback 
(0.71; -0.37, 1.8).  Biofeedback evaluation: weak against (100% agreement). 
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Capsaicin: Two reviews included two trials and 153 participants.  The most recent review, 
a narrative review of two trials, considered data on 153 patients [92].  Both showed some 
evidence of positive effect in terms of pain relief, although results were not consistent for 
other outcomes.  Capsaicin gel is generally considered safe, although many users report a 
mild burning sensation when applied to the skin. However, the number of patients and trials 
was small and were therefore limited in the extent to which they can provide evidence for 
toxicity.  Capsaicin evaluation: Weak against (86% agreement). 
Chiropractic: Three reviews included up to 13 trials and 102 participants.  The most recent 
review summarised three studies [87].  One study was an open pilot study, one quasi-
randomised, and in the third no between-group differences were observed in terms of pain 
.  The studies were poor quality and lacked robust interpretable data.  Chiropractic 
evaluation: Strong against (93% agreement). 
Cognitive behavioural therapies (CBTs): Five reviews included up to 30 trials and at least 
2031 participants.  One high quality review included 23 trials, comprising >2000 patients, 
although the quality of individual trials was reported as generally poor [56].  CBTs were 
effective in reducing pain (-0.29; -0.49, -0.17) and disability (-0.30; -0.51, -0.08)  at the 
end of treatment, compared to a variety of controls groups, and results were sustained long 
term.  Behavioural therapy evaluation: Weak for (100% agreement). 
Exercise: 20 reviews included up to 34 trials and at least 2494 participants2.  The largest, a 
Cochrane review, considered 47 different exercise interventions [39].  Aerobic exercise was 
associated with improvements in pain (0.65; -0.09, 1.39) and physical function (0.66; 0.41, 
0.92).  Busch et al [40] reviewed five trials with 219 participants and concluded that 
resistance training resulted in a significant improvement in pain (-3.3cm on a 10cm scale; -
6.35, -0.26) as well as function, compared to control.  There is some consistency with 
regards to aerobic and strengthening exercises, although insufficient evidence to suggest 
superiority of one over the other; land and aquatic exercise appear equally effective [54].  
Exercise therapy evaluation: Strong for (100% agreement). 
Hydrotherapy / spa therapy: Four reviews included up to 21 trials and 1306 participants.  
One high quality review included ten trials, 446 participants, and compared a median of 
4hrs hydrotherapy (range 200-300mins) against various comparators [74].  There was a 
significant improvement in pain (-0.78; -1.42, -0.13) at the end of therapy, maintained in 
the longer term (median 14 weeks), although the review authors noted that no trials 
 
2 It is unclear from some of the reviews how many participants were included.  The number of participants 
represents the minimum about which we can be confident. 
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conducted an ITT analysis.  There was consistency with regards to the evidence for 
hydrotherapy and balneotherapy, although little evidence to suggest superiority of one over 
the other [75].  Hydrotherapy evaluation: Weak for (93% agreement). 
Hypnotherapy: One review included four trials, although the number of participants is 
unclear [89].  Although six trials of hypnotherapy and/or guided imagery were reviewed, 
only four examined hypnotherapy in isolation.  Median treatment duration (where reported) 
was 360 minutes and hypnotherapy was compared with a variety of control therapies: 
cognitive intervention, active control (physical therapy / massage / relaxation / autogenic 
training), and treatment as usual.  A meta-analysis is presented on all six trials, and isolated 
data for hypnotherapy is not presented.  Two of the four hypnotherapy trials report some 
significant benefit in terms of pain, the other two demonstrate null, non-significant 
results.  Hypnotherapy evaluation: Weak against (86% agreement). 
 
Massage: Six reviews have been reported and  one meta-analysis with nine trials and 404 
patients [61] with sessions lasting 25-90 mins, and treatment duration ranging from 1-24 
weeks (median five weeks).  Comparator treatments, included TENS, standard care, guided 
relaxation and acupuncture.  Methodological problems were noted with all of the studies, 
only four were at low risk of bias in terms of random allocation, and only two were analysed 
as ITT.  Overall, massage was not associated with a significant improvement in pain (0.37; 
-0.19, 0.93) and of the two ITT analyses, one favoured massage and one favoured control 
(both significant).  A sub-group analysis revealed some evidence of a positive effect with 
massage of ≥5 weeks duration, although this was based solely on lower quality trials.  
Massage evaluation: Weak against (86% agreement). 
Meditative movement: Six reviews, including up to eight trials and 559 participants focused 
on qigong, yoga, tai chi, or a combination of these therapies.  However, there was 
insufficient evidence to make individual recommendations.  One review included 7 trials, 
with 362 participants randomised to tai chi, yoga, qigong, or body awareness therapy[78]. 
Total treatment time ranged from 12-24hrs and was compared to a variety of controls, 
including treatment as usual and active control groups (aerobics, wellness education and 
stretching).  At the end of therapy, improvements were seen in sleep (-0.61; -0.95, -0.27) 
and fatigue (-0.66; -0.99, -0.34) some of which were maintained in the longer term.  
Meditative movement evaluation: Weak for (71% agreement). 
Mindfulness / mind-body therapy: Six reviews included up to 13 trials and 1209 participants.  
One recent review, a meta-analysis of 6 trials, with 674 patients [82] provided evidence 
that mindfulness-based stress reduction resulted in improvements in pain ( -0.23; -0.46, -
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0.01)  immediately post-treatment, when compared to usual care, and when compared to 
active control interventions (-0.44; -0.73, -0.16).  However, these effects were not robust 
against bias.  Mindfulness / mind-body therapy evaluation: Weak for (73% agreement). 
Multi-component therapy: Two reviews including up to 27 trials and 2407 participants 
examined the additional benefit of combining therapies, compared to individual therapy.  
Häuser et al [58] conducted a review of management involving both educational or 
psychological therapies and exercise.  In a meta-analysis of nine trials and 1119 patients, 
multi-component therapy was effective in reducing pain (-0.37; -0.62, -0.13), and fatigue, 
immediately post-treatment, compared to waiting-list, relaxation, treatment as usual, and 
education. .  However effects were short-lived.  Multi-component therapy evaluation: Weak 
for (93% agreement). 
S-Adenosyl methionine (SAMe): Two reviews each included one trial with, in combination, 
74 participants.  De Silva et al [91] reported that, after the end of treatment, significant 
improvements were observed in pain and fatigue compared to placebo.  Sim and Adams [50] 
reviewed a trial comparing SAMe with transcutaneous electrical nerve stimulation (TENS) 
but data on the main trial comparison is omitted.  Side-effects are usually mild and 
infrequent.  However, the number of patients and trials were small and therefore cannot 
provide a robust assessment of toxicity and safety.  SAMe evaluation: Weak against (93% 
agreement). 
Other complementary and alternative therapies: Three reviews of guided imagery included 
up to six trials and 357 participants.  The highest quality, including only one trial, provided 
some evidence that guided imagery may be effective in reducing pain ( -1.52; -2.17, -
0.87)[88]. Two reviews of homeopathy, including four trials and 163 participants [95,96].  
Both contained a review including only four randomised trials, each of which showed some 
benefit of homeopathy, on some outcomes.  However, none of the individual trials were 
without serious flaws.  Other complementary and alternative therapies (guided imagery, 
homeopathy): strong against (93% agreement). 
Reviews were identified that examined electrothermal and phototherapeutic therapy [97]; 
phytothermotherapy [98]; music therapy, journaling/story-telling [102], and static magnet 
therapy [99], although each was insufficient to allow a recommendation. Marlow et al [100] 
examined the effectiveness of transcranial magnetic and/or direct current stimulation.  
Eight trials included 244 participants, although not all were analysed by ITT, and appropriate 
group comparisons were not presented for all studies.  Overall, there was little evidence to 
support either therapy, and several studies reported an unacceptably high rate of adverse 
events and/or discontinuation due to headache. 
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EULAR Revised Recommendations: 
In terms of overall principles we recommend, based on unanimous expert opinion, that 
optimal management requires prompt diagnosis, and providing the patient with information 
(including written material) about the condition. There should be a comprehensive 
assessment of pain, function, and the psychosocial context.  Management should take the 
form of a graduated approach with the aim of improving health-related quality of life. It 
should focus firstly on non-pharmacological modalities. This is based on availability, cost, 
safety issues and patient preference. We have used the evaluation of individual therapies 
(above) to make ten specific recommendations, all based on evidence from systematic 
reviews and all but one from meta-analysis. The recommendations are given in Table 3 and 
a flow chart of how these therapies may be used in management is shown in Figure 2.  
We were unanimous in providing a “strong for” recommendation for the use of exercise, 
particularly given its effect on pain, physical function and well-being, availability, relatively 
low cost and lack of safety concerns. The available evidence did not allow us to distinguish 
between the benefits of aerobic or strengthening. We gave “weak for” recommendations in 
relation to meditative movement therapies (which improved sleep, fatigue and quality of 
life) or mindfulness-based stress reduction (which improved pain and quality of life); the 
physical therapies acupuncture or hydrotherapy for which there was evidence that they 
improved pain/fatigue and pain/quality of life respectively. The effects seen in pragmatic 
trials of such therapies, will include specific and non-specific effects and it is not possible 
to disentangle these. There were some non-pharmacological therapies we did not 
recommend because of lack of effectiveness and/or low study quality: biofeedback, 
capsaicin, hypnotherapy, massage, SAMe and other complementary and alternative 
therapies. We provided a “strong against” evaluation for chiropractic based on safety 
concerns.  
In case of lack of effect of the above therapeutic approaches, we recommend individualized 
treatment according to patient need. Psychological therapies (“weak for”) should be 
considered for those with mood disorder or unhelpful coping strategies: CBT was effective 
at producing modest, long-term reductions in pain, disability and improving mood. 
Pharmacological therapies (all “weak for”) should be considered for those with severe pain 
(duloxetine, pregabalin, tramadol) or sleep disturbance (amitriptyline, cyclobenzaprine, 
pregabalin). Multimodal rehabilitation (“weak for”) programs should be considered for those 
with severe disability – in comparison to individual therapies those which were multi-modal 
improved a range of short-term outcomes. We did not recommend several pharmacological 
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therapies including NSAIDs, MAOIs, SSRIs, because of lack of efficacy and specifically gave a 
“strong against” evaluation to growth hormone, sodium oxybate, strong opioids and 




The previous EULAR recommendations provided an important milestone in the management 
of fibromyalgia. There were nine recommendations, but only three were supported by strong 
evidence from the scientific literature; most were based on expert opinion. Since that time 
there have been a considerable number of trials published addressing issues in the 
management of fibromyalgia. The availability of systematic reviews and meta-analysis of 
RCTs for all the most common approaches to management allowed us to concentrate on 
these.  
 
Comparison with 2007 EULAR Recommendations 
Despite the very large increase in the amount of trial data and summarised in meta-analyses, 
there are no major changes to the approach of managing patients with fibromyalgia, 
although we provide new evidence in support for some additional non-pharmacological 
therapies. In addition, all the recommendations are now firmly evidence-based.  We now 
recommend that non-pharmacological therapy should be first-line therapy and then if there 
is a lack of effect that there should be individualised therapy according to patient need, 
which may include pharmacological therapy. 
Comparison with other recommendations 
There are three recent guidelines on the management of FM from Canada, Israel and 
Germany which have been compared with respect to their recommendations [103]. These 
guidelines and our EULAR recommendations are in agreement on the principles of approach 
to management, the need for tailored therapy to the individual and the first-line role of 
non-pharmacological therapies. There are differences between our guidelines and previous, 
which can partly be explained by us using more recently available evidence. There are 
differences in the strength of recommendations relating to pharmacological therapies: 
anticonvulsants and SNRIs were strongly recommended by the Canadian and Israeli 
guidelines while the German and these EULAR guidelines provide a weak recommendation.  
There are also differences in relation to individual non-pharmacological therapies across 
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guidelines in terms of whether they were assessed. For example meditative movement is 
strongly recommended by the German guidelines, but recommended only for a minority of 
patients in Israel, while these EULAR guidelines provide a “weak for” recommendation. 
The committee recommend that an update is conducted after 5 years in order to determine 
whether for those therapies with relatively little current evidence, further trials have been 




In the course of discussion we identified important questions in terms of guiding 
management where there was either insufficient (or often no) evidence base to guide 
decisions i.e. “research gaps”. We discussed their relatively priority taking into account 
their potential to guide management, the likelihood that such studies could be conducted 
and were likely to be funded. We identified five such priority questions: 
• Which type of exercise is most effective: strength and/or aerobic training? 
• Is combined pharmacological and non-pharmacological approaches to management 
more effective than single modality management? 
• Are there characteristics of patients with fibromyalgia which predict response to 
specific therapies? 
• How should fibromyalgia be managed when it occurs as a co-morbidity to 
inflammatory arthritis? 
• What aspects of a healthcare system optimise outcome for patients (who is best for 
the management of FM patients?) 
Some of these questions are best answered by randomised controlled trials. Given, however 
the expense of such studies and that they can take almost 10 years from identifying the 
questions to be answered to results being obtained, alternatives including registers and 
observational studies should be considered. These can be complemented by qualitative 
studies to determine the needs of patients.  
 
Dissemination 
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These recommendations will be disseminated, by the international working group, through 
national rheumatology societies. This will include scientific meetings, newsletters, 
continuing education programmes. We will produce a summary of the recommendations 
suitable for dissemination through EULAR-affiliated patient groups and through national 
patient societies. We will investigate assessing agreement with the recommendations in the 
target population.  
 
Summary 
In summary, these revised EULAR recommendations newly incorporate a decade of evidence 
in relation to the pharmacological and non-pharmacological management of fibromyalgia. 
They allow EULAR to move from recommendations which are predominantly based on expert 
opinion to ones which are firmly based on scientific evidence from high-quality reviews and 
meta-analyses. Despite this evidence, however, the size of effect for many treatments is 
relatively modest .We propose focussing on the research priorities we outline to address 
issues clarifying to whom certain interventions may best be delivered, their effect in 
combination, matching patients to therapies and the organisation of health care systems to 
optimise outcome. 
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Figure 2  Management recommendations as flowchart
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10-50mg/day; 8-24 weeks Low There was no analysis of safety but no 
difference in discontinuation rates compared 





three studies with fixed doses of 300, 
450, 600 mg/day; one with fixed doses of 
150, 300 or 450 mg/day; one flexible 
dosing study of 300 or 450 mg/day; 8-14 
weeks 
High Increased likelihood of withdrawal due to 
adverse events RR 1.68, 95% CI (1.36, 2.07); 
NNH 12 95% CI (9, 17). No difference in 





10-40mg; 2-24 weeks Moderate There was no analysis of adverse outcomes in 
the trials reviewed although dropout across 
trials was large (Cyclobenzaprine 29%, 
placebo 43%) Only 2 studies conducted ITT 
 
3 According to the method of quality evaluation used in the review 







0.0125 mg/kg/d; adjusted to maintain 
IGF-1 level of 250 ng/mL after first 
month, 0.0125 mg/kg/d; 9 months-1 year 
NE4 Safety concerns include sleep apnoea and 
carpal tunnel syndrome. 
Monoamine 
oxidase 
inhibitors [24]  
3 (241) 
AMSTAR=9 
Pirlindole 150 mg/d, Moclobemide 150-
300 mg/d; 4 - 12 weeks 
Low MAOIs are known to cause potentially fatal 
hypertensive crises, serotonin syndrome and 
psychosis when they interact with foods 
containing tyramine and medications (many 
of which are commonly used in the treatment 
of FM), including SSRIs, tricyclic 
antidepressants and tramadol. The clinical 
trials had restrictions on concomitant 
medications. 
NSAIDs [19] 2 (242) 
AMSTAR=7 
ibuprofen 600mg QDS, tenoxicam 
20mg/d; 6-8 weeks 
Low The adverse event profile, although not 
considered in this review, is well established 




inhibitors (SNRIs) – 
Duloxetine [29]  
6 (2249) 
AMSTAR=10 
20-120 mg/d; 12-28 weeks Moderate Dropout rates due to side effects across 
studies higher than with placebo. No 





100 or 200 mg/day; 12-27 weeks High Dropout rates due to side effects across 
studies were double compared to placebo but 
 
4 Not Evaluated 




inhibitors (SNRIs) – 
Milnacipran [28]  









20-40 mg/d citalopram, 20-80mg/day 




Acceptability and tolerability were similar to 
placebo NNTH  40 95% CI (19,66).Although 
several studies excluded patients with 
depression/anxiety, Hauser et al [24] showed 
a small effect of SSRIs in improving depressed 





4.5-6g/day; 8-14 weeks NE There is the potential for abuse and central 
nervous system effects associated with abuse 
such as seizure, respiratory depression, and 
decreased levels of consciousness 
Tramadol [20] 1 (313) 
AMSTAR=3 
37.5mg Tramadol/325mg paracetamol 
4x/d; 3 months; 
High No significant difference in discontinuation 
due to adverse events (RR 1.62, 95% CI (0.94, 
2.80)). A high-quality review (AMSTAR score 
7) identified a single study, which amongst 
persons who tolerated and benefitted from 
Tramadol, demonstrated a lower 
discontinuation rate, in a double-blind phase, 
compared to placebo [19]. 
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Dosages; durations of treatment 
Overall Trial 
quality6 
Safety and comments 
Acupuncture [68] 9 (395) 
AMSTAR=11 
Treatment sessions ranged from 3 to 
13wks (median = 4), with needle 
retention ranging from 20-30mins.  Only 
one study provided journal references 
for the acupuncture point selection, and 
the description of the type of needle 
stimulation / manipulation was clear in 
only three studies 
Moderate One in six people who had acupuncture, and 
one in three controls, reported adverse 
events.  Such events were minor and lasted 
less than one day.  No serious adverse 
events were reported in any trials. 
Biofeedback [90] 7 (321) 
AMSTAR=8 
Electro-myographic (EMG) biofeedback. 
Individual sessions varied between 45 
and 180mins, and the number of 
sessions varied between 6 and 16. 
Poor Only two7 trials reported adverse event 
data.  4% of patients in one trial receiving 
EMG biofeedback reported stress.  And 74% 
of patients in another, receiving EEG 
biofeedback reported a variety of side 
 
5 Total number of persons randomised 
6 According to the method of quality evaluation used in the review 
7 Elsewhere in the review, it reports that three studies reported on adverse events.  However, in the table where this data is presented, it is only clear for two.  However, in 
a third trial, there were no dropouts due to side effects. 





20-22 sessions of (where reported) 
30min duration. 
effects, including: headache, fatigue, and 
sleep problems. 
Capsaicin [92] 2 (153) 
AMSTAR=5 
Topical application of Capsicum annuum 
L. cream, either: 
0.025%capsaicin for 4wks,or 0.075% for 
12wks. 
Not reported Patients reported moderate, transient, 
burning or stinging 
Chiropractic [87]  3 (102) 
AMSTAR=4 
Little detail is given for any trials, but 
treatment elements included massage, 
stretching, spinal manipulation, 
education, and resistance training. 
Low Around 50% of patients experience mild to 







Median duration of therapy = 10wks, 
with a median number of 10 sessions, 
and median total hours = 18hrs.  All bar 
two studies delivered therapy face-to-
face.  Median follow-up (where this was 
performed 17/23 studies) = 6 months. 
Low The assessment of safety in most studies was 
insufficient. 
Two studies reported dropout, due to 
worsening of co-morbid mental disorders.  
However, CBT is generally considered safe.  
Exercise [39] 34 (2276) 
AMSTAR=9 
Exercise programmes lasting 2.5 to 
24wks.  Aerobic exercise for >=20mins, 
once a day (or twice for >=10mins), 2 to 
Moderate Although patients may initially notice a 
deterioration in symptoms, exercise is 
 
8 This data was not contained in this review.  The initial recommendation for chiropractic was Weak Against.  However, after discussion, this was downgraded to Strong 
against, due to potential safety concerns. 
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3 days a week.  Strength training with 
>=8 repetitions per exercise, 2 to 3 
times a week. 
generally considered safe, especially when 





Wide variation in precise treatment 
strategy between trials.  Most consisted 
of water or mud baths at body 
temperature 36-37°C), or slightly above 
(40-45°C), with a median treatment 
time of 240mins (range 200-300), over 
several weeks. 
Low Three studies reported no side effects of 
treatment; one reported slight flashes in 
10% of the patients.  The remaining trials 
did not explicitly mention safety. 
Hypnotherapy [89] 4 (152) 
AMSTAR=11 
Some variation between trials ranging 
(where reported) from 300 to 420mins, 
delivered over 10 to 26wks. 
Good Adverse events were not reported in any of 
the trials. 
Massage [61] 9 (404) 
AMSTAR=7 
Massage therapy time lasted 25-90mins, 










Wide variation in treatments between 
trials, and included yoga, tai chi, 
qigong, or body awareness therapy.  
Median (range) duration of treatment = 
16 (6-24) hrs, over 4-12wks. 
Moderate Although no serious adverse events were 
reported, six participants (3.1%) withdrew 
from the trials because of adverse events 
(increase of pain; muscle inflammation; 
chlorine hypersensitivity).  The review 
authors concluded that the acceptance and 
safety of all 
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Some variation between trials.  Single 2-
3.5hr session per week, for 8-10wks.  
Four out of six programmes also 
included daily home practice (30-
45mins) plus a single all-day retreat. 






Enormous variation in treatment 
strategies between trials.  Most included 
different combinations of exercise (land 
and/or water based); education; 
relaxation; and/or some other specific 
therapeutic component (e.g. Tai Chi; or 
massage) 





1 (44)  
AMSTAR=6 
400mg tablet, twice a day, for 6wks Moderate Mild adverse effects such as stomach upset 
and dizziness were reported. 
Other: Guided 
imagery [89] 
1 (48)  
AMSTAR=9 
Audiotape-led, individual, guided 
imagery: 30 min daily for 6wks 
recommended.  Median of 44 exercises 
(range 37-136) 





Variation between trials.  Two studied 
individualised homeopathic treatment, 
Low to 
moderate 
No information was provided on safety. 
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consisting of an initial consultation (and 
treatment), plus follow-up interviews 
every 4-8wks.  Two studied Arnica 
montana, Bryoniaalba or Rhus 
toxicodendron (potency 6c) daily for 
between 1 and 3 months. 
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Table 3: Recommendations 
 
Recommendation Level of 
evidence 
Grade Strength of 
recommendation 
Agreement9 
Overarching Principles:  
Optimal management requires prompt diagnosis. Full understanding of 
fibromyalgia requires comprehensive assessment of pain, function, and 
psychosocial context.  It should be recognised as a complex and 
heterogeneous condition where there is abnormal pain processing and other 
secondary features.  In general, the management of FM should take the form 
of a graduated approach 
IV D  100% 
Management of fibromyalgia should aim at improving health-related quality 
of life balancing benefit and risk of treatment which often requires a 
multidisciplinary approach with a combination of non-pharmacological and 
pharmacological treatment modalities tailored according to: pain intensity, 
function, associated features (such as depression), fatigue, sleep disturbance 
and patient preferences and comorbidities; by shared decision making with 
the patient. Initial management should focus on non-pharmacological 
therapies 
IV D  100% 
Specific Recommendations 
Non-Pharmacological Management 
Aerobic and strengthening exercise Ia A Strong for 100% 
 
9 % of working group scoring at least 7 on 0-10 numerical rating scale assessing agreemen 
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Cognitive Behavioural Therapies Ia A Weak for 100% 
Multicomponent therapies Ia A Weak for 93% 
Defined physical therapies: Acupuncture or hydrotherapy Ia A Weak for 93% 
Meditative movement therapies (qigong, yoga, tai chi) and Mindfulness Based 
Stress Reduction 
Ia A Weak for  71-73% 
Pharmacological Management 
Amitryptiline (at low dose) Ia A Weak for 100% 
Duloxetine or Milnacipran Ia A Weak for 100% 
Tramadol Ib A Weak for 100% 
Pregabalin Ia A  Weak for 94% 
Cyclobenzaprine Ia A Weak for 75% 
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The generalisability of randomised controlled trials will be compromised if markers of treatment 
outcome also affect trial recruitment.  In a large trial of chronic widespread pain (CWP), we aimed 
to determine the extent to which randomised participants represented eligible patients, and 
whether factors predicting randomisation also influenced trial outcome. Adults from eight UK 
general practices were surveyed to determine eligibility for a trial of two interventions (exercise, 
and cognitive behavioural therapy (CBT)).  Amongst those eligible, logistic regression identified 
factors associated with randomisation.  The main trial analysis was recomputed, weighting for the 
inverse of the likelihood of randomisation, and the numbers needed to treat (NNT) were calculated 
for each treatment. 884 persons were identified as eligible for the trial, of whom 442 (50%) were 
randomised.  Several factors were associated with the likelihood of randomisation: higher Body 
Mass Index (BMI) (odds ratio: 1.99; 0.85-4.61); more severe/disabling pain (1.90; 1.21-2.97); 
having a treatment preference (2.11; 1.48-3.00); and expressing positivity about interventions 
offered (exercise: 2.66; 1.95-3.62; CBT: 3.20; 2.15-4.76).  Adjusting for this selection bias 
decreased the treatment effect associated with exercise and CBT but increased that observed for 
combined therapy.  All were associated with changes in NNT. This has important implications for 
the interpretation of pain trials generally. 
 






Randomised controlled trials (RCTs) remain the gold standard for assessing the efficacy and 
effectiveness of interventions.  However, typically, they are conducted with highly selected 
patient populations and the results then generalised to wider patient populations.  The 
appropriateness of this generalisation is based, at least in part, on the extent to which the 
randomised patients resemble the entire eligible patient population, and the belief that the 
biological effect will be the same in other populations. A concern with the external validity of 
trials (including those concerned with pain) has led to renewed interest in “Real World Evidence” 
(i.e. observational data) as perhaps providing more appropriate evidence on treatment 
effectiveness in settings in which they may be typically applied. 
 
These assumptions may not hold true.  It is known that certain population groups are, generally, 
more willing to be randomised than others – these include the less well educated [6,12] and those 
with more severe symptoms [2,6] – and the generalisability of trial results may be compromised if 
certain patient characteristics that are associated with trial recruitment are also markers of the 
trial treatment outcome.  However, the extent to which this is the case for individual trials is 
often impossible to gauge, as trial recruitment frequently occurs in such a way that detailed 
information on eligible but non-randomised patients is not available. 
 
Recent reviews and meta-analyses have shown that eligible individuals may be less likely to enter 
a trial if they have strong treatment preferences [11,16].  In addition, treatment preference may 
be associated with prognostic indicators in trial participants, such as anxiety [15], and symptom 
severity [2,11].  There is also evidence that, among trial participants, treatment effect differs 
according to a priori treatment preferences [11,16]. 
 
We conducted an RCT of the management of chronic widespread pain in primary care – the 
MUSICIAN study (Managing Unexplained Symptoms In primary Care: Involving traditional and 
Accessible New approaches [13].  The trial was a factorial 2*2 design and interventions were (a) 
prescribed exercise delivered by trained fitness instructors, and including access to a fitness 
facility; (b) cognitive behavioural therapy (CBT) delivered over the telephone by trained 
therapists; (c) both of the above; or (d) usual care.  We found that both exercise and CBT were 
associated with important and statistically significant improvements in patient global assessment 
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in both the medium and long-term, although no additional benefit was gained from receiving both 
treatments [1,13].  Trial patients were identified using a large population-based survey.  This gave 
rise to a unique opportunity to gather detailed information from a large pool of eligible individuals; 
to characterise those who did and those who did not consent to randomisation; and to determine 
the influence of treatment preference on the likelihood that an eligible individual would be 
randomised. 
 
Thus, using data from the MUSICIAN study, the aims of the current study were, firstly, to examine 
factors that may affect the generalisability of trial results and secondly, to examine the extent to 
which external validity may be compromised, by determining whether factors predicting 




The MUSICIAN study was a 2x2 factorial RCT investigating the management of chronic widespread 
pain (registration number: ISRCTN67013851), the methods and main results (including CONSORT 
statement) of which have been described elsewhere [1,13,14]. In brief, potential trial participants 
were identified by means of a large-scale postal questionnaire survey, mailed to all 45,994 
individuals aged 25 years and older registered with eight general practitioners in the city of 
Aberdeen, Scotland, and North Cheshire, England.  As over 95% of UK residents are registered at 
a GP practice, and these practices were located in areas of varying levels of socioeconomic status, 
this was considered to be suitably representative of the general population.  Questionnaire 
respondents were potentially eligible to be randomised if they reported: 
(a) Pain consistent with the American College of Rheumatology definition of chronic 
widespread pain in their 1990 classification criteria for fibromyalgia [21]; 
(b) Pain of some impact, defined as a score of ≥1 on the Chronic Pain Grade [20];  and 
(c) Pain for which they had consulted their general practitioner at least once, within the 
previous twelve months. 
In addition, trial inclusion criteria required patients to consent to be contacted again, and to have: 
(d) No health condition identified as requiring an alternative treatment; 
(e) Access to a land-line telephone; and 
(f) No contra-indications to exercise.  (Note: pain alone was not considered a contra-
indication.) 
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The questionnaire provided brief information about the exercise and CBT treatments offered in 
the trial (although, at this stage, participants did not know that they might be invited to take part 
in a trial).  It also elicited information about participants’ familiarity with these treatments; how 
positive they would be about receiving the treatments (using a 0-10 visual analogue scale); and 
how effective they believed they would be, were they to receive them (on a five point Likert scale 
from ‘much improved’, to ‘much worse’).  Treatment preference was assessed by a single question 
asking participants which of the available treatments they would opt for, were they to have been 
given a choice.  
 
Survey respondents who were potentially eligible for the RCT were then mailed information about 
the trial itself, after which they were contacted by a research nurse to confirm eligibility and 
arrange an initial assessment appointment in a local clinical research facility.  At this appointment, 
participants completed an additional questionnaire which contained measures of psychological 
distress (General Health Questionnaire (GHQ) [9]);  sleep problems (Sleep Problems Scale [10]); 
fatigue (Chalder Fatigue Scale [4]); and fear of movement (Tampa Scale for Kinesiophobia [18]); 
and, if eligibility was confirmed and consent was obtained, randomisation took place. 
 
The primary outcome for the trial was a seven-point, patient global impression change score, 
assessed by self-completion questionnaire, at six and nine months post-randomisation.  Patients 
were asked to rate how they felt their health had changed since the period prior to entering the 
trial, ranging from 1 (‘very much worse’) to 7 (‘very much better’).  Questionnaire non-
respondents were asked the same question verbally, by telephone interview. 
 
Analysis 
Firstly, amongst individuals surveyed, responders and non-responders were compared and among 
survey respondents eligible for randomisation, differences were examined between those 
individuals who were / were not subsequently randomised.  This was done using χ2 tests and non-
parametric tests for trend [5] and the magnitude of any differences characterised using logistic 
regression.  Thus, differences are expressed as odds ratios with 95% confidence intervals (95%CI).  
Secondly, a forward stepwise regression model was constructed, to identify which variables 
independently predicted randomisation.  If not already dichotomous, these variables were then 
dichotomized and N*2 categories were created, where N represented the number of factors in the 
multivariable regression model.  The primary trial analysis (presented elsewhere [13]) was then 
recomputed, weighting for the inverse of the likelihood of randomisation, for every given 
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combination of N*2 categories. Finally, the number needed to treat (NNT) was calculated for each 
of the treatments, based on the weighted odds ratios. 
 
Statistical analysis was conducted using STATA 11.1 from STATACORP, Texas.  NNTs were 




Of 45,994 individuals invited to participate in the survey, useable questionnaire responses were 
received from 15,313 (33%).  Women were significantly more likely to respond than men (37% 
versus 29%; chi2=328.1, p<0.001) and there was a significant increase in response rate with age 
(21% among those aged 25-40yrs, increasing to 45% in those >60yrs; non-parametric test for trend 
p<0.001).  Of the 15,313 responders, 1844 (12%) reported chronic widespread pain of whom 884 
(48%) were eligible to take part in the trial and 442 (50%) were eventually randomised.  Of the 
442 responders not randomised, 94 were subsequently found to be ineligible, and one died before 
they attended the screening visit.  Thus, there were 347 participants who met all trial inclusion 
criteria, but were not randomised.  The flow of participants from initial survey invitation to 
subsequent randomisation is shown in Figure 1. 
 
The median age of eligible participants was 57yrs (inter-quartile range: 46-66yrs), and 68% were 
female.  Two-thirds (67%) rated their health as ‘good’, or better; 28% had a body mass index 
>30kgm-2; and 51% were ex- or current smokers.  Of the eligible survey participants, those aged 
41-60yrs were significantly more likely to be randomised than younger respondents (odds ratio: 
1.54; 95%CI: 1.02-2.33).  However, this effect was not linear and there was no further increase in 
the likelihood of randomisation among those aged >60yrs (1.31; 0.87-1.98).  Also, there was no 
difference in the likelihood of randomisation between men and women (odds ratio for women: 
1.23; 0.91-1.66). 
 
A significant trend existed, such that participants with higher BMI (p=0.03) and higher Chronic Pain 
Grade (signifying more severe and / or disabling pain) (p=0.002) were more likely to be randomised 
than other individuals (Table 1).  Similarly, participants with a treatment preference were twice 
as likely to be randomised as those without (2.11; 1.48-3.00), and this effect existed irrespective 
of whether the preference was for exercise, CBT, or both (Table 2).  Positivity about receiving 
either exercise (2.66; 1.95-3.62) or CBT (3.20; 2.15-4.76) was associated with an increase in the 
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likelihood of randomisation, although no such effect was observed with participant expectations 
of outcome, for either treatment (Table 2). 
 
Five factors were found to be independently associated with randomisation: age, positivity about 
exercise, positivity about CBT, more severe/disabling Chronic Pain Grade, and taking regular 
exercise.  Weighting the analysis by the inverse of the likelihood of randomisation (essentially, 
simulating the effect of all eligible non-participants actually being randomised) resulted in slight 
difference in the treatment effect estimates at both six and nine months.  For the single therapies, 
at six months, the weighted model resulted in an 11% decrease in the magnitude of treatment 
effect for CBT (from an odds ratio of 6.45; 2.42-17.2 to 5.72; 1.92-17.0) and a 25% decrease in the 
treatment effect associated with exercise (from 7.28; 2.79-19.0 to 5.49; 1.89-16.0).  In contrast, 
the weighted model gave a 16% increase in the estimate of treatment effect of the combined 
therapy (Table 3).  The same pattern was true at nine months, although the magnitude of the 
changes in effect estimates was less (5% decrease, 11% decrease and 19% increase, respectively).  
For CBT, the weighted model produced no change in the number needed to treat.  However, for 
exercise, there was an increase in the NNT from 4 to 5, for improvement at six months, and from 
7 to 8 for improvement at nine months.  For the combined therapy, NNT fell from 5 to 4 for 




In the context of a large randomised controlled trial examining the effectiveness of exercise 
therapy and CBT for chronic widespread musculoskeletal pain, we have shown that individuals who 
were randomised were different, in a number of ways, from the entire eligible patient population 
that was originally identified.  Randomised individuals had a higher BMI, and more severe and / or 
disabling pain.  They were also more likely to have a treatment preference, for either or both of 
available trial treatments, and be more positive about receiving either of the treatments available 
in the trial.  We have demonstrated that this selection bias resulted in a change in treatment 
effect estimation, and in the associated NNT, although the changes noted were modest.  
 
The design of the MUSICIAN study and, specifically, the opportunity to collect a large amount of 
data on individuals who were eligible to participate in the trial, but who were not ultimately 
randomised, allowed an assessment of potential selection bias which is rare in trials.  This 
notwithstanding, there are a number of methodological issues to discuss, in interpreting these 
findings. The first issue is the timing of data collection.  All predictors of randomisation were 
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collected by population survey typically 1-2 weeks prior to randomisation.  Although this has the 
advantage that participants completed these questions naïve to their eligibility for the trial, it 
may be that participants report different treatment preferences, positivity and expectations in 
what they believe to be a hypothetical situation, than they would if actually faced with the 
possibility of receiving either therapy. Secondly, only one-third of the survey questionnaires were 
returned.  Population survey questionnaire response rates are falling over time [8] and 
participation rates of 33% are not uncommon.  The current study aimed to determine whether 
trial participants were different from eligible nut non-randomised participants.  By definition, 
individuals who failed to complete the initial survey questionnaire were not eligible for the trial.  
This study looked at how refusal to participate after the identification of eligible patients affected 
representativeness; a separate source of selection bias (not under examination in the current 
study) comes from not being able to identify eligible patients in the first place.  Although the 
prevalence of chronic widespread pain in the current study was very similar to other large 
population studies [13], we know that responders / non-responders differ with respect to age and 
gender.  The differences were 24% and 8.0% respectively, with older individuals and women 
significantly more likely to respond than other individuals, and among all respondents, these 
individuals were also significantly more likely to be randomised.  This illustrates further that trial 
participants are different from the wider eligible patient population and would suggest that, if 
anything, we have underestimated these differences. 
 
Our findings concur with other studies which have shown that trial participants differ from the 
wider eligible population in a number of ways.  That participants with severe and / or disabling 
pain were more likely to be randomised is perhaps no surprise.  These individuals may be more 
willing than other participants to try novel or hard-to-access treatments.  It is also plausible that 
those with a higher BMI may have been more willing to enter the trial, in order to benefit 
(potentially) from the exercise therapy.  What is particularly pertinent, however, is not why 
randomised / non-randomised participants are different, but the fact they are different with 
respect to a number of important prognostic markers. 
 
Our findings also show that eligible individuals with a preference for one or both of the 
investigative treatments in the MUSICIAN trial were more likely to be randomised than those no 
preference.  This is likely to be at least partially explained by the nature of the interventions 
offered in the MUSICIAN trial.  In the UK, neither prescribed exercise (including free gym 
membership for six months, and complimentary access to a fitness instructor) nor CBT are 
routinely available for chronic widespread pain in primary care.  Previous trials have reported that 
a strong treatment preference was a key reason for refusing randomisation [7,11,17,19] and this 
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also has important implications for the generalisability of findings.  A recent meta-analysis of 
eleven musculoskeletal trials found that, among participants, treatment preference was an 
important determinant of outcome [16]. 
 
We have also shown that the factors that influence whether a potential participant is likely to be 
randomised into a trial also influence trial outcome.  Re-computing the main trial analysis, to 
adjust for the fact that the randomised participants are different from the total eligible patient 
population, gave intriguing findings.  For the single therapies, our weighted model resulted in a 
decrease in treatment effect, suggesting that any selection bias (in the original analysis) acted to 
overestimate treatment effects.  Whereas, for combined therapy, the opposite was true, 
suggesting that any selection bias led to an underestimate of the effect of treatment.  In the 
context of the current trial, where the treatment effect sizes were large (ORrange: 6.45 to 7.28 at 
six months, and 3.41 to 5.57 at nine months) an over- or under-estimate of the magnitude observed 
in the current study makes little difference to the overall conclusions of the trial.  However, many 
trials have smaller effect sizes and, while it is impossible to predict what the results would be, 
over- / under-estimates of between 10 and 24% may have important implications in interpretation 
of trial findings.  As in the current study, even minor changes in effect size, may result in changes 
in NNT, and this may have potentially important implications for estimates of the cost-
effectiveness of treatments.  In the original MUSICIAN trial for the primary outcome [13] exercise 
was not cost effective, and the cost effectiveness of CBT was marginal.  In this context, even 
minor errors in estimation of effect measures are important.  
 
In summary, the status of randomised controlled trials as the gold standard method for 
determining the effectiveness of healthcare interventions is based upon their inherent internal 
validity and the ability to control potential confounding variables, but they are commonly 
conducted on highly selected patient groups.  Their real world value, therefore, depends on the 
assumption that these patient groups adequately represent the entire eligible patient population, 
yet rarely is information available to test this assumption.  Capitalising on a unique opportunity 
to collect data on a wider eligible population we have shown, firstly, that trial participants differ 
not only in terms of clinical variables, but also in terms of treatment preference; and, secondly, 
that the factors associated with trial participation also influence trial outcome.  This has important 
implications for trials generally and emphasises that, where possible, collecting information on 
eligible but non-randomised patients allows a better estimate of treatment effectiveness.  
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Figures and Tables 
Figure 1: Flow of participants in the study 
 
        
Sent questionnaire 
n = 45,994 
    
            
            
                  
                  
    
Questionnaire returned 
completed 
n = 15,313 (33.3%) 
  Questionnaire not returned, 
returned blank, or not 
useable1 
n = 30,681 
      
      
                  
                  
Eligible for randomisation 
(met inclusion criteria)2 
n = 884 (5.8%) 
  Did not meet trial inclusion 
criteria 
n = 14,429 
    
      
      
                  
        Total invited, but not randomised n = 442 
        – Unable to contact n = 51 
        – Deceased n = 1 
Invited, and randomised 
n = 442 (50%) 
  – Refused to participate n = 256 
  – Did not attend appointment n = 40 
  – Identified as not eligible3 n = 94 
  
1 Includes one (eligible) person who returned a questionnaire but died before being invited. 
2 
Includes six people marked as not eligible, but invited due to error, one of whom was 
subsequently randomised. 
3 
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Table 1:  Differences in demographics and health, between eligible survey participants who were / were not randomised 
 
  Randomised Odds ratio (95%CI) 
  Yes No Crude Age adjusted 
Age (years) 25-40 61 64 1.00 – 
 41-60 197 134 1.54 (1.02-2.33) – 
 >60 184 147 1.31 (0.87-1.98) – 
Gender Male 135 120 1.00 1.00 
 Female 307 225 1.21 (0.90-1.64) 1.23 (0.91-1.66) 
Self-rated health Excellent 7 10 1.00 1.00 
 Very good 76 63 1.72 (0.62-4.79) 1.70 (0.61-5.47) 
 Good 210 158 1.90 (0.71-5.10) 1.84 (0.68-4.96) 
 Fair 127 96 1.89 (0.69-5.15) 1.82 (0.66-4.98) 
 Poor 20 16 1.79 (0.55-5.74) 1.71 (0.53-5.54) 
BMI (kgm-2) ≤20 
15 
 
15 1.00 1.00 
 20.1-25.0 133 119 1.13 (0.53-2.40) 1.10 (0.51-2.36) 
 25.1-30.0 157 128 1.23 (0.58-2.60) 1.16 (0.54-2.49) 
 30.1-35.0 74 53 1.40 (0.63-3.10) 1.30 (0.58-2.91) 
 >35.0 62 31 2.00 (0.87-4.61) 1.99 (0.85-4.61) 
Smoking status Never 219 161 1.00 1.00 
 Ex-smoker 154 111 1.02 (0.74-1.40) 1.02 (0.74-1.40) 
 Current smoker 63 67 0.69 (0.46-1.03) 0.70 (0.47-1.05) 
Regular exercise1 None 84 82 1.00 1.00 
 1-2 times per week 177 113 1.53 (1.04-2.25) 1.55 (1.05-2.28) 
 3-4 times per week 100 75 1.30 (0.85-1.99) 1.33 (0.86-2.04) 
 ≥5 times per week 79 72 1.07 (0.69-1.66) 1.08 (0.69-1.69) 
Chronic Pain Grade2 I 86 100 1.00 1.00 
 II 152 117 1.51 (1.04-2.20) 1.53 (1.05-2.23) 
 III 85 53 1.86 (1.19-2.92) 1.90 (1.21-2.99) 
 IV 86 53 1.89 (1.21-2.95) 1.90 (1.21-2.97) 
1 Number of times per week doing 30minutes of moderate physical activity or walking that increased the heart rate or increased breathing. 
2 Due to trial eligibility criteria, there were no participants with a Chronic Pain Grade = 0. 
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Table 2:  Differences in treatment preference and expectation, between eligible survey participants who were / were not 
randomised 
 
  Randomised Odds ratio (95%CI) 
  Yes No Crude Age adjusted 
Treatment preference No1 68 95 1.00 1.00 
 Yes 362 245 2.06 (1.45-2.93) 2.11 (1.48-3.00) 
Treatment preference None1 68 95 1.00 1.00 
 Exercise 170 151 1.57 (1.07-2.30) 1.60 (1.09-2.34) 
 CBT 27 16 2.36 (1.18-4.71) 2.38 (1.18-4.76) 
 Both treatments 165 78 2.96 (1.96-4.46) 2.10 (2.04-4.70) 
Expectations of 
exercise2 
Improve 347 236 1.00 1.00 
 No change 58 64 1.62 (1.10-2.40) 1.67 (1.12-2.48) 
 Worsen 21 17 1.36 (0.66-2.83) 1.34 (0.64-2.79) 
Expectations of CBT2 Improve 228 129 1.00 1.00 
 No change 175 168 1.70 (1.25-2.30) 1.74 (1.28-2.37) 
 Worsen 3 5 0.58 (0.14-2.45) 0.55 (0.13-2.33) 
Positivity re: 
exercise3,4 
Low 113 159 1.00 1.00 
 Moderate / High 325 182 2.51 (1.86-3.40) 2.66 (1.95-3.62) 
Positivity re: CBT3 Low 125 154 1.00 1.00 
 Moderate 165 116 1.75 (1.25-2.45) 1.85 (1.31-2.60) 
 High 141 60 2.90 (1.97-4.25) 3.20 (2.15-4.76) 
1 Includes participants with no preference, and those who responded ‘don’t know’. 
2 The imagined effect of six months of treatment, on participants’ chronic pain. 
3 How positive participants would be about receiving the treatment, one a 0-10 scale; divided into tertiles for analysis. 
4 Due to the skewed distribution of positivity regarding exercise, the moderate and high tertiles form one category. 
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Improvement1 at 6 months post 
randomisation 
Odds ratio (95%CI) [NNT] 
Improvement1 at 9 months post 
randomisation 











1.00 1.00 1.00 1.00 
CBT 
6.45 (2.42-
17.2)  [NNT=4] 
5.72 (1.92-17.0)  
[NNT= 4] 
5.57 (2.34-
13.3)  [NNT=5] 




19.0)  [NNT=4] 
5.49 (1.89-16.0)  
[NNT= 5] 
3.41 (1.42-
8.15)  [NNT=7] 
3.02 (1.18-7.76)  
[NNT= 8] 
CBT + Exercise 
6.76 (2.56-
17.8)  [NNT=4] 
7.86 (2.69-23.0)  
[NNT= 4] 
5.18 (2.19-
12.3)  [NNT=5] 
6.19 (2.41-15.9)  
[NNT= 4] 
1 
‘Much better’ or ‘very much better’ on patient global change score on how patients 
felt their health had changed since entering the trial, from 1 (‘very much worse’) to 
7 (‘very much better’). 
2 
Effect estimates and NNTs differ slightly from those in the original manuscript7 
because we have excluded individuals with missing values for variables used in the 
weighting calculation. 
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Objective: It is uncertain whether persons with chronic widespread pain (CWP) experience 
premature mortality. Using the largest study conducted, we determine whether such a 
relationship exists,  estimate its magnitude and establish what factors mediate any 
relationship. 
Methods: UK Biobank, a cohort study of 0.5 million people aged 40-69 years, recruited 
throughout Great Britain 2006-10. Participants reporting “pain all over the body” for >3 
months were compared with persons without chronic pain.. Information on death (with 
cause) was available until mid-2015. We incorporated these results in a meta-analysis with 
other published reports to calculate a pooled estimate of excess risk.. 
Results: 7130 participants reported CWP and they experienced excess mortality (Mortality 
Risk Ratio 2.43, 95% Confidence Interval 2.17, 2.72). Specific causes of death in excess were 
cancer (1.73adjusted age and sex; 1.46, 2.05); cardiovascular (3.24adjusted age and sex; 2.55, 4.11); 
respiratory (5.66adjusted age and sex; 4.00, 8.03); and other disease-related causes (4.04adjusted age 
and sex; 3.05, 5.34). Excess risk was substantially reduced after adjustment for low levels of 
physical activity, high body mass index (BMI), poor quality diet and smoking. In meta-
analysis, all studies showed significant excess all-cause ( combined estimate  1.59 (1.05, 
2.42)). cardiovascular and cancer mortality. 
Conclusions: Evidence is now clear that persons with CWP experience excess mortality. UK 
Biobank results considerably reduce uncertainty around the magnitude of excess risk, and 
are consistent with the excess being explained by adverse lifestyle factors, which could be 
targeted in the management of such patients. 





Persons with CWP, the characteristic symptom of fibromyalgia, have been reported to 
experience premature mortality. The original observation, in a UK study, found 30% excess 
mortality was explained primarily by increased cancer incidence and reduced survival [1,2]. 
A subsequent UK study, confirmed the 30% excess mortality, primarily from increased cancer 
and cardiovascular deaths [3]. 
Studies to identify the mediators of such a relationship have focussed on low levels of 
physical activity, since the specific cancers contributing to excess mortality (female breast, 
prostate and colon) have been linked to low physical activity [4,5]. It has been hypothesised 
that CWP may lead to low levels of physical activity and this was confirmed by a longitudinal 
study [6]. Further studies have suggested additional lifestyle mediators of excess mortality: 
overweight has been shown to predict CWP onset and persistence [7,8]; persons with CWP 
have been reported as more likely to smoke and women with CWP have been shown to have 
poorer quality diet [9].  
However not all studies conducted have found an excess mortality amongst persons with 
CWP. Meta-analyses have reported considerable heterogeneity which has been attributed to 
differences in study populations, follow-up time, pain phenotype, methods of analysis and 
use of confounding factors [10,11]. Currently there is considerable uncertainty as to whether 
there is an excess mortality risk. It is important to determine whether an excess risk exists 
and if so to quantify it, since there remains the potential, as part of managing patients with 
CWP or fibromyalgia, to modify the mediators of any excess risk.  
 
We therefore now report on the largest study to examine the relationship between chronic 
widespread pain and mortality experience, and with considerably more detailed information 
on potential mediators of any excess risk. Further we include these results in a meta-





Detailed methods used by UK Biobank have been published previously [12] and we provide 
only summary details of relevance to the current analysis. The study aimed to recruit around 
half a million persons aged 40-69 years who were registered with a general practitioner 
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within the NHS. Approximately 9.2 million invitations were issued, between 2006-10, to 
people living within 25 miles of one of 22 assessment centres throughout Great Britain.  
At the assessment centre, participants completed questionnaires including items on lifestyle 
and environment. Information on pain was collected by means of a touch screen 
questionnaire. Participants were asked “In the last month have you experienced any of the 
following that interfered with your usual activities?” If they answered positively, they were 
then provided with a list which included individual regional pain sites, or alternatively they 
could choose the response “pain all over the body”. Subjects who reported “pain all over 
the body” were not offered the option of choosing any further regional sites. Respondents 
were asked whether the reported pain had lasted at least three months and those with “pain 
all over the body” which had lasted three months were defined as having chronic widespread 
pain (CWP). Participants were identified on the Office for National Statistics (ONS) records. 
ONS collects information on cause of death from civil registration records. For registered 
deaths, the underlying cause of death is derived from the sequence of conditions leading 
directly to the death and is recorded on the death certificate.  The current analysis uses 
data on vital status up to August 2015. 
The determinants or exposures which we considered in terms of mediating any relationship 
between CWP and mortality were focussed on factors potentially modifiable as part of the 
management of CWP:  
• age (in five-year groups) and sex,  
• body mass index (BMI), derived from measured height and weight, categorised 
according to standard cut-offs of the World Health Organisation. 
• physical activity: minutes of walking per week (“In a typical week, on how many days 
did you walk for at least 10mins  at a time” and “How many minutes did you usually 
spend walking on a typical day?”); minutes of moderate activity per week (“In a 
typical week, on how many days did you do 10mins or more of moderate physical 
activities like carrying light loads, cycling at a normal pace (do not include walking)”  
and “How many minutes did you usually spend doing moderate activities on a typical 
day ?” ); minutes of vigorous activity per week (as before but vigorous defined as 
“activities that make you sweat or breathe had such as fast cycling, aerobics, heavy 
lifting”. These were categorised as nil and then by quartiles. 
• Diet: Participants were asked (i) “On average how many heaped tablespoons of 
cooked vegetables would you eat per day?  (Do not include potatoes.)” (ii) “On 
average how many heaped tablespoons of salad or raw vegetables would you eat per 
day?  (Include lettuce and tomato in sandwiches)” (iii) “About how many pieces of 
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fresh fruit would you eat per day?” (iv) “About how many pieces of dried fruit would 
you eat per day?” Total daily “portions” of cooked vegetables, raw vegetables, salad 
consumption were calculated and re-coded as quintiles. Frequency of alcohol 
consumption was determined with response categories: Never; Daily or almost daily; 
Three or four times a week; Once or twice a week; One to three times a month; 
Special occasions only. The latter two categories were combined into “Less 
frequently than once or twice per week” 
• Smoking status; a history of smoking was recorded which allowed us to classify 
respondents as current , never (or very rare) or ex-smokers, the latter group being 
divided into ex-regular and ex-occasional smokers.   
 
UK Biobank Analysis 
We used Poisson regression models, with robust estimation of standard errors to model the 
relationship between CWP and all-cause mortality, adjusted for age-group and sex. We 
tested and confirmed that the mediating variables were not collinear. We compared persons 
with CWP to persons who did not report any chronic pain. We additionally examined specific 
major causes of death as outcomes including cardiovascular disease, respiratory disease and 
cancer. We report the MRiR including all deaths in the follow-up period, but exclude deaths 
in the first two years of follow-up from all subsequent analyses, since CWP may be a 
manifestation of an existing illness. Starting with a basic model containing CWP, age-group 
and sex, we added, individually, lifestyle factors or markers which could possibly mediate 
any observed relationship. We then added all such potential mediators to a final model.  
Associations are expressed as Mortality Risk Ratios (MRiR) with 95% Confidence Intervals (CI).  
 
Meta-analysis 
We used (in a modified way) and updated a search conducted by Smith et al [10] which 
identified studies examining the relationship between chronic pain and/or widespread pain 
and mortality.  Although their review focussed generally on chronic pain, our update 
focussed only on studies examining widespread pain or chronic widespread pain. A second 
difference is that although previous meta-analyses extracted effect measures which were 
maximally adjusted for potential confounding factors we have extracted data that is (as 
close as possible) only adjusted for age and sex. The difference is that we are answering 
the question “Do persons with CWP experience excess mortality (in comparison to those 
without chronic pain)” whereas using fully-adjusted effect measures is answering the 
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question of whether the report of pain (per se) is associated with excess mortality. Thus the 
data on effect on measures extracted from studies which they identified as eligible, may be 
different.  
We re-ran the published search strategy (in Appendix S1 of the original meta-analysis) from 
January 2014 (in order to ensure that articles published close to the time of the previous 
search were not missed) to January 2017.  
Studies were eligible for the current meta-analysis provided that they: 
• Were observational studies 
• Sampled from a population sampling frame (or an approximation to such) 
• Identified persons with widespread pain (WP) or chronic widespread pain (including 
fibromyalgia) and a comparison group of persons without such pain. The definition 
of widespread pain should involve recognised criteria or the reporting of pain all over 
the body. 
• Provided either a Mortality Rate Ratio (MRtR) or Mortality Risk Ratio (MRiR) 
quantifying the relationship between WP or CWP and mortality 
• Were published as a manuscript in English in a peer-reviewed journal 
Identified abstracts were screened by two authors and any disagreement resolved by 
discussion.  We also checked studies included in the meta-analysis by Smith et al [10] to 
determine that they met the above eligibility criteria. Meta-analysis was conducted using a 
random effects model, to reflect known differences in studies including geographical 
location, phenotypes and follow-up.  The effect measures extracted from the eligible 
studies (MRrR or MRiR) were as closely as possible only adjusted for age and sex. In the 
meta-analysis, conducted using RevMan software, MRR has been used to signify the 
combined estimates using MRtR and MRiR. Sources of heterogeneity in effect measures were 
explored, specifically in relation to the geographical area in which the study was conducted 





From 502,627 UK Biobank participants, 2193 (0.4%) did not answer the pain questions and 
are therefore excluded from this analysis. Amongst the remaining 500,434 persons, 7130 
reported CWP (prevalence 1.4%) while 281,718 reported that they did not have  any chronic 
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pain. These two sub-cohorts are the study population for the current analysis and their 
characteristics are shown in Table 1.  The CWP and the “no chronic pain” groups had the 
same median age (58 years). Persons with CWP were less likely to be male (36.3% v. 50%); 
were more likely to be heavier than normal weight (80.4% v. 63.5%), be a current smoker 
(18.6% v. 9.3%) and not to drink any alcohol (22.7% v. 6.7%). They also undertook physical 
activity less often,  In total there were 12,799 deaths in the study population within the 
period of observation: 7486 (58%) classified as being due to cancer, 2691 (21%) 
cardiovascular disease, 728 (6%) respiratory disease, 436 (3%) due to external causes, and 
1458 (11%) were classified as 'other’. 
 
After adjusting for age and sex, participants with CWP had a more than two fold risk of 
dying in the follow-up period (MRiR 2.56, 95% CI (2.32,2.82)), an excess which remained 
largely unchanged when deaths occurring in the first two years of follow-up were excluded 
(2.43; 2.17, 2.72). Deaths occurring in the first two years are excluded from all further 
analyses. Specific causes of death in excess were cancer (1.73 adjusted age and sex; 1.46, 2.05); 
cardiovascular (3.24 adjusted age and sex; 2.55, 4.11); respiratory (5.66 adjusted age and sex; 4.00, 8.03); 
and other disease-related causes (4.04 adjusted age and sex; 3.05, 5.34), while the excess of deaths 
from external causes was not statistically significant (1.55 adjusted age and sex; 0.68, 3.49). 
 
We then examined to what extent the factors which were identified as being associated 
with pain status, also predicted death in the period of follow-up (Table 2). Age-adjusted 
risk of death was lower in women (MRiR 0.58 (0.56, 0.60). Age and gender adjusted risk was 
higher in obese participants (35-39 kgm-2 v. normal weight 5.54  (5.08, 6.03), ≥40kgm
-2 9.02 
(8.23, 9.89) those who reported no walking (v. 1-100 mins/week: 4.15 (3.77, 4.57) or no 
moderate physical activity (v. 1-60 mins/week: 2.95 (2.74, 3.19). Risk of death was also 
higher in smokers (current smokers  2.54 (2.39, 2.70), ex-smokers 1.44 (1.36, 1.52)), and 
persons who reported never drinking alcohol (v. daily drinkers 6.18 (5.68, 6.73).  
 
Finally, we tested to what extent adjusting the risk models for these measured lifestyle 
variables attenuated the relationship between CWP and excess mortality (Table 3). Such 
attenuation would be consistent with the effects being mediated through such variable(s). 
When we did this, each class of variable (physical activity, BMI, smoking, diet including 
alcohol) when added to the model containing only pain status (CWP/no chronic pain), age-
group and sex resulted in a small attenuation of effect from a MRiR of 2.4 to MiRRs in the 
range 2.0 to 2.2. However, when all such potentially mediating variables were entered in 
to the model the MiRR reduced to 1.47 (1.24, 1.73). In cause-of-death specific models with 
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potential mediating variables there remained an excess risk of cardiovascular 1.99 (1.41, 
2.80), respiratory 1.91 (1.08, 3.36) and “other disease” deaths 2.14 (1.42, 3.21) but the 
there was no longer an excess risk of cancer death 1.06  (0.82, 1.38) and external deaths 
1.01 (0.30, 3.40). 
 
Meta-analysis 
Our search identified 3171 unique publications, of which 15 proceeded to abstract screening 
and one to full-text screening and subsequent inclusion [12]. Of the five studies included in 
the meta-analysis of Smith et al [10], one did not meet eligibility criteria for the current 
meta-analysis [13], since the pain phenotype did not include any measure of 
“widespreadness”. Instead the phenotype examined was multiple joint pain. Thus a total of 
six studies (including the current analysis) were eligible for the current meta-analysis 
[1,3,12,14,15]. Characteristics of studies identified as eligible are given in Table 4. One 
study presented data only to one decimal place and thus in the meta-analysis was identified 
as having a non-symmetrical log-transformed confidence interval [3]. We therefore 
contacted the first author of the publication and they provided more precise data (for 
analyses only adjusted for age and sex).  Eligible studies included 580, 020 participants from 
three European countries (Norway, Sweden and the United Kingdom). There was significant 
heterogeneity between studies: I2 = 98% for all-cause mortality, 95% for cardiovascular, 96% 
for respiratory and 91% for cancer (all p<0.001). All studies showed significant excess of all-
cause mortality and the combined estimate of this was 57% (MRR 1.57; 1.06, 2.33). For 
cardiovascular mortality, three out of five studies showed a significant association and the 
combined estimate of this was 63% (1.63; 0.98, 2.70). For respiratory mortality, only one 
out of three studies showed a significant excess mortality and there was considerable 
uncertainty around the pooled estimate of excess risk (1.70; 0.45, 6.45). For cancer, three 
out of five studies showed significant excess mortality and the pooled estimate was 51% 
(1.51; 1.06, 2.13) (Figure 1). 
We investigated the source of heterogeneity with respect to the relationship between CWP 
and all-cause mortality. When restricted by geographical area, the meta-analysis showed 
that considerable heterogeneity was present in studies conducted in Great Britain 
(I2=90%)(MRR 1.60; 1.06,2.42) but not in in studies conducted in Scandinavia (I2=0%) (MRR 
1.06; 1.02,1.10). Similarly when analysis was restricted to those studies with prevalence of 
CWP in the 10-20% mid-range i.e. excluding those with the extreme prevalence estimates,  
there was no evidence of heterogeneity (I2=0%)(MRR 1.30, 1.07-1.58). 
 
Discussion 




Using data from UK Biobank, involving over half a million study participants, we have 
demonstrated that persons with CWP have an important excess of risk of dying in the 
medium and long-term. This excess risk was evident across all disease and non-disease 
categories. The meta-analysis of this relationship, shows that all six studies conducted find 
excess mortality, and estimates the excess risk across all studies at 59%, although there is 
significant heterogeneity. Similar excesses of cancer and cardiovascular mortality are 
observed. In UK Biobank, adjustment for lifestyle factors substantially reduced the excess 
risk and this observation is consistent with them mediating the relationship between CWP 
and mortality   
 
Methodological issues 
The main strengths of UK Biobank in addressing this question   include that it uses a  sampling 
frame  which is considered to have almost complete population coverage10. Although the 
participation rate was low (5.5%), we have previously published an analysis which 
demonstrates that the prevalence of regional pains in UK Biobank is very similar to more 
traditional pain epidemiological studies with higher participation, and that the study 
reproduces known relationships with aetiological factors. The large sample has allowed us 
to examine specific causes of death, to exclude deaths within two years of the assessment 
(since widespread pain may be a manifestation of a disease linked to death e.g. metastatic 
cancer) and consider the role of mediating factors. 
The phenotype used in studies which have examined the relationship with mortality has 
varied considerably. They have included WP according to the definition within the American 
College of Rheumatology (ACR) criteria (1990) for fibromyalgia [1,3], and modifications of 
the ACR 1990 FM criteria in terms of pain timing and distribution [12,15] or bespoke 
definitions to capture “widespreadness” [14]. The comparison populations also differ: 
persons who are free of pain [1,3,14], free of chronic pain [15] or who simply do not meet 
the phenotype [12] are variously used.  Some studies had an additional criterion that WP 
required to be chronic, although studies of widespread pain have shown that the vast 
majority of persons with WP report chronic symptoms (81% in UK Biobank).   These have 
resulted in prevalence proportions within population-based studies of between 1.4-23.1% 
and suggest important differences in the symptomatic populations studied. Interestingly the 
study with the highest prevalence [12] reported a markedly lower excess risk of mortality.  
 
10 http://www.adls.ac.uk/department-of-health/gp-patient-register-dataset/?detail  
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UK Biobank has used the most stringent definition, which has resulted in a prevalence similar 
to that of fibromyalgia [16], and across all-cause and disease-specific mortality reports some 
of the highest excess mortality. This is consistent with the hypothesis that the greatest 
excess mortality is amongst those with the more severe symptoms. Sensitivity analyses 
confirmed that heterogeneity in risk estimates was indeed partly explained by differences 
in prevalence, as well by geographical area.   
We have approached the analysis in a different way to some previous studies on this topic. 
We adjusted for the confounding factors of age and sex. Given that the question we are 
asking is “Do patients with CWP experience prematurely mortality?” we believed that no 
further adjustment should be made.  However when excess mortality is observed it is of 
relevance to examine mediators – since these can become targets for intervention. Previous 
studies have identified lack of physical activity and poor quality diet as the variables which 
may explain a relationship. UK Biobank has a rich source of data to allow the assessment of 
these potential mediators. They nevertheless represent markers of these lifestyle factors 
rather than comprehensive assessments. Despite this, adjustment for these lifestyle markers 
almost completely explained cancer and “non-disease” excess mortality and explained 56% 
, 80% and 62% of the excess mortality for cardiovascular, respiratory and “other-disease”, 
respectively.  
 
Comparison with other studies and coherence of evidence 
UK Biobank has provided results which are generally consistent with previously conducted 
studies. For cardiovascular mortality it has provided the largest estimate for excess 
mortality. It is the first study to suggest a relationship between CWP and excess mortality 
from respiratory disease. 
The meta-analysis of Smith et al [10] conducted on this topic chose to extract the most 
fully-adjusted model available in included studies which means that this examines a subtly 
different question of whether pain directly increases mortality risk (independent of any 
lifestyle, psychosocial or clinical factors)11. We believe that the most clinically relevant 
question for clinicians managing patients with WP/CWP or fibromyalgia is what factors can 
be modified which could reduce any excess mortality which such patients experience. We 
also excluded one study included in the previous meta-analysis. The study of Macfarlane et 
al [13] was not eligible for this analysis as it examined the mortality consequences of multi-
 
11 We note that the data included in the Smith et al [10] meta-analysis for the study of McBeth et al [3], do not 
correspond to the data in the original manuscript.   
76 | P a g e  
 
 
joint pain (at least 4 joints). There was no requirement for pain to be widespread. All 
included studies had some requirement for the pain to be widespread or for the participant 
to endorse that the pain was all over their body. Even if the study of Macfarlane et al [13], 
which did not find any excess mortality MRiR (0.86; 0.74,1.01), had been included in the 
meta-analysis, the combined estimate would still have suggested an important excess. 
Exclusion of a phenotype that excludes a measure of “widespreadness” is supported by a 
proposed modification to the 2011 research criteria for fibromyalgia which requires that 
multi-site pain is also widespread across the body [17]. The meta-analysis of Åsberg et al 
[18] concluded that “pooled data gave no evidence for a higher mortality rate among 
individuals with chronic widespread musculoskeletal complaints”. This put emphasis on a 
pooled unadjusted MRR of 1.69 which was not statistically significant, and a markedly 
reduced excess  (MRR 1.13) after full adjustment. The inclusion of UK Biobank, considering 
age- and sex- adjusted risks, has provided a similar pooled estimate of excess risk (MRR 
1.59) and is now statistically significant.  
 
We conclude that the evidence is now clear that persons with CWP experience excess 
mortality. UK Biobank results considerably reduce uncertainty around the magnitude excess 
risk, demonstrate that the risk is unlikely to be due to the experience of pain per se, but is 
substantially explained by lifestyle factors associated with having pain (poor diet, low levels 
of physical activity, smoking, high BMI). These provide important targets for intervention in 
managing patients with CWP. Optimal management of fibromyalgia should include exercise, 
but this is often not provided in a structured and supported way to facilitate long-term 
behaviour change. Few patients with CWP or fibromyalgia receive specific supported care 
in improving diet or stopping smoking. The data from this study shows that changing the 
habits of persons with CWP to be similar to persons without CWP could reduce mortality by 
around 35%. Such approaches should have high priority in the routine care of such patients.  
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Figure 1: Forest plots of pain and all-cause and disease specific mortality 
 




b) Cardiovascular mortality 
 
 
Study MRR Lower CI Upper CI Weight 
 Macfarlane et al, 2001 1.31 1.05 1.64 18% 
Andersson, 2009 1.54 1.01 2.35 16% 
McBeth et al, 2009 1.28 1.05 1.57 18% 
Nitter and Forseth, 2012 2.80 1.29 6.07 11% 
Åsberg et al, 2016 1.06 1.02 1.10 19% 
Macfarlane et al, 2017 2.43 2.17 2.72 19% 
Pooled 1.57 1.06 2.33  
Study MRR Lower CI Upper CI Weight 
Macfarlane et al, 2001 1.12 0.78 1.61 20% 
Andersson, 2009 2.17 1.12 4.21 16% 
McBeth et al, 2009 1.49 1.12 1.98 21% 
Åsberg et al, 2016 1.05 0.99 1.11 22% 
Macfarlane et al, 2017 3.24 2.55 4.11 21% 
Pooled 1.63 0.98 2.70  
 








Study MRR Lower CI Upper CI Weight 
Macfarlane et al, 2001 1.01 0.57 1.79 33% 
McBeth et al, 2009 0.84 0.54 1.31 33% 
Macfarlane et al, 2017 5.66 3.99 8.02 34% 
Pooled 1.70 0.45 6.45  
Study MRR Lower CI Upper CI Weight 
Macfarlane et al, 2001 2.07 1.37 3.13 19% 
Andersson, 2009 1.15 0.52 2.55 11% 
McBeth et al, 2009 1.75 1.14 2.69 19% 
Åsberg et al, 2016 1.05 0.99 1.11 26% 
Macfarlane et al, 2017 1.73 1.46 2.05 25% 
Pooled 1.51 1.06 2.13  





Table 1: Characteristics of persons with CWP and no chronic pain in UK Biobank study 
Characteristic CWP 
(n= 7,130) 
No chronic pain 
(n=281,718 ) 
Died during follow-up (n, %) 405 (5.7%) 6,493 (2.3%) 
Died in first two years of follow-up (n,%) 95 (1.3%) 1,224 (0.4%) 
Age (median years, IQR) 58 (50, 63) 58 (52, 63) 
Sex (% male) 2,586 (36.3%) 135,186 (50.0%) 
Body Mass Index (kgm-2) 
- underweight (< 18.5) 
- normal (18.5-24.9) 
- overweight (25.0-29.9) 
- obese (30.0-34.9) 
- obese (35.0-39.9) 















Physical Activity (mean mins/week; sd): 
- walking 
- moderate activity 









Physical Activity (climbing stairs per day) 
- None 
- 1-5 times 
- 6-10 times 
- 11-15 times 
- 16-20 times 















Smoking status (n,%) 
- current smoker 
- ex-regular smoker 
- ex-occasional smoker 











Diet: fruit and vegetable consumption 
(median portions/day, IQR) 
 
8 (5, 11) 
 
7 (5, 10) 
Alcohol consumption (n, %) 
- daily or almost daily 
- 3-4 times/week 
- 1-2 times/week 
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Table 2: Relationship between demographic and lifestyle factors and risk of death 























2.43 (2.17, 2.72) 
Reference 
 
1.47 (1.24, 1.73) 
Reference 























1.60 (1.37, 1.87) 
2.50 (2.17, 2.89) 
3.80 (3.32, 4.36) 
5.61 (4.92, 6.39) 




1.60 (1.25, 2.07) 
2.46 (1.95, 3.11) 
3.61 (2.90, 4.51) 
5.59 (4.51, 6.92) 












0.58 (0.56, 0.60) 
 
Reference 
0.59 (0.55, 0.63) 
Body Mass Index (kgm-2) 
- underweight (< 
18.5) 
- normal (18.5-24.9) 
- overweight (25.0-
29.9) 
- obese (30.0-34.9) 
- obese (35.0-39.9) 
















1.86 (1.40, 2.50) 
Reference 
1.70 (1.59, 1.82) 
3.20 (2.98, 3.43) 
5.54 (5.08, 6.03) 
9.02 (8.23, 9.89) 
 
2.73 (2.07, 3.60) 
Reference 
0.93 (0.86, 1.01) 
1.11 (1.01, 1.22) 
1.35 (1.16, 1.58) 
1.94 (1.59, 2.36) 












































4.15 (3.77, 4.57) 
Reference 
0.73 (0.68, 0.79) 
0.64 (0.59, 0.69) 
0.85 (0.79, 0.92) 
 
 
2.95 (2.74, 3.19) 
Reference 
0.91 (0.83, 0.99) 
0.87 (0.79, 0.95) 
1.30 (1.20, 1.42) 
 
 
1.19 (0.99, 1.43) 
Reference 
0.98 (0.90, 1.07) 
0.92 (0.83, 1.01) 
0.89 (0.79, 0.99) 
 
 
1.14 (1.02, 1.27) 
Reference 
0.99 (0.90, 1.10) 
0.98 (0.88, 1.10) 
1.09 (0.97, 1.22) 
 
12 Adjusted for age and/or sex as applicable and excluding first two years of follow-up 
13 All variables entered in to the statistical model and mutually adjusted 
14 Deaths within two years of the baseline assessment are excluded  
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0.37 (0.34, 0.40) 
0.30 (0.28, 0.33) 
0.27 (0.24, 0.30) 
0.43 (0.39, 0.47) 
 
 
1.29 (1.20, 1.38) 
Reference 
0.43 (0.41, 0.46) 
0.33 (0.30,0.36) 
0.37 (0.33, 0.41) 




0.77 (0.69, 0.85) 
0.78 (0.70, 0.87) 
0.76 (0.68, 0.85) 
0.79 (0.70, 0.89) 
 
 
1.02 (0.91, 1.14) 
Reference 
0.83 (0.76, 0.91) 
0.86 (0.77, 0.95) 
0.69 (0.60, 0.80) 
0.92 (0.80, 1.07) 
Smoking status 
- current smoker 
- ex-regular smoker 
- ex-occasional 
smoker 












2.54 (2.39, 2.70) 





2.31 (2.10, 2.54) 
1.55 (1.43, 1.67) 
1.09 (0.97, 1.22) 
Reference 
Alcohol consumption 
- daily or almost daily 
- 3-4 times/week 
- 1-2 times/week 
















0.96 (0.87, 1.06) 
1.57 (1.44, 1.72) 
3.08 (2.84, 3.34) 
6.18 (5.68, 6.73) 
 
Reference 
0.92 (0.84, 1.02) 
0.97 (0.88, 1.07) 
1.08 (0.98, 1.20) 
1.49 (1.32, 
1.69)) 
Diet: fruit and vegetable 
consumption 
- Lowest consumption 
- Quintile 2 
- Quintile 3 
- Quintile 4 


















0.74 (0.69, 0.80) 
0.78 (0.71, 0.86) 
0.75 (0.69, 0.80) 




0.90 (0.82, 0.98) 
0.88 (0.78, 0.99) 
0.88 (0.80, 0.97) 
0.86 (0.77, 0.95) 
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Table 3: Relationship between pain status and risk of death, adjusting for potential 
mediating variables 
Variables added to basic 
model15 
Participants16 
included in model 
(N) 
MRR17 (95% Cl): 
CWP v. no 
chronic pain 
MRR (95% CI) CWP 
v. no chronic 
pain (participants 
with full data)18 
No additional variables 287,529 2.43 (2.17, 2.72) 2.23 (1.90, 2.62) 
+ Body Mass Index 
category19 
287,529 2.13 (1.90, 2.39) 1.98 (1.68, 2.33) 
+ Physical activity: 
walking 
253,579 2.09 (1.82, 2.40) 2.08 (1.76, 2.44) 
+ Physical activity: 
moderate 
249,309 2.23 (1.96, 2.54) 2.06 (1.75, 2.42) 
+ Physical activity: 
vigorous 
258,755 2.22 (1.97, 2.51) 2.01 (1.71, 2.36) 
+ Physical activity: stairs 283,221 2.12 (1.88, 2.38) 2.07 (1.76, 2.43) 
+ Smoking 286,590 2.16 (1.94, 2.42) 2.01 (1.71, 2.37) 
+ Diet: alcohol 
consumption 
287,320 2.21 (1.97, 2.47) 2.05 (1.74, 2.41) 
+ Diet: fruit and 
vegetables 
242,346 2.30 (2.02, 2.60) 2.21 (1.88, 2.60) 
Full multivariable model20 193,676 1.47 (1.24, 1.73) 1.47 (1.24, 1.73) 
 
 
15 Pain status (chronic widespread pain v. no chronic pain), age and sex are entered in all models 
16 Deaths occurring within two years of the baseline assessment are excluded  
17 Mortality Risk Ratio 
18 Restricted to 193,676 participants with data on all variables included in the full model 
19 Each line represents the basic model with the addition of the single variable stated 
20 All additional variables entered into model: age, sex, body mass index, physical activity (walking, moderate 
and vigorous activities, climbing stairs), diet (fruit and vegetable, alcohol consumption), smoking status 
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according to  
definition in 
ACR 1990 










with GP in 
22 areas 






































12.9% 89/2038 18 
 
21 There was no requirement to have pain on both sides of the body 
22 Current analysis 
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Background: Opioids have, at most, small benefits for non-cancer pain in the medium and 
long-term but there is good evidence that they cause harm. The current study describes the 
characteristics and clinical status of people taking regular opioids in Great Britain and 
determines whether use is associated with mortality risk. 
 
Methods; An analysis of participants in UK Biobank, a prospective population-based study. 
At recruitment (2006-10) participants reported medicines which they regularly used in 
addition to lifestyle and health-related factors. Information was available on deaths until 
October 2016.  
 
Findings: There were 466 486 participants (54% women) aged 40-69 years and without a prior 
history of cancer of whom 5.5% were regularly using opioids. Use increased with age-group, 
was more common in females (6.3% v. 4.6%) and 87% of persons using them reported chronic 
pain. The highest rates of use (~1 in 9) were in people with low household income, who left 
school <16 years and lived in areas with high deprivation.  Amongst 15032 people who could 
not work because of ill-health, 1 in 3 were regularly taking opioids.  Regular users reported 
insomnia (88.7%), a recent major recent life event (57.3%) and were much more likely than 
non-users to rate their health as poor (RR 5.5, 99% CI (4.9, 6.1)). Those taking weak (4.2% 
of participants) or strong (1.4%) opioids were more likely to die during follow-up (6.9% and 
9.1% respectively v. 3.3% in non-users) an excess which remained after adjustment for 
demographic, socio-economic, health and lifestyle factors (MRR 1.18 99% CI (1.06, 1.32) and 
1.20 99% CI (1.01, 1.43)) respectively. 
 
Interpretation: Regular use of opioids is common in Great Britain, particularly in groups of 
low socio-economic status. Most users still report chronic pain, poor health generally and 









Chronic pain is an important public health problem – around 2 in 10 of the general population 
sample reported persistent and intense pain in one pan-European study (1) while a meta-
analysis of epidemiological studies conducted world-wide found that 3 in 10 persons had 
chronic pain (2). The aetiology of chronic pain is multifactorial and complex, with onset of 
pain often in early adulthood. Long-term prospective studies demonstrate an increased risk 
related to adverse social environment in early life, as well as physically and emotionally 
traumatic events (3-6).  A review of factors which predict an episode of pain becoming 
chronic, and causing long-term disability, found the strongest evidence in relation to clinical 
factors (disabling, persistent and multi-site pain), older age, and mood (7). A consequence 
of chronic pain is an increased risk of death (8). Data from UK Biobank has shown, 
specifically,  that persons with chronic widespread pain (CWP) have a markedly increased 
risk of dying during follow-up (mortality risk ratio (MRR) 2.43, 99%CI 2.17 to 2.72), an excess 
risk that was partly explained by low levels of physical activity, high body mass index, poor 
quality diet and tobacco smoking (9). 
 
In managing chronic pain, although there will be differences in relation to specific 
diagnoses, both non-pharmacologic and pharmacologic approaches are generally important. 
Supported self-management is a cornerstone of common pain conditions from early in the 
course of symptoms through to long-term management. Non-pharmacologic approaches 
include physical activity, physical, behavioural and relaxation therapies and for conditions 
such as low back pain, pain and fibromyalgia, these will be the primary approaches to 
management (10,11). A wide range of analgesics have been used in the management of 
chronic pain – however a key recommendation from guidelines of management is regular 
review and stopping medications which are not effective (12). 
 
The World Health Organisation (WHO) analgesic ladder has provided a framework for the 
use of analgesics in patients with cancer pain (13). The approach recommends that 
analgesics used should initially be non-opioids, and then opioids, with the expectation that 
the strength and dose of opioids would increase as cancer progressed. Success in the use of 
this approach in cancer patients at the end-of-life has led to the same approach being used 
for patients with chronic non-cancer pain. The idea that increasing pain intensity 
necessitates stronger medicines in higher doses may hold well for cancer pain where disease 
burden is progressing. Using this approach more generally, for non-cancer pain, has had the 
consequence of a dramatic increase in the use of prescription opioids, most obviously in the 
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United States (14). It has also made evident the negative consequences of such widespread 
use. Reported pain intensity in chronic non-cancer pain has little to do with tissue damage 
and escalation of potent medicines is not justified (15). There is good evidence of an 
increased risk for serious harm (Including overdose, opioid misuse, fractures, myocardial 
infarction, and markers of sexual dysfunction)   At most they are likely to have only small 
benefits  (in terms of pain, function and quality of life) in the medium and long-term (16) - 
indeed a recent meta-analysis assessed their benefits as similar to non-opioid analgesics in 
the management of non-cancer chronic pain, although the evidence came primarily from 
low quality studies (16,17). 
 
The purpose of this analysis is therefore to describe the epidemiology of opioid use in Great 
Britain, the health and quality of life of people using them and to examine whether their 




This study report adheres to STROBE (Strengthening the Reporting of Observational Studies 
in Epidemiology) guidelines (18). 
 
UK Biobank recruited around half a million persons aged 40-69 years who were registered 
with a general practitioner within the National Health Service (NHS) (see reference 19 for 
detailed methods). Approximately 9.2 million invitations were issued, between 2006-10, to 
people living within 25 miles of one of 22 assessment centres across Great Britain. At the 
assessment centre, participants responded to questions, including on demography, social, 
health and lifestyle factors, by using a touchscreen. Indices of multiple deprivation (at the 
small area level) were used for England, Scotland and Wales to determine the quintile of 
deprivation of their residential area (within the country of residence). 
 
Pain and medications 
In terms of pain, participants were asked “In the last month have you experienced any of 
the following that interfered with your usual activities?” If they answered positively, they 
were then provided with a list which included seven individual regional pain sites, or 
alternatively they could choose the response “pain all over the body”. Respondents were 
asked whether the reported pain had lasted at least three months and those who reported 
this for at least one site (or pain all over the body) were categorised as having “chronic 
pain”. Participants were asked if they were taking regular prescription medication and if 
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so, in a nurse-led interview, were then asked what these were. Information was collected 
on regular treatments. It did not include short-term medications (such as a course of 
antibiotics) or prescribed medication that had not been taken. Interviewers chose the 
generic or trade name of the treatment from a list. Information on dose and formulation 
was not collected. For this analysis, the full list of treatments was searched for generic or 
trade names of opioids, including drugs listed in sub-paragraphs 4.7.1 (Non-Opioid Analgesics 
and Compound Preparations) and 4.7.2 (Opioid Analgesics) of the British National Formulary 
(BNF: https://www.bnf.org/products/bnf-online). Those that were not commonly 
prescribed for pain or did not appear in the BNF sub-paragraphs 4.7.1 and 4.7.2 were not 
coded as opioids. Treatments that contained an opioid listed in sub-paragraph 4.7.1 were 
classed as ‘Combination’ opioids. Other opioids were classed according to their chemical 
class (i.e. Codeine, Dihydrocodeine, etc.). Participants who took any opioid in the Tramadol, 
Morphine, Buprenorphine, Oxycodone, Fentanyl, or Hydromorphine categories were classed 
as taking a strong opioid. 
 
Vital status and causes of death 
For the purposes of collecting information on vital status, participants were identified on 
the Office for National Statistics (ONS) records. ONS collects information on cause of death 
from civil registration records. For registered deaths, the underlying cause of death is 
derived from the sequence of conditions leading directly to the death and is recorded on 
the death certificate.  The analysis uses the UK Biobank dataset provided to us in April 2019, 
which contains death information up to 31 October 2016. 
 
Statistical Analysis 
Descriptive analyses are reported for the use of prescription opioids by demography and 
social factors and in relation to pain status. In all analyses, persons who reported a previous 
diagnosis of cancer (other than non-melanoma skin cancer) were removed, as opioids may 
have been prescribed because of cancer pain in such persons. Relationships with use are 
described using modified Poisson regression with robust error variances (20) and are 
expressed as crude risk ratios (RR) and adjusted for (as indicated in specific models) age, 
gender, ethnicity, region, primary employment status, university degree, deprivation, 
income and pain status, namely, the number of body sites in which pain was reported or 
pain all over the body and whether pain had lasted more than three months (i.e. chronic 
pain). 
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In examining the relationship between opioid use and subsequent mortality, the proportion 
of persons who died during follow-up according to their regular use of opioids at the time 
of recruitment, is described. Poisson regression models, with robust estimation of standard 
errors were used to quantify the relationship expressed as Mortality Risk Ratios (MRR) with 
adjustment for pain status, socio-economic factors, and lifestyle factors shown previously 
to be potential mediators of the relationship between chronic pain and mortality. 
 
Role of the funding source 




There were 466486 persons who were recruited to UK Biobank who did not report a prior 
diagnosis of cancer (other than non-melanoma skin cancer) and these were eligible for the 
current analysis. Of these, 25864 reported regular use of opioid medication, which 
represents 5.5% of participants. There were striking associations with socio-demographic 
factors and use of such medications (see Table 1). Use increased with age-group and was 
more common in females than males (6.3% v. 4.6% adjusted for demographic, employment 
status, education level and economic factors RR 1.43(1.39-1.48)). There was little variation 
by ethnic group except that use of opioids was uncommon amongst persons of Chinese origin 
(1.7% adjusted RR 0.45 99% CI (0.27-0.74) in comparison to persons identifying as “white”). 
There were marked differences between areas of residence, from 2.8% in South-East England 
to 7.6% in the North-East of England (adjusted RR 1.75 99% CI (1.61-1.91)). The highest rates 
of reported use were found in persons with low household income (11.1% in those reporting 
annual household income of £18000), those who left school before 16 years (10.6%) and who 
lived in areas with the highest levels of deprivation (9.2%). Amongst the 15032 people who 
reported that they could not work because of ill-health 33.7% were regularly taking opioids. 
A total of 6419 persons (1.3%) reported regular use of strong opioids. Use of strong opioids 
also showed a strong relationship with area of residence, high levels of deprivation, low 
income and not working due to ill-health (supplementary table). 
 
The most common opioid reported was combined preparations, and thereafter codeine and 
dihydrocodeine. The most common strong opioids were tramadol then morphine and 
buprenorphine (Table 2). Of persons reporting taking regular opioids, 23731 (5.1%) reported 
using a single opioid, 1976 (0.4%) were taking two opioids and 157 (0.03%) were taking 3 or 
more. 




The vast majority (87.3%) of persons regularly taking opioids reported chronic pain: the 
likelihood of taking opioids increased with greater number of reported pain sites from 3.8% 
in those reporting one site up to 30.7% in those who reported 7 sites or “pain all over the 
body” RR (16.66 99% CI (15.42-17.99)) adjusted for age, gender, demographic factors, socio-
economic factors and primary employment (Table 3). When the relationship was examined 
by the reporting of pain at individual sites, with adjustment as above plus total number of 
pain sites reported, all individual pain sites, with the exception of facial pain, were 
associated with an excess risk of regular opioid use (data not shown).  The associations 
shown in Table 1 were not explained when adjusted for pain status (chronic pain and number 
of pain sites) although some were attenuated, most noticeably female gender (RR 1.23 95% 
CI (1.19-1.26)) and amongst those living in areas with the highest level of deprivation (RR 
1.50 95% CI (1.42-1.58)). 
 
The relationship of opioid use with health, lifestyle factors and life events is detailed in 
Table 4. After adjustment for potential confounding factors, persons rating their health as 
“poor” were considerably more likely to regularly take opioids compared to those rating 
their health as “excellent” (RR 5.44 99% CI (4.89-6.05) as were those reporting only minimal 
physical activity. Those reporting poor quality sleep (both less and more than the average 
of 7-8 hours, as well as usually suffering from insomnia (RR 1.56 99% CI (1.48-1.64)) and 
poorer mental health (i.e. reported having consulted a GP for “anxiety, nerves or 
depression” (RR 1.29 99% CI (1.25-1.34)) were also more likely to report regular opioid use. 
There was a “dose-risk” relationship between the number of adverse events in last two years 
and likelihood of using opioids such that those reporting at least four such events were over 
50% more likely to be taking opioids regularly (RR 1.55 99% CI (1.36-1.76)). 
 
The relationship between opioid consumption and mortality 
16432 persons died during follow-up. Of participants who at recruitment were not regularly 
taking opioids, 3.3% died during follow-up (428 per 100 000 person-years (py)); in comparison 
6.9% of those taking weak opioids (892 per 100 000 py) and 9.1% of those taking strong 
opioids died (1194 per 100 000py) (age and sex adjusted Mortality Risk Ratio (MRR) 1.86, 
99% CI (1.73, 2.00) and 2.59 99% CI (2.34, 2.88) respectively) (Table 5). Chronic pain was 
also related to excess mortality; for example, of persons who at recruitment reported “pain 
all over their body” or pain at all seven regional sites 6.8% died during follow-up in 
comparison to 3.2% of persons with no pain (MRR 2.29, 99% CI 2.06, 2.56). In addition 
lifestyle factors (physical activity, BMI, diet (including alcohol consumption and cigarette 
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smoking), socio-economic factors (years of education, income and level of deprivation of 
area of residence) and morbidities were also importantly linked with risk of mortality. When 
adjustment was  made for all these factors, there remained an association between regular 
opioid use at recruitment and risk of death over the following 6-10 years  (MRR weak opioids 
1.18 99% CI (1.06, 1.33)), strong opioids (MRR 1.20 99% CI (1.01, 1.43)). Of the deaths which 
occurred amongst persons using regular opioids 39% were cancer deaths (in comparison to 
53% in non-opioid users) , 28% were cardiovascular (v. 23%), 11% were respiratory (v. 6%), 




Regular use of opioids in UK Biobank participants was very strongly related to socio-
economic factors: around 1 in 10 people with the lowest level of incomes, those living areas 
with the highest levels of deprivation and who left education at a young age, reported 
regular opioid use, while this rose to 1 in 3 of persons reporting that they were unable to 
work due to ill-health. After adjusting for pain status and socio-economic factors, regularly 
taking opioids was associated with poorer physical and mental health and quality of life 
(such as sleep quality) and was associated with increased risk of death, even after 
additionally taking into account lifestyle factors and other morbidities. The increased risk 
of death was not primarily as a result of non-disease deaths.  
 
UK Biobank is a very large study, but the proportion of people invited who agreed to take 
part was low (just over 5%). There is evidence that those taking part are healthier than the 
general population: specifically they are less likely to be obese, to smoke, and to drink 
alcohol on a daily basis and they have fewer self-reported health conditions. Rates of all-
cause mortality have been shown at age 70-74 years to be 46% and 56% lower in men and 
women, respectively than the wider population (21). The valid assessment, however, of an 
exposure outcome relationship does not rely on a population being representative of the 
underlying population aged 40-69 years who were eligible to take part. Thus our estimate 
of the use of opioids in Great Britain, although high, is likely to be an underestimate. We 
have previously compared the prevalence of chronic pain in UK Biobank with other 
epidemiological studies which measured chronic pain, and shown, for example, that the 
estimates of prevalence of chronic pain and regional pain using UK Biobank were within 2% 
of the National Child Development Study (22).  The second methodological issue in 
examining factors associated with the use of opioids is the strong relationship with their use 
in chronic pain. We do not think that regular opioid use is a cause of chronic pain and so we 
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have adjusted for the presence of chronic pain and the number of pain sites. However, we 
do not have a measure of the severity of chronic pain and therefore there may be residual 
confounding e.g. if more severe pain was linked to greater interference with sleep and a 
greater likelihood of opioid use.  There is also limited information on opioids in this study. 
We are not aware of the dose of opioids or for how long they have been used at the time of 
recruitment, nor of changes over follow-up; neither is information available on non-
prescription (“over the counter”) opioid use. Thus, for example, we cannot examine 
whether the relationship with poor physical and mental health, for example, is related to 
dose. 
 
The factors associated with regular opioid use in this study (after adjustment for pain status) 
namely depression, anxiety and insomnia are recognised adverse effects of opioid use (23). 
The results do not necessarily mean that opioids themselves are leading to an increased risk 
of death. There could be unmeasured confounders of the relationship – if so, these factors 
need to be relatively common, be related to opioid use and be risk factors for premature 
death. Specifically, there could be confounding by indication, namely that persons are 
receiving opioids for unmeasured aspects of their clinical condition which are themselves 
related to an increased risk of death. Such a scenario may explain some or all of the 
association observed. The association of opioid use and misuse with premature death is well-
documented, although that typically has been related to non-disease related deaths 
(e.g.24). Non-disease related deaths were relatively uncommon in this analysis and not 
responsible for the excess mortality. Long term opioid use has been shown to relate to an 
increased risk of death  by a number of potential mechanisms including the very common 
finding of disruption of nocturnal respiratory control leading to both respiratory and 
cardiovascular morbidity (25,26).  Studies of opioids and cancer have primarily focussed on 
the use of opioids during cancer surgery and subsequent survival.  Two studies have reported 
a higher recurrence rate of breast and prostate cancers (27,28) although the only study of 
opioid use after surgery found no increased risk of recurrence in breast cancer patients (29). 
A recent study of approximately 90 000 persons, using electronic records within UK general 
practice, has however linked the initial prescription of tramadol, in patients over 50 years 
with osteoarthritis, to higher mortality rates over the subsequent year (hazard ratio 1.71 
95% CI (1.41,2.07) v. patients receiving nonsteroidal anti-inflammatory drugs) (30). 
 
We have previously published data from Scotland, using record linkage, which demonstrated 
a sizeable increase in the prescriptions for opioids across the ten-year period from 2003 
(31). This study showed that 18% of the population in Scotland had been prescribed an opioid 
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in the past year, much higher than the proportion reported in the current study (6.5% 
persons from Scotland reported regular opioid use). There are likely to be at least three 
reasons for the discrepancy: the current study is based on “regular use of medication” while 
the previous study was based on a record of at least one prescription; the selection effects 
in participating; and that we have excluded persons with a cancer diagnosis in this analysis. 
The large variations in regular use of opioids across GB in this study, replicate a recent study 
from England (32) which found that high prescribing was related to deprivation, large 
primary care list size and rurality. A further study, from one area of Scotland, which 
analysed prescribing of analgesics between 1995-2010 also found that persons living in 
deprived areas (as well as those receiving large numbers of non- analgesic drugs) were most 
likely to be prescribed a strong opioid (33). 
 
It is no surprise that users of opioids are likely to report chronic pain: we assume this is the 
reason for opioid use. However the data show high levels of continuing poor health among 
those using opioids including inability to work, poor physical and mental health, quality of 
life and poor sleep These findings accord with previous findings from a large epidemiological 
study in Denmark which noted that “opioid treatment of long-term/chronic non-cancer pain 
does not seem to fulfil any of the key outcome opioid treatment goals”. (34) 
 
Much evidence on the so-called “opioid epidemic” has come from the United States where 
the Center for Disease Control (CDC) has developed a guideline  to improve the way opioids 
are prescribed to “ensure patients have access to safer, more effective chronic pain 
treatment while reducing the number of people who misuse or overdose from these drugs” 
(35) and the Scottish Intercollegiate Guidelines Network (SIGN) have recently revised their 
guideline on managing chronic pain in order to update recommendations on opioids (12) . 
The latter suggest early review of patients newly prescribed opioid medication and at least 
annual review thereafter. This manuscript has demonstrated high levels of regular opioid 
use amongst people in the United Kingdom, particularly those in lower socio-economic 
groups.  Amongst users, chronic pain is still common, and a large proportion report poor 
physical and mental health, while the majority report sleep problems. This study adds to 
current evidence in showing that regular users also experience an increased risk of death 
(but not primarily as a result of non-disease deaths). It emphasises the need to take into 
account such potential harms and lack of benefit of regular opioid use in considering the 
long-term management of patients with pain. 
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Table 1 – Regular use of any opioid analgesics by social and demographic factors 
 
 
  Opioid Use 
No: n (%) 
Opioid Use 





40-45 48522 (96.6) 1705 (3.4) 1 [Ref] 
45-49 61043 (96.1) 2462 (3.9) 1.08 (1.00-1.17) 
50-54 68858 (95.4) 3357 (4.7) 1.15 (1.07-1.24) 
55-59 79942 (94.4) 4739 (5.6) 1.16 (1.08-1.24) 
60-64 103711 (93.7) 7020 (6.3) 1.17 (1.08-1.26) 
65-70 78546 (92.3) 6581 (7.7) 1.31 (1.20-1.42) 
Gender  
Male 206841 (95.4) 10057 (4.6) 1 [Ref] 
Female 233781 (93.7) 15807 (6.3) 1.43 (1.39-1.48) 
Ethnicity 
 
White 413507 (94.4) 24380 (5.6) 1 [Ref] 
Mixed 2632 (94.4) 155 (5.6) 1.07 (0.88-1.30) 
Asian or Asian British 9135 (95.3) 452 (4.7) 1.01 (0.89-1.13) 
Black or Black British 7275 (94.2) 448 (5.8) 1.17 (1.04-1.31) 
Chinese 1485 (98.3) 25 (1.7) 0.45 (0.27-0.74) 
Other ethnicity 4111 (94.3) 246 (5.7) 1.19 (1.01-1.39) 
Not known 2477 (94.0) 158 (6.0) 1.12 (0.92-1.37) 
Area of 
residence  
South East England 39283 (92.2) 1149 (2.8) 1 [Ref] 
London 61745 (96.9) 1975 (3.1) 0.83 (0.76-0.91) 
South West England 38136 (95.5) 1803 (4.5) 1.38 (1.25-1.51) 
East Midlands 29809 (94.8) 1634 (5.2) 1.30 (1.18-1.43) 
Yorkshire and 
Humberside 
65101 (94.1) 4056 (5.9) 1.46 (1.34-1.58) 
West Midlands 39129 (93.9) 2564 (6.1) 1.43 (1.31-1.57) 
Scotland 31321 (93.5) 2178 (6.5) 1.55 (1.42-1.70) 
North West England 68346 (93.2) 4973 (6.8) 1.51 (1.39-1.64) 
Wales 17784 (92.7) 1407 (7.3) 1.81 (1.64-2.00) 







<16 84320 (89.4) 10033 (10.6) 1.24 (1.19-1.29) 
16 92270 (93.9) 6041 (6.1) 1 [Ref] 
17 33972 (95.1) 1741 (4.9) 0.90 (0.84-0.96) 
18 35749 (96.1) 1440 (3.9) 0.81 (0.75-0.87) 
>18 38710 (96.0) 1619 (4.0) 0.80 (0.75-0.86) 
Not known 155601 (96.9) 4990 (3.1) 0.71 (0.68-0.75) 
Deprivation 
 
Lowest quintile 90127 (96.4) 3353 (3.6) 1 [Ref] 
2 88996 (95.8) 3899 (4.2) 1.10 (1.04-1.16) 
3 88556 (95.1) 4563 (4.9) 1.22 (1.16-1.29) 
4 87765 (94.2) 5420 (5.8) 1.41 (1.34-1.49) 
Highest quintile 84634 (90.8) 8597 (9.2) 1.75 (1.65-1.84) 
Not known 544 (94.4) 32 (95.6) 1.45 (0.93-2.25) 
Average 
Household 
Income (£)  
Less than 18000 78618 (88.9) 9820 (11.1) 1 [Ref] 
18000 to 30999 94514 (94.7) 5322 (5.3) 0.81 (0.78-0.85) 
31000 to 51999 100399 (96.7) 3447 (3.3) 0.69 (0.66-0.73) 
52000 to 100000 80166 (98.0) 1616 (2.0) 0.53 (0.49-0.57) 
 
23 Risk Ratio 
24 Adjusted for age, gender, ethnicity, region, age completed education, primary employment status, 
deprivation, and income  
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>100000 21481 (98.9) 240 (1.1) 0.34 (0.29-0.40) 
Not known 65444 (92.4) 5419 (7.6) 0.89 (0.85-0.93) 
Primary 
Employment  
Employed  264171 (97.1) 7952 (2.9) 1 [Ref] 
Retired 138296 (92.4) 11346 (7.6) 1.76 (1.67-1.85) 
Looking after home 12331 (94.9) 666 (5.1) 1.43 (1.29-1.58) 
Not working due to 
health 
9963 (66.3) 5069 (33.7) 6.62 (6.30-6.94) 
Unemployed 7475 (95.1) 383 (4.9) 1.23 (1.07-1.40) 
Unpaid work 2053 (95.5) 97 (4.5) 1.33 (1.03-1.72) 
Student 1241 (96.2) 49 (3.8) 1.11 (0.77-1.60) 













26 Combined = preparations listed in the BNF Sub-paragraph ‘Non-Opioid Analgesics and Compound Prep’, e.g. 
co-codamol, co-codaprin, etc. 




      
Opioid drug/preparation25 N % 
Weak Opioids   
Combined26 17065 3.7 
Codeine 2304 0.5 
Dihydrocodeine 1617 0.4 
Meptazinol 67 0.0 
Pethidine 24 0.0 
Dextropropoxyphene 1 0.0 
Strong Opioids   
Tramadol 5346 1.2 
Morphine 508 0.1 
Buprenorphine 349 0.1 
Oxycodone 220 0.0 
Fentanyl 233 0.0 
Hydromorphone 7 0.0 
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Table 4 Regular use of any opioid analgesic in relation to health status 
 
27 Risk Ratio 
28 Adjusted for age, gender, ethnicity, region, primary employment, age completed education, deprivation, and 
income 
  Opioid Use 
No, n (%) 
Opioid Use 
Yes, n (%) 
Adjusted RR27 28 
(99% CI) 
Chronic pain No 259318 
(98.8) 
3271 (1.2) 1 [Reference] 









1797 (1.0) 1 [Reference} 
 1 123042 
(96.2) 
4925 (3.8) 3.72 (3.47-4.00) 
 2 71910 (92.9) 5468 (7.1) 6.27 (5.85-6.72) 
 3 35369 (87.1) 5225 (12.9) 10.14 (9.46-10.87) 
 4 14521 (81.0) 3396 (19.0) 13.32 (12.38-14.33) 
 5 5044 (74.3) 1748 (25.7) 15.84 (14.59-17.20) 
 6 1387 (69.7) 604 (30.3) 17.60 (15.81-19.60) 
 7 or all 
over 
5793 (69.3) 2568 (30.7) 16.66 (15.42-17.99) 





















29 Adjusted for age, gender, ethnicity, region, primary employment, age completed education, deprivation, 
income, any chronic pain, and number of pain sites 
 
 Opioid Use 
No, n (%) 
Opioid Use 
Yes, n (%) 
Adjusted RR29 
Hours of sleep 
4 or less 4010 (77.5) 1163 (22.5) 1.55 (1.45-1.67) 
5 or 6 101161 (92.7) 8024 (7.4) 1.23 (1.19-1.27) 
7 or 8 300512 (95.9) 12923 (4.1) 1 [Reference] 
9 or 10 30068 (91.5) 2794 (8.5) 1.21 (1.16-1.28) 




110911 (97.4) 2926 (2.6) 1 [Reference] 
Sometimes 212122 (95.5) 10105 (4.5) 1.21 (1.15-1.27) 
Usually 116227 (90.1) 12749 (9.9) 1.56 (1.48-1.64) 
Overall activity 
Minimal 84354 (91.9) 7407 (8.1) 1 [Reference] 
Low 74214 (95.7) 3368 (4.3) 0.74 (0.70-0.77) 
Adequate 120525 (95.3) 5929 (4.7) 0.74 (0.71-0.77) 
High 125585 (96.3) 4803 (3.7) 0.67 (0.64-0.70) 
Overall health 
rating 
Excellent 77541 (99.1) 732 (0.9) 1 [Reference] 
Good 261428 (96.9) 8327 (3.1) 1.98 (1.80-2.19) 
Fair 84888 (88.9) 10598 
(11.1) 
3.92 (3.54-4.33) 
Poor 13908 (70.2) 5908 (29.8) 5.44 (4.89-6.05) 
Seen doctor for 
anxiety/ 
nerves/depression 
No 293787 (96.1) 11907 (3.9) 1 [Reference] 
Yes 142478 (91.3) 13598 (8.7) 1.29 (1.25-1.34) 
Adverse events in 





0 245686 (95.8) 10801 (4.2) 1 [Reference] 
1 139738 (93.8) 9301 (6.2) 1.16 (1.12-1.20) 
2 39180 (91.4) 3693 (8.6) 1.26 (1.20-1.31) 
3 7710 (87.0) 1147 (13.0) 1.37 (1.27-1.47) 
4 or more 1201 (80.3) 295 (19.7) 1.55 (1.36-1.76) 
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Table 5 Predictors of death during follow-up period 
 
Recruitment characteristic Death during follow-up MRR30 (99% CI) MRR31 (99% CI) 
  No: N (%) Yes: N (%)   
Regular Opioid use None 426534 (96.7%) 14513 (3.3%) 1 [Reference] 1 [Reference] 
Weak 18136 (93.1%) 1336 (6.9%) 1.86 (1.73, 2.00) 1.18 (1.06, 1.33) 
Strong 5853 (90.9%) 583 (9.1%) 2.59 (2.34, 2.88) 1.20 (1.01, 1.43) 
Chronic Pain No 254379 (96.8%) 8417 (3.2%) 1 [Reference] 1 [Reference] 
Yes 194172 (96.1%) 7900 (3.9%) 1.22 (1.17, 1.27) 0.85 (0.78, 0.93) 
Number of pain 
sites 
0 179617 (96.8%) 6004 (3.2%) 1 [Reference] 1 [Reference] 
1 123741 (96.6%) 4334 (3.4%) 1.06 (1.01, 1.11) 1.07 (0.97, 1.17) 
2 74684 (96.4%) 2794 (3.6%) 1.17 (1.11, 1.24) 1.05 (0.94, 1.17) 
3 38990 (95.9%) 1665 (4.1%) 1.36 (1.27, 1.46) 1.09 (0.96, 1.25) 
4 17245 (96.1%) 700 (3.9%) 1.35 (1.23, 1.50) 0.94 (0.79, 1.12) 
5 6517 (95.8%) 286 (4.2%) 1.58 (1.35, 1.83) 0.85 (0.66, 1.09) 
6 1913 (96.0%) 80 (4.0%) 1.65 (1.25, 2.19) 1.07 (0.73, 1.56) 
7 or all over 7803 (93.2%) 567 (6.8%) 2.29 (2.06, 2.56) 1.19 (0.98, 1.45) 
Age Category 
(years) 
40-45 49892 (99.2%) 396 (0.8%) 1 [Reference] 1 [Reference] 
45-49 62760 (98.7%) 796 (1.3%) 1.61 (1.37, 1.88) 1.71 (1.33, 2.20) 
50-54 70924 (98.1%) 1361 (1.9%) 2.43 (2.10, 2.81) 2.33 (1.84, 2.95) 
55-59 82301 (97.1%) 2464 (2.9%) 3.73 (3.25, 4.28) 3.41 (2.72, 4.28) 
60-64 105927 (95.6%) 4905 (4.4%) 5.63 (4.92, 6.43) 4.64 (3.72, 5.80) 
65-69 78706 (92.4%) 6508 (7.6%) 9.50 (8.32, 10.85) 6.89 (5.51, 8.62) 
Gender Male 206662 (95.2%) 10364 (4.8%) 1 [Reference] 1 [Reference] 
Female 243848 (97.6%) 6066 (2.4%) 0.53 (0.51, 0.55) 0.51 (0.48, 0.55) 
Body Mass Index 
(kgm-2) 
Underweight (< 18.5) 2208 (93.0%) 166 (7.0%) 2.83 (2.34, 3.43) 1.76 (1.31, 2.38) 
Normal (18.5-24.9) 146451 (97.1%) 4308 (2.9%) 1 [Reference] 1 [Reference] 
 
30 Mortality Risk Ratio adjusted for age and gender 
31 Fully adjusted mortality risk ratio – i.e. adjusted for all factors in table 





190832 (96.6%) 6674 (3.4%) 0.96 (0.91, 1.01) 0.87 (0.81, 0.94) 
Obese (30.0-34.9) 77950 (95.9%) 3302 (4.1%) 1.17 (1.10, 1.24) 0.94 (0.86, 1.02) 
Obese (35.0-39.9) 22033 (95.2%) 1116 (4.8%) 1.55 (1.42, 1.68) 1.05 (0.93, 1.20) 




0 9251 (93.7%) 622 (6.3%) 1.90 (1.71, 2.11) 1.22 (1.05, 1.40) 
1-100 101757 (96.6%) 3594 (3.4%) 1 [Reference] 1 [Reference] 
101-210 115233 (96.7%) 3939 (3.3%) 0.91 (0.86, 0.96) 0.97 (0.89, 1.05) 
211-420 90340 (96.8%) 2983 (3.2%) 0.87 (0.82, 0.93) 0.92 (0.84, 1.01) 




0 54253 (95.3%) 2691 (4.7%) 1.58 (1.47, 1.69) 1.11 (1.005, 1.23) 
1-60 93837 (97.1%) 2787 (2.9%) 1 [Reference] 1 [Reference] 
61-150 79046 (97.0%) 2446 (3.0%) 0.98 (0.91, 1.05) 0.98 (0.89, 1.09) 
151-360 79792 (96.9%) 2564 (3.1%) 0.95 (0.88, 1.01) 1.01 (0.91, 1.11) 




0 158097 (95.6%) 7323 (4.4%) 1 [Reference] 1 [Reference] 
1-40 71056 (91.2%) 2053 (2.8%) 0.65 (0.61, 0.69) 0.87 (0.79, 0.95) 
41-90 62605 (97.4%) 1689 (2.6%) 0.64 (0.60, 0.69) 0.88 (0.79, 0.97) 
91-180 57870 (97.5%) 1536 (2.5%) 0.63 (0.59, 0.68) 0.85 (0.76, 0.95) 
>180 51434 (97.2%) 1486 (2.8%) 0.65 (0.60, 0.69) 0.84 (0.75, 0.93) 
Physical activity 
(stairs times/day) 
0 38711 (94.1%) 2425 (5.9%) 1.12 (1.05, 1.20) 1.02 (0.93, 1.11) 
1-5 89429 (95.7%) 3984 (4.3%) 1 [Reference] 1 [Reference] 
6-10 161615 (96.9%) 5114 (3.1%) 0.71 (0.67, 0.75) 0.85 (0.79, 0.92) 
11-15 82692 (97.3%) 2301 (2.7%) 0.63 (0.59, 0.68) 0.82 (0.75, 0.91) 
16-20 38451 (97.3%) 1058 (2.7%) 0.63 (0.57, 0.68) 0.80 (0.70, 0.92) 
>20 31363 (97.3%) 876 (2.7%) 0.68 (0.62, 0.75) 0.81 (0.69, 0.94) 
Diet (Fruit and 
Vegetable 
Consumption) 
Lowest consumption 101510 (95.9%) 4393 (4.1%) 1 [Reference] 1 [Reference] 
Quintile 2 91076 (96.7%) 3119 (3.3%) 0.77 (0.73, 0.82) 0.91 (0.84, 0.99) 
Quintile 3 40106 (96.8%) 1343 (3.2%) 0.75 (0.69, 0.81) 0.92 (0.82, 1.02) 
Quintile 4 80665 (96.8%) 2641 (3.2%) 0.73 (0.68, 0.77) 0.91 (0.83, 0.99) 
Highest Consumption 64907 (96.7%) 2205 (3.3%) 0.75 (0.70, 0.80) 0.90 (0.82, 0.99) 
(almost) daily 90705 (95.9%) 3843 (4.1%) 1 [Reference] 1 [Reference] 





3-4 times/week 104889 (97.1%) 3127 (2.9%) 0.82 (0.78, 0.88) 0.90 (0.82, 0.98) 
1-2 times/week 116686 (96.9%) 3715 (3.1%) 0.94 (0.89, 0.99) 0.91 (0.83, 0.99) 
<1 time/week 101408 (96.5%) 3698 (3.5%) 1.15 (1.08, 1.22) 0.95 (0.86, 1.04) 
Never 35463 (94.7%) 1966 (5.3%) 1.59 (1.48, 1.70) 1.23 (1.10, 1.37) 
Cigarette Smoking Current smoker 45818 (92.8%) 3546 (7.2%) 3.12 (2.96, 3.29) 2.44 (2.24, 2.65) 
Ex-regular 101104 (95.1%) 5253 (4.9%) 1.59 (1.51, 1.66) 1.46 (1.35, 1.57) 
Ex-occasional 51343 (97.1%) 1536 (2.9%) 1.09 (1.02, 1.17) 1.14 (1.02, 1.27) 
Never 249750 (97.7%) 5942 (2.3%) 1 [Reference] 1 [Reference] 
Morbidity32 0 120558 (98.0%) 2416 (2.0%) 1 [Reference] 1 [Reference] 
1 122894 (97.4%) 3285 (2.6%) 1.15 (1.07, 1.23) 1.07 (0.97, 1.19) 
2 88310 (96.4%) 3299 (3.6%) 1.40 (1.31, 1.50) 1.22 (1.10, 1.36) 
3 54451 (95.2%) 2743 (4.8%) 1.72 (1.60, 1.85) 1.47 (1.32, 1.64) 
4 30396 (94.4%) 1819 (5.4%) 1.93 (1.78, 2.09) 1.51 (1.34, 1.71) 
5 16020 (93.2%) 1169 (6.8%) 2.27 (2.08, 2.49) 1.65 (1.43, 1.90) 
6 8481 (82.6%) 680 (7.4%) 2.49 (2.23, 2.78) 1.70 (1.43, 2.01) 
7 4437 (91.3%) 421 (8.7%) 2.91 (2.56, 3.32) 1.83 (1.49, 2.25) 
8 2257 (90.6%) 233 (9.4%) 3.15 (2.67, 3.73) 2.22 (1.74, 2.84) 
9 1259 (89.9%) 142 (10.1%) 3.63 (2.94, 4.48) 2.59 (1.92, 3.49) 
>=10 1147 (86.6%) 223 (13.4%) 4.77 (4.04, 5.63) 2.95 (2.27, 3.82) 
Age completed full 
time education 
<16 88210 (93.8%) 5824 (6.2%) 1 [Reference] 1 [Reference] 
16 95204 (96.8%) 3202 (3.3%) 0.78 (0.74, 0.83) 0.93 (0.86, 0.999) 
17 34717 (97.1%) 1030 (2.9%) 0.69 (0.63, 0.75) 0.88 (0.78, 0.98) 
18 36264 (97.4%) 953 (2.6%) 0.67 (0.62, 0.74) 0.95 (0.84, 1.06) 
>18 39102 (96.9%) 1264 (3.1%) 0.70 (0.65, 0.76) 1.02 (0.92, 1.13) 
Average household 
income 
Less than 18000 83059 (93.8%) 5480 (6.2%) 1 [Reference] 1 [Reference] 
18000 to 30999 96144 (96.2%) 3788 (3.8%) 0.66 (0.62, 0.69) 0.85 (0.79, 0.92) 
31000 to 51999 101608 (97.8%) 2339 (2.3%) 0.47 (0.44, 0.51) 0.68 (0.61, 0.75) 
52000 to 100000 80513 (98.4%) 1334 (1.6%) 0.39 (0.36, 0.43) 0.61 (0.53, 0.70) 
>100000 21443 (98.7%) 293 (1.4%) 0.33 (0.29, 0.39) 0.51 (0.37, 0.71) 
Do not know 18475 (94.8%) 1011 (5.2%) 1.02 (0.94, 1.11) 1.03 (0.89, 1.19) 
 
32 Self-reported illness (non-cancer) at baseline 
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Prefer not to answer 44092 (96.2%) 1752 (3.8%) 0.69 (0.64, 0.74) 0.79 (0.70, 0.88) 
Deprivation Lowest quintile 90849 (97.1%) 2727 (2.9%) 1 [Reference] 1 [Reference] 
2 90161 (97.0%) 2826 (3.0%) 1.04 (0.97, 1.12) 0.93 (0.84, 1.03) 
3 90242 (96.8%) 2962 (3.2%) 1.12 (1.05, 1.20) 1.00 (0.91, 1.11) 
4 89972 (96.5%) 3302 (3.5%) 1.32 (1.24, 1.41) 1.08 (0.98, 1.19) 
Highest quintile 88726 (95.1%) 4596 (4.9%) 1.92 (1.81, 2.04) 1.22 (1.11, 1.35) 
Seen doctor for 
anxiety/ 
nerves/depression 
No 295416 (96.6%) 10519 (3.4%) 1 [Reference] 1 [Reference] 
Yes 150588 (96.4%) 5695 (3.6%) 1.26 (1.21, 1.31) 0.98 (0.92, 1.04) 
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Objective: To estimate the proportion of patients with axial spondyloarthritis (axSpA) who 
meet criteria for fibromyalgia (FM) and to characterise such patients.  
 
Methods: The British Society for Rheumatology Biologics Register of Ankylosing Spondylitis 
(BSRBR-AS) recruits two cohorts of patients who meet ASAS criteria for axSpA across 83 
centres in the United Kingdom.  Patients are either newly starting (biologic cohort) or naïve 
(non-biologic cohort) to biologic therapy and are followed prospectively. At recruitment and 
follow-up, clinical information and measurements are recorded, while patients complete 
the 2011 research criteria for FM, assessments of disease activity and impact.  
 
Results: 1504 patients (68% male) were eligible for the current analysis of whom 311 (20.7%) 
met criteria for FM.  Prevalence was similar among those who fulfilled modified New York 
(mNY) criteria (19.7%), and ASAS imaging but not mNY criteria (25.2%), but lower among 
those who only fulfilled ASAS clinical criteria (9.5%). Patients who met FM criteria reported 
significantly worse disease activity, function, global severity scores, quality of life and were 
more likely to have moderate/severe levels of mood disorder and clinically important 
fatigue. They reported work impairment around half the time. Meeting FM criteria was not 
related to elevated C-reactive protein, or most extra-spinal manifestations, but was 
associated with a higher likelihood of having received biologic therapy.  
 
Conclusion: Developing management approaches that address the significant unmet needs 
of the 1 in 5 axSpA patients who meet criteria for FM should be a research priority. 





Fibromyalgia (FM) may be more common in patients with axial spondyloarthritis (axSpA) 
than in the general population. In comparison to a population prevalence of 2-4% based on 
American College of Rheumatology (ACR) 1990 criteria (1), studies in ankylosing spondylitis 
(AS) patients from Turkey (prevalence 12.6%; n=119), Italy (prevalence 12.7%; n=211) and 
Brazil (prevalence 15%; n=71) have all reported similar excess prevalence (2-4). This is 
consistent with the observation of a high prevalence of FM in inflammatory rheumatic 
diseases generally (5). However, distinguishing axSpA and FM is problematic, given that the 
ACR 1990 criteria require the report of axial skeleton pain, which is the key clinical feature 
of axSpA, while enthesitis may result in multi-site pain which is the cardinal feature of FM, 
and included in all established or proposed sets of FM criteria (6-8). A pooled analysis of 
data from clinical trials treating AS patients with etanercept, sulfasalzine or placebo has 
shown higher disease burden and poorer response to treatment in women. They identified 
the possibility that this may be due to concomitant FM, and proposed this as a priority for 
future research (9,10). 
 
FM may distort responses to some of the key patient reported measures used in axSpA such 
as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing 
Spondylitis Functional Index (BASFI). In the previously-mentioned study from Turkey: 
comparing those patients with and without FM, there was no difference in C-reactive protein 
(CRP) or Erythrocyte Sedimentation Rate (ESR) but those with FM had higher BASDAI scores 
(3). In July 2013, the US Food and Drug Administration (FDA) met to consider whether 
patients who had non-radiographic axSpA, based on criteria of the Assessment of 
SpondyloArthritis international Society (ASAS) (11), should be eligible for new therapies. 
The FDA committee recognized the unmet need for effective pharmacologic therapy for 
patients who either only had positive MRI changes, or were HLA-B27 positive with other 
characteristic SpA features. They were, however, concerned about the possibility, 
especially in those without MRI changes, that patients with highly prevalent conditions such 
as mechanical back pain or FM might be incorrectly diagnosed with inflammatory spondylitis 
and be inappropriately treated with expensive and potentially toxic biologic therapies.   This 
highlights the need to understand better, the characteristics of patients who have 
overlapping axSpA and FM, to assess and distinguish the two conditions, and develop 
treatment strategies that can effectively work in parallel. As an initial step in such 
endeavours the current study, within a national axSpA register aimed to a) determine the 
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prevalence of FM amongst patients who meet ASAS criteria for axSpA and b) to identify 
clinical and patient-reported measures which distinguish axSpA patients with co-morbid FM. 
 
Patients and Methods 
 
The British Society for Rheumatology Biologics Register of Ankylosing Spondylitis (BSRBR-AS) 
is a prospective cohort study which has recruited patients who meet ASAS defined axSpA 
from 83 secondary care centres in the United Kingdom with the first centres recruiting from 
December 2012. Patients meeting only the ASAS clinical criteria have been eligible to be 
recruited since November 2014. All patients are naïve to anti-TNF biologic therapy at the 
time of recruitment but may either be starting such therapy (Adalimumab, Etanercept or 
Certulizumab Pegol) or continuing on current therapy.  The study protocol has previously 
been published (12) but in brief patients starting biologic therapy have clinical and patient 
reported information collected at recruitment, 3, 6 and 12 months. Those not on biologics, 
have information collected at recruitment and annually thereafter, but may transfer to the 
follow-up schedule of patients on biologic therapy if they commence such therapy at a later 
date. From September 2015, the patient-reported data included the 2011 FM research 
criteria (8). Satisfying the criteria depended on the presence of widespread pain and somatic 
symptoms.  
 
Patients on the register were included in the current analysis if they had completed the 
2011 FM research criteria either at recruitment or follow-up. We used data from the first 
completion of the items which contribute to this criteria. Information on clinical status at 
recruitment allowed us to determine whether patients were known to meet an imaging 
criteria for axSpA (modified New York (mNY) criteria (13) or ASAS imaging criteria (11)) or 
not (ASAS clinical criteria). Data collected from or measured on each patient included:  
 
• Bath Indices of disease activity (BASDAI), function (BASFI), metrology index (BASMI) 
and global assessment (BAS-G) (14), each scored to provide a scale from 0 (best) to 10 
(worst).   
• Extra-spinal manifestations including uveitis, psoriasis, inflammatory bowel disease, 
swollen and tender forty-four joint count, as per ASAS recommendations (15)   
Quality of life was measured by: 
•  the 18-item Ankylosing Spondylitis Quality of Life (ASQoL) scale (14), providing a 
score from 0 (good quality of life (QoL)) to 18 (poor QoL)  
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• EQ-5D, a five-item generic scale with score from 0 (equivalent to death) to 1 (best 
possible health (although scores less than 0 (worse than death) are also possible) (16) 
Other patient reported measures collected were:   
• A sleep disturbance score (SDS) consisting of four items with each scored from 0-5 
(total score 0-20) with higher scores indicating worse problems (17). 
• Chalder fatigue scale (CFS) an eleven item scale measuring the extent and severity 
of fatigue. Each item was scored as 0 or 1 providing a total score 0-11 with higher scores 
indicating worse fatigue. A score of 4 or more is taken to indicate significant fatigue (18).  
• Hospital Anxiety and Depression Scale (HADS) (19) provides a measure of emotional 
distress, anxiety disorders and depression in somatic, psychiatric and primary care patients 
and in the general population. It has been shown to have a two-factor structure 
corresponding to the anxiety and depression subscales (20). Each subscale has seven items 
scored 0-3 providing a total score for each of anxiety and depression between 0-21 with 
higher scores indicating higher levels of anxiety or depression. Scale scores are categorised 
as 0-7 (normal), 8-10 (mild), 11-14 (moderate), 15-21 (severe).  
• Work Productivity and Activity Impairment Questionnaire: Specific Health Problem 
(WPAI: SHP), a validated instrument to measure impairments in work, including both 
absenteeism and presenteeism (21).   
 
Height and weight (for the calculation of Body Mass Index (BMI)), and C-reactive protein 
(CRP) were measured. We constructed a co-morbidity index based on the number reported 
by the clinician (from myocardial infarction, angina, congestive cardiac failure, stroke, 
hypertension, diabetes, asthma, chronic bronchitis or emphysema, peptic ulcer, liver 
disease, renal disease, tuberculosis, demyelination, depression or cancer).  
 
An area-level deprivation score was calculated (the index of multiple deprivation (IMD)) 
using comparable official government individual indices from the relevant countries within 
the UK. These were the English (EIMD), Scottish (SIMD) and Welsh (WIMD) Index of Multiple 
Deprivation respectively, and were all based on lower-level census areas, which represent 
neighbourhoods. All indices include income, employment, health, education, housing and 
crime/community safety. SIMD and WIMD include access to services, while in EIMD this is 
combined with the housing domain. Additionally, EIMD adds living environment and WIMD 
adds physical environment. IMD was categorised into quintiles and standardised to be 
presented as representing most deprived as 1 and least deprived as 5, following SIMD 
practice. 
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We compared axSpA patients, according to whether they met 2011 FM research criteria, 
across the range of clinical and patient reported measures listed above, using t-tests 
(continuous outcomes), two-sample proportion tests (binary outcomes), chi-square test 
(categorical non-ordered outcomes) and non-parametric tests for trend (ordinal outcomes) 
or comparing distributions (Mann Whitney U test) as appropriate. 95% Confidence intervals 
(CI) are given for effect estimates. This analysis used data from the January 2017 version of 




Amongst 2449 participants on the BSRBR-AS, 1504 (68% male) were eligible for the current 
analysis: 553 (35.4%) were in the biologic-exposed cohort. The study population is described 
in Table 1: they had a median age of 51.2 years,  reported a median time since symptom 
onset of 19 years, 82.2% of those who had been tested were HLA B-27 positive and 
approximately 1 in 6 were current smokers. Most participants (69.2%) met the mNY criteria 
for AS, an additional 26.5% fulfilled ASAS imaging criteria but not mNY, and 4.3% fulfilled 
only ASAS clinical criteria.    311 (20.7%) met 2011 research criteria for FM.  The proportion 
meeting FM criteria in each of these groups was 19.7%, 25.2% and 9.5% respectively 
(p=0.006). The proportion meeting FM criteria was higher in females (26.1% v. 18.2%, 
p<0.001) but there was no difference by age-group (p=0.56). HLA-B27 positive patients 
(17.0%) were less likely than negative (32.1%) or untested (21.7%) patients to meet FM 
criteria (p<0.001). Prevalence did vary by level of deprivation: those in the most deprived 
quintile had a prevalence of 38.0%, those in the least deprived had a prevalence of 13.8% 
and in the intermediate quintiles prevalence varied between 17.5%-20.3% (p< 0.001).  
 
AxSpA Disease Indices  
Persons who met 2011 FM research criteria had markedly worse indices of disease (Table 2). 
They had significantly worse disease activity, function, metrology and global status.  C-
reactive protein measurement was available on 1034 participants. There was no significant 
difference, between those who did and did not meet FM criteria, in the proportion of 
participants having a CRP which exceeded 1 mg/dl (39.3% v. 38.7% p=0.86), nor was there 
any difference in the overall distribution (Mann Whitney U test (p=0.82)) nor within either 
the biologic (p=0.53) or non-biologic (p=0.76) cohorts.  
 
Patient reported measures 
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Quality of Life was significantly worse in those who met FM research criteria whether 
measured by a disease specific or generic measure (Table 3). Patients meeting FM criteria 
scored significantly more highly on the HADS anxiety and depression subscales. Of those who 
met FM criteria, 39.9% were classified as having moderate/severe depression in comparison 
to 7.0% in those who did not (p<0.001). The comparable figures for anxiety were 55.3% and 
17.9% respectively (p<0.001)  They also scored more highly for sleep disturbance and levels 
of fatigue with 79.2% exceeding the cut-off for clinically important fatigue in the FM group 
in comparison to 34.2% in the non-FM group(p < 0.001).   
 
Clinical status and therapy 
Patients who satisfied FM research criteria had higher BMI (28.7 v. 27.6 kgm-2 difference 
1.2; 0.3,2.0), and a greater swollen (mean 0.47 v. 0.21 difference 0.26; 0.03, 0.49) and 
tender (mean 1.3 v. 0.5; difference 0.8; 0.4, 1.2) joint count. They were also more likely 
to report at least one co-morbidity (36.9% v. 19.9%, p<0.001).  In contrast, there was only 
a small and not statistically significant excess in proportion of persons reporting extra-spinal 
manifestations amongst patients positive for FM criteria (uveitis 19.0% v. 18.0%; psoriasis 
9.2% v. 6.4%; inflammatory bowel disease 8.5% v. 7.0%). Persons meeting FM research 
criteria were more likely to be on biologic therapy (50.5% vs 31.5%).  
 
Work-related factors 
Patients meeting criteria for FM had a significantly greater percentage of work time missed 
(15.1% v. 2.5%; difference 12.7%; 9.7%, 15.4%) and reported that when present, their work 




This national study, the largest to have been conducted on the co-occurrence of axSpA and 
FM has demonstrated that around 1 in 5 patients with axSpA meet current research criteria 
for FM. The proportion was not higher in those meeting only ASAS clinical criteria. Patients 
who meet FM criteria have considerably worse disease indices, have a significantly greater 
number of physical and psychological co-morbidities, markedly poorer quality of life (as 
measured by generic and disease-specific scales) and they report a much greater impact on 
work than those who do not fulfil the FM criteria. In contrast there are no differences in 
measured inflammation nor in most extra-spinal disease manifestations. Patients meeting 
FM criteria were more likely to have been started on biologic therapy. 
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This multi-centre study involves a relatively unselected secondary care patient population 
– recruitment takes place across specialist and non-specialist centres and this analysis 
involves data from patients naïve to anti-TNF biologic therapy, those newly starting and 
those previously started (although all patients on recruitment to the register are naïve to 
biologic therapy).  Therefore the results are likely to represent the prevalence of persons 
who meet FM criteria in a typical secondary care axSpA population.  The key methodological 
issue in the current study is that the 2011 FM research criteria used in this study have not 
specifically been validated for use in patients with axSpA. Indeed neither these nor any 
other criteria set (nor screening instrument) for FM have been validated for use in patients 
with any type of inflammatory arthritis. The 2010 preliminary diagnostic criteria (for 
clinician completion) and the 2011 research criteria (for patient completion) both require 
that the following is fulfilled “The patient does not have a disorder that would otherwise 
explain the pain” (7,8). However this is challenging for the clinician to determine and almost 
impossible for the patient to assess, and it is noteworthy that most studies which have 
implemented the 2010 or 2011 FM research criteria have ignored this specific requirement, 
as we have done in the current study. Irrespective of this, applying these criteria are 
identifying patients with significant unmet need. 
 
In a study by Almódovar et al (22), conducted in Spain, AS patients with an elevated 
BASDAI/Bath Ankylosing Spondylitis Radiological Index (BASRI) or BASFI/BASRI ratio, had a 
high probability of having a FM diagnosis. In the same study, there was also some evidence 
that patients with AS and FM (in comparison to those with AS only) responded less well to 
management strategies such as NSAID therapy. Because of the distortion of the patient 
reported measures which influence management decisions (such as BASDAI, which includes 
items on both pain and fatigue), it has been hypothesised that some patients with AS and 
FM may inappropriately receive biologic therapy. This is consistent with data from the 
current study: patients meeting FM were more likely to receive biologic therapy but also 
more likely to stop or switch such therapy. Nevertheless, although patients who met FM 
research criteria did not demonstrate any differences in most extra-spinal manifestation of 
disease, they did have a greater number of swollen and tender joints which might imply 
greater disease activity. The only other study, of which we are aware, which has used similar 
FM criteria (the 2010 preliminary diagnostic criteria for FM which are the clinician version 
of the 2011 research criteria) studied 91 patients with axSpA in clinics in Germany and 
reported that 34.1% met the 2010 FM criteria (23). In contrast, a much lower proportion 
(14.3%) met the 1990 ACR FM classification criteria. A study by Bello et al (24) used the self-
administered Fibromyalgia Rapid Screening tool (FiRST) (25) to screen 196 patients with a 
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clinical diagnosis of spondyloarthritis, attending a single tertiary care university hospital in 
France.  They reported a FM prevalence of 21%. There was no difference in the prevalence 
of FM in patients satisfying the imaging or clinical ASAS criteria. Patients with co-existing 
FM also had higher BASDAI, spinal pain and BASFI scores. There was no statistically 
significant difference in the proportion of patients with or without FM receiving anti-TNF 
therapy, however patients with FM who received anti-TNF therapy were, much less likely to 
be on the same therapy two years later (28.1% v. 41.7%, p=0.01). 
 
The European League Against Rheumatism (EULAR) has recently revised its 
recommendations for the management of FM and all specific recommendations are now 
based on either systematic review or meta-analysis (26). However, the working group noted 
that there were no trials informing how to treat FM when it occurred together with an 
inflammatory arthritis: this was therefore made a priority recommendation for future 
research.  There are effective therapies for FM (albeit that most have modest effect sizes) 
including non-pharmacological and pharmacological approaches. Indeed there is consensus, 
reflected in recommendations produced at national and international level that non-
pharmacological therapies, principally cognitive behaviour therapy and exercise should 
constitute first-line therapy (27). Whether such therapies are as effective in managing FM 
as a co-morbidity, alongside best care for an inflammatory condition, and improve long-
term outcome remains to be determined.  
 
Even in the absence of validated criteria for FM in inflammatory arthritis patients, the 2011 
FM research criteria identify a group of axSpA patients who have markedly worse patient 
reported disease activity measures, high levels of co-morbidity and with clinically important 
differences in measures of quality of life. They are also less likely to remain on initial-
prescribed biologic therapy. For example the ASQoL scores of patients who satisfy FM 
criteria (13.1) indicate worse quality of life than the patient acceptable clinical state (8.0) 
(28) and in relation to centile charts for BASDAI, patients who meet criteria for FM have a 
mean score between the 75th and 90th centile (29).  Almost 4 out of 5 of patients with axSpA 
who meet FM criteria have significant fatigue, and although there is some circularity in the 
observations (for example, fatigue is a single item in the 2011 FM research criteria) it is 
emphasising that the items of the FM criteria when taken together are identifying a group 
with very significant unmet needs. This is particularly true in relation to work with, amongst 
patients meeting criteria for FM, 17% of work time missed and impaired performance during 
more than half of their working time.  
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In summary this study has shown that an important proportion of axSpA patients meet 
current research criteria for FM, but the proportion is no greater in those meeting only ASAS 
clinical criteria. They have markedly worse disease indices and this may therefore represent 
an unmet and unrecognised need amongst axSpA patients. A recent large-scale survey of a 
patient group, the National Ankylosing Spondylitis Society in the United Kingdom, identified 
“developing a greater understanding of the impact of dealing with other conditions 
associated with AS” as one of their top ten research priorities (30). Future research should 
validate the use of FM research criteria sets in patients with inflammatory arthritis 
(including axSpA) and investigate effective management strategies for patients in whom 
these rheumatic conditions co-occur.  
 
Acknowledgements and Author Contribution 
The British Society for Rheumatology (BSR) Biologics Register in Ankylosing Spondylitis is 
funded by the BSR and they have receive funds for this from Pfizer, AbbVie and UCB. These 
companies receive advance copies of manuscripts and can provide comments but have no 
input into determining the topics for analysis, publication and no input into the work 
involved in this analysis. We are grateful to the staff at the register recruiting centres, 
details of whom are available at:  
http://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritis.php and to the 
BSRBR-AS administration team:  currently Dr. Claudia Zabke, Dr. Elizabeth A. Ferguson-
Jones, Barry Morris and previously Lindsay Grant, Jo Gibson, Louise Mitchell, Karen Meldrum 
and Georgia Mannion-Krase. This work is part of the Fibromyalgia Optimal Management for 
patients with axial Spondyloarthritis (FOMAxS) study on which GJM, EP, KRM, KLH, SS, JP 
and FA are investigators or collaborators. This analysis is part-funded by Arthritis Research 
UK (Grant No: 21378). Other investigators are: Euthalia Roussou and Philip Mease.  GJM 
conceived the idea for the study, devised the analysis plan and drafted the manuscript. GTJ 
is responsible for data management on BSRBR-AS and with MSB conducted this analysis. All 
authors provided input in to the study plan and critically reviewed the manuscript, providing 
important scientific content.  
 
Author Declaration 
None of the authors declare any conflict of interest with respect to this manuscript.  
 
 




1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics 
of fibromyalgia in the general population. Arthritis Rheum. 1995;38(1):19-28. 
2. Salaffi F, De Angelis R, Carotti M, Gutierrez M, Sarzi-Puttini P, Atzeni F. Fibromyalgia 
in patients with axial spondyloarthritis: epidemiological profile and effect on 
measures of disease activity. Rheumatol Int. 2014;34(8):1103-10. 
3. Haliloglu S, Carlioglu A, Akdeniz D, Karaaslan Y, Kosar A. Fibromyalgia in patients 
with other rheumatic diseases: prevalence and relationship with disease activity. 
Rheumatol Int. 2014;34(9):1275-80. 
4. Azevedo VF, Paiva Edos S, Felippe LR, Moreira RA. Occurrence of fibromyalgia in 
patients with ankylosing spondylitis. Rev Bras Reumatol. 2010;50(6):646-50. 
5. Clauw DJ, Katz P. The Overlap Between Fibromyalgia and Inflammatory Rheumatic  
Disease: When and Why Does it Occur? J Clin Rheumatol. 1995;1(6):335-42.  
6. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell 
P, Campbell SM, Abeles M, Clark P, et al. The American College of Rheumatology 
1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria 
Committee. Arthritis Rheum. 1990;33(2):160-72. 
7. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, 
Russell IJ, Winfield JB, Yunus MB. The American College of Rheumatology preliminary 
diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis 
Care Res (Hoboken). 2010;62(5):600-10. 
8. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, 
Russell AS, Russell IJ, Winfield JB. Fibromyalgia criteria and severity scales for 
clinical and epidemiological studies: a modification of the ACR Preliminary 
Diagnostic Criteria for Fibromyalgia. J Rheumatol. 2011;38(6):1113-22. 
9. van der Horst-Bruinsma IE, van der Weijden M, Bruijnen S, et al, Low percentage of 
MRI changes in clinically suspected axial spondyloarthritis. Ann Rheum Dis 
2012;71(Suppl 3):689. 
10. van der Horst-Bruinsma IE. Treatment of non-radiographic axial spondyloarthritis: it 
is only the beginning. Ann Rheum Dis. 2013;72(6):789-90. 
11. Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun  J, 
Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, 
Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, 
Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis 
international Society classification criteria for axial spondyloarthritis (part II): 
validation and final selection. Ann Rheum Dis. 2009;68(6):777-83. 
121 | P a g e  
 
 
12. Macfarlane GJ, Barnish MS, Jones EA, Kay L, Keat A, Meldrum KT, Pathan E, Sturrock 
RD, Zabke C, McNamee P, Jones GT. The British Society for Rheumatology Biologics 
Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective 
cohort study of the long-term safety and quality of life outcomes of  biologic 
treatment. BMC Musculoskelet Disord. 2015;16:347. 
13. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for 
ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis 
Rheum. 1984;27(4):361-8. 
14. Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: 
Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality 
of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), 
Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis 
Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados 
Functional Index (DFI), and Health Assessment Questionnaire for the 
Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S47-
58.  
15. Dougados M, Braun J, Vargas RB, Gossec L, Maksymowych W, Sieper J, van der Heijde 
D. ASAS recommendations for variables to be collected in clinical 
trials/epidemiological studies of spondyloarthritis. Ann Rheum Dis. 2012;71(6):1103-
4. 
16. Gusi N, Olivares PR, Rajendram R. The EQ-5D Health-Related Quality of Life 
Questionnaire in Handbook of Disease Burdens and Quality of Life Measures, Preedy 
V.R., Watson R.R (eds)  pp 87-99, Springer (2010). 
17. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep 
problems in clinical research. J Clin Epidemiol. 1988;41(4):313-21. 
18. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP. 
Development of a fatigue scale. J Psychosom Res. 1993;37(2):147–153. 
19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr 
Scand. 1983 ;67(6):361-70. 
20. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and 
Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69-77. 
21. Reilly MC, Zbrozek AS, Dukes E: The validity and reproducibility of a work 
productivity and activity impairment measure. PharmacoEconomics 1993; 4(5):353-
365. 
22. Almodóvar R, Carmona L, Zarco P, Collantes E, González C, Mulero J, Sueiro JL, 
Gratacós J, Torre-Alonso JC, Juanola X, Batlle E, Ariza R, Font P. Fibromyalgia in 
122 | P a g e  
 
 
patients with ankylosing spondylitis: prevalence and utility of the measures of 
activity, function and radiological damage. Clin Exp Rheumatol. 2010;28(6 Suppl 
63):S33-9  
23. Baraliakos X, Regel A, Kiltz U, Menne H-J, Dybowski F, Igelmann M, Kalthoff L, Krause 
D, Saracbasi E, Schmitz-Borz E, Braun J.  Patients with fibromyalgia (FM) do not fulfil 
classification criteria for Axial Spondyloarthritis (axSpA) but patients with AxSpA may 
fulfil classification criteria for FM. Arthritis and Rheumatology 2015; 67 (suppl 10) 
doi: 10.1002/art.39448. 
24. Bello N, Etcheto A, Béal C, Dougados M, Moltό A. Evaluation of the impact of 
fibromyalgia in disease activity and treatment effect in spondyloarthritis. Arthritis 
Research and Therapy 2016;18:42. 
25. Perrot S, Bouhassira S, Fermanian J, Cercle d’Etude de la Douleur en Rheumatologie. 
Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST). Pain 
2010;150:250-6. 
26. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Hauser W, Fluß E, Choy E, Kosek E, 
Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot 
S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the 
management of fibromyalgia. Ann Rheum Dis 2017 Feb;76(2):318-328. 
27. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014 Apr 16;311(15):1547-55. 
28. Maksymowych WP, Richardson R, Mallon C, van der Heijde D, Boonen A. Evaluation 
and validation of the patient acceptable symptom state (PASS) in patients with 
ankylosing spondylitis. Arthritis Rheum 2007; 57: 133–9. 
29. Taylor AL, Balakrishnan C, Calin A. Reference centile charts for measures of disease 
activity, functional impairment, and metrology in ankylosing spondylitis. Arthritis 
Rheum. 1998;41(6):1119-25. 
30. Cook D, Dickenson S, Garces-Bovett C, Godacre L. Research Priorities 2013-18. 
National Ankylosing Spondylitis Society (2013) http://nass.co.uk/research/ Accessed 
Sept 2016. 
 




Table 1 Characteristics of study population 
Characteristic   
Age (years) Median (IQR) 51.2 (40.1-63.1) 
Gender N; % male 1025, 68.2% 
Time since symptom 
onset (years) 
Median (IQR) 19 (9-33) 
HLA-B27 status N; % positive 765; 82.2% of those 
tested 
N; % negative 165; 17.8% of those 
tested 
N 511 
CRP in mg/dL Median (IQR) 0.55 (0.10-2.00) 
Smoking status N; % current 247; 16.7% 
N; % former 578; 39.2% 
N; % never 651; 44.1% 
Diagnostic criteria N; % fulfilling mNY33 
criteria 
1026; 69.2% 
N; % fulfilling ASAS34 
imaging but not mNY 
criteria 
393; 26.5% 
N; % fulfilling ASAS 




33 modified New York 
34 Assessment of SpondyloArthropathy international Society 
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2011 research criteria for fibromyalgia 
FM positive FM negative 
 Mean 
Score 
95% CI Mean 
Score 
95% CI Difference 95% CI 
Disease Activity 
(BASDAI) 
6.7 6.5, 6.9 3.6 3.5, 3.8 3.1 2.8, 3.3 
Function (BASFI) 6.6 6.4, 6.9 3.7 3.6, 3.9 2.9 2.6, 3.3 
Metrology (BASMI) 4.2 4.0, 4.5 3.6 3.5, 3.8 0.6 0.3, 0.9 
Global (BAS-G) 6.9 6.7, 7.2 3.7 3.6, 3.8 3.2 2.9, 3.6 
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Table 3: A comparison of axSpA patient reported measures according to 2011 research 




2011 research criteria for fibromyalgia 
FM positive FM negative 
 Mean 
Score 
95% CI Mean 
Score 
95% CI Difference 95% CI 
Quality of Life (ASQoL) 13.1 12.7, 13.6 6.1 5.8, 6.4 7.1 6.4, 7.7 
Quality of Life (EQ-5D) 0.45 0.42, 0.48 0.76 0.74, 0.77 -0.31 -0.33,-0.28 
Depression (HADS-
depression) 
9.4 8.9, 9.8 4.6 4.4, 4.8 4.8 4.3, 5.2 
Anxiety (HADS 
anxiety) 
11.0 10.5, 11.5 6.4 6.2,6.6 4.7 4.1, 5.2 
Sleep (SDS) 13.4 12.7, 14.0 8.1 7.8, 8.4 5.3 4.5, 6.0 
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Objective: To quantify the extent to which co-morbid fibromyalgia (FM) is associated with 
higher disease activity, worse quality of life and poorer response to TNF inhibition (TNFi) in 
patients with axSpa. 
 
Methods: A prospective study recruiting across 83 centres in the United Kingdom. Clinical 
information and patient reported measures were available, including 2011 criteria for FM. 
Multivariable linear regression was used to model the effect of meeting the FM criteria on 
disease activity, quality of life and response to TNFi. 
 
Results: 1757 participants were eligible for analyses of whom 22.1% met criteria for FM. 
Those with comorbid FM criteria had higher disease activity (BASDAI average difference 
FM+ve - FM-ve 1.04; 95% CI 0.75, 1.33) and worse quality of life (ASQoL difference 1.42; 95% 
CI 0.88, 1.96) after adjusting for demographic, clinical and lifestyle factors. Amongst 291 
participants who commenced biologic therapy, BASDAI scores in those with co-morbid FM 
were 2.0 higher at baseline but reduced to 1.1 higher at 12 months. There was no significant 
difference in likelihood of meeting ASAS20 criteria at 12 months. Less improvement in 
disease activity and quality of life over three months of TNFi therapy was most strongly 
related to high scores on the FM criteria symptom severity (SSS) component. 
  
Conclusion: Fulfilling criteria for FM has a modest impact on assessment of axSpa disease 
activity and quality of life, and does not significantly influence response to biologic therapy. 









The issue of fibromyalgia (FM) as a co-morbidity to axial Spondyloarthritis (axSpa) is of 
considerable recent interest.  In July 2013, the US Food and Drug Administration met to 
consider Tumour Necrosis Factor inhibitors (TNFi) in patients with non-radiographic axSpa 
based on the International Association for Ankylosing Spondylitis (ASAS) classification 
criteria.1 The FDA Arthritis Advisory Committee recognised the unmet need for effective 
pharmacologic therapy for patients who had positive MRI rather than radiographic changes, 
or based on positive HLA-B27 plus other characteristic SpA features, but who did not fulfil 
the modified New York (mNY) criteria for AS.2 However, they were concerned about the 
specificity of the ASAS criteria3 and the possibility that patients with highly prevalent 
conditions such as mechanical back pain or FM might be incorrectly diagnosed with non-
radiographic axSpa and be inappropriately treated with TNFi medications. This highlights 
the need to understand better the characteristics of axSpa patients who have co-morbid FM, 
in order to assess and distinguish the two conditions (including when they co-exist), and to 
develop treatment strategies that can effectively work in parallel. 
 
This led to research which sought to understand how often axSpa and FM co-occur. 
Notwithstanding the fact that research criteria for FM have not been validated in the context 
of inflammatory rheumatic conditions, studies have sought to understand how often people 
with axSpa met one or more of the criteria for FM. These demonstrated that co-occurrence 
was common. We have shown that 21% of 1504 persons within the British Society for 
Rheumatology Biologics Register of axial spondyloarthritis (BSRBR-AS) met 2011 criteria for 
FM (also known as the modified 2010 criteria and as “research criteria”).4 In a smaller study 
of 200 patients meeting ASAS criteria for axSpa, Baraliakos et al5 found that 24% met the 
above research criteria, while 14% met the previous 1990 American College of Rheumatology 
(ACR) criteria. This is consistent with the observation of high prevalence of FM in 
inflammatory rheumatic diseases generally.6 However, identifying co-morbid FM in people 
with axSpa is challenging. The ACR 1990 criteria for FM require the report of axial skeleton 
pain, which is one of the key clinical features of axSpa. These criteria, as well as the 2011 
criteria, require multi-site pain which is also reported by axSpa patients due to inflammatory 
enthesitis/synovitis.7,8 
 
The key issue is distinguishing and providing appropriate management for both conditions 
when they occur together. A pooled analysis of data from clinical trials treating axSpa 
patients with etanercept, sulphasalazine or placebo showed a higher disease burden and 
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poorer response to treatment in women and identified the possibility that this may be due 
to concomitant FM.9,10 We currently do not know how patients with co-morbid FM respond 
to TNFi therapy in comparison to those without. However, several standard disease indices 
(such as the Bath Ankylosing Spondylitis Disease Index (BASDAI), as well as wider measures 
of disease impact (such as the Ankylosing Spondylitis Quality of Life Index (ASQoL)) are based 
entirely on patient report and may be inflated due to co-morbid FM. This could lead to 
inappropriate management since guidelines include BASDAI score as one determinant for use 
of TNFi therapy.11-13  
 
The purpose of this analysis is therefore two-fold. Amongst people with axSpa: 
• to quantify the extent to which meeting criteria for FM is associated with higher 
measures of disease activity and impact (Aim 1). 
• to determine whether meeting research criteria for FM is associated with poorer 




The BSRBR-AS is a prospective cohort study which has recruited patients who have a 
physician diagnosis of axSpa and meet the Assessment of SpondyloArthritis international 
Society (ASAS) defined criteria from 83 secondary care centres in the United Kingdom. 
Recruitment started in December 2012, initially for people meeting the ASAS imaging 
criteria for axSpa. Patients meeting only ASAS clinical criteria were subsequently eligible to 
be recruited in November 2014. All participants are naïve to TNFi therapy at the time of 
recruitment but may either be starting such therapy or continuing on current non-TNFi 
therapy.  The study protocol has previously been published14 but, in brief, participants 
starting TNFi therapy have clinical and patient reported information collected at the start 
of therapy, 3, 6 and 12 months later. Those not on TNFi therapy have information collected 
at recruitment and annually thereafter, but may transfer to the follow-up schedule of 
participants on TNFi therapy if they commenced such therapy during the course of the study. 
Eligible TNFi therapies were adalimumab, etanercept and certolizumab pegol. From 
September 2015, the patient-reported data included the 2011 FM criteria.  
 
Data collected from or measured on each participant at recruitment and each follow-up 
point included:  
• BASDAI, Bath Ankylosing Spondylitis Functional (BASFI) and metrology (BASMI) 
Indices.15-17 
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• The 18-item ASQoL scale, providing a score from 0 (good quality of life (QoL)) to 18 
(poor QoL).18 
• 2011 FM criteria8: There are two components to the criteria; the Widespread Pain 
Index (WPI) and the Symptom Severity Scale (SSS). The WPI records in how many of 19 body 
areas the respondent reports pain in the past week (score 0-19). For the SSS, respondents 
indicate the severity of fatigue, waking unrefreshed and cognitive symptoms “brain fog” 
over the past week (scored 0-3 each). The criteria also include 3 items on whether 
depression, headaches, pain or cramps in the lower abdomen have occurred in the past 6 
month (score 1 each if present), giving a maximum total score of 12.  
• Hospital Anxiety and Depression Scale (HADS) provides a measure of emotional 
distress, anxiety disorders and depression.  There are two subscales, for anxiety and 
depression each with scores ranging from 0-21, higher scores indicating more severe 
problems.19  
• Cigarette smoking : current, ex-smoker, never smoker 
 
C-reactive protein (CRP) was measured at recruitment but was only measured subsequently 
if clinically indicated. A measure of socio-economic status, the Index of Multiple Deprivation 
(IMD), was derived from the postcode of residence of participants and categorised into 
quintiles with references to their country of residence.20,21  
 
Analysis  
Aim 1: participants were included if they had completed the FM criteria either at 
recruitment or follow-up. Data from the first completion of the items which contribute to 
this criteria were used (and are referred to as “baseline”). The effect of FM status on 
baseline BASDAI and ASQoL was firstly determined. Thereafter, multivariate linear 
regression analyses were used to evaluate the influence of FM status on a) baseline disease 
activity (BASDAI) adjusted for BASMI and CRP (both measured within 3 months of the self-
report data), BASFI, age group, gender, IMD, disease management (on TNFi) and smoking 
status, and b) baseline ASQoL adjusted for BASDAI, BASFI, BASMI, age group, gender, IMD, 
disease management and smoking status. As the availability of CRP restricted numbers 
available for analysis and it was shown not to be related to BASDAI, it was only included in 
an additional (sensitivity analysis) model predicting ASQoL.  Both the BASDAI and ASQoL 
analyses were first conducted with a dichotomous FM status variable and then using the WPI 
and SSS components of the criteria instead.  
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Aim 2: participants were included in this analysis if they had completed FM research criteria 
within the six months before, or one month after, commencing TNFi therapy for the first 
time. They were also required to have completed at least one follow-up questionnaire 3, 6 
and/or 12 months later.  Two-sample t-tests were used to compare differences in BASDAI 
and ASQoL between patients meeting FM criteria (called “FM+ve”) and those who did not 
(“FM-ve”) at baseline, 3 months, 6 months and 12 months, as well as ASAS20 and ASAS40 
responses at each of these follow-up points. In predicting the contribution of FM status on 
change in BASDAI after 3 months, adjustment was made for baseline BASDAI, BASFI, age 
group, IMD, gender and smoking status, while in the analysis predicting ASQoL change after 
3 months, adjustment was made additionally for baseline ASQoL. Analysis was again 
conducted first with dichotomous FM criteria status and then with the WPI and SSS 
components of the criteria.  Inclusion of clinically-measured variables reduced the sample 
size available to the analysis but a sensitivity analysis with CRP and BASMI was included to 
investigate their effects. We separately included baseline HADS to determine if this 
mediated the relationship between FM status and treatment response. 
 





A total of 1757 participants (67% male) completed the research criteria for FM on at least 
one occasion and were eligible for the current analyses. Their median age was 50.8 years, 
with a median time since symptom onset of 27 years, and 80.2% of those who had been 
tested were HLA B27 positive. Most participants (66.8%) met the mNY criteria for AS, an 
additional 28.4% fulfilled ASAS imaging criteria but not mNY, and 4.8% fulfilled only ASAS 
clinical criteria for axSpa. 
 
Influence of FM status on disease activity and quality of life (Aim 1).  
Those who were FM+ve at baseline (n=388; 22.1%) had higher BASDAI scores than those FM-
ve (6.7 v. 3.6; Difference 3.1, 95% CI (2.8,3.3)). Higher BASDAI score was independently 
predicted by being FM+ve (1.04 higher average scores) in a multivariable linear regression 
model (which included participants who had a CRP within 3 months of the self-reported 
information, n=1093) (Table 1). Additional predictors were higher BASFI (0.67 average 
increase in BASDAI per unit increase in BASFI), lower BASMI (0.14/unit), younger age group, 
and not being on a TNFi (0.34 higher average score). BASDAI was not significantly related to 
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CRP, gender, smoking or IMD.  When the individual component scores of the FM criteria were 
entered in the model (instead of the dichotomous FM variable), BASDAI was related both to 
the WPI score (0.11 average increase in BASDAI for every additional area of pain reported) 
and the SSS (0.20 average increase/unit).  
 
Those who were FM+ve at baseline had poorer quality of life scores than those FM-ve (13.1 
v. 6.1; difference 7.0 95% CI (6.5,7.6)). Poorer quality of life at baseline was predicted, on 
multivariable analysis, by being FM+ve (1.42 higher average ASQoL) in addition to higher 
BASDAI score (0.85 increase in ASQoL per unit increase in BASDAI), higher BASFI (1.00/unit), 
lower BASMI (0.13/unit), female gender (0.74 higher average ASQoL score), and being a 
current smoker (0.94 higher average score) (Table 2). Quality of life increased with older 
age group but was not related to TNFi management or IMD. When the FM component scores 
were entered, poorer quality was life was strongly related to SSS (0.50 increase in 
ASQoL/unit) with a 0.09 in increase in ASQoL per unit increase in WPI. As a sensitivity 
analysis, when the CRP was included in Model 2 it was not related to quality of life (co-
efficient 0.00 95% CI (-0.02,0.02)).  
 
Response to TNFi therapy according to FM status (Aim 2) 
There were a total of 291 participants who commenced TNFi therapy and had completed FM 
criteria within the required timescale. Of these 139, 123 and 74 had reached the follow-up 
and completed a questionnaire 3, 6 and 12 months later, respectively.  At the time of 
commencing TNFi therapy, participants who were FM+ve had significantly higher BASDAI 
scores (7.2 v. 5.2; difference 2.0 95% CI (1.5,2.4)).  They continued to have higher scores 
throughout follow-up, although the magnitude of the difference reduced over time: 3 
months (5.7 v. 3.7; 1.9 (1.0,2.8)), 6 months (4.8 v. 3.2; 1.6 (0.7,2.6)) and 12 months (4.1 v. 
3.1; 1.1 (-0.0,2.2)). Quality of life was poorer amongst those FM+ve (14.0 v. 9.4; difference 
4.6 95% CI (3.5,5.7)) and remained so: 3 months (10.5 v. 7.0; 3.5 (1.5,5.5)), 6 months (10.2 
v. 5.6; 4.6 (2.5,6.6)) and 12 months (9.0 v. 5.4; 3.6 (0.9,6.3)) (Figure 1). It is noteable in 
FM+ve patients that BASDAI continues to reduce throughout the 12 month follow-up period. 
Throughout follow-up those originally FM+ve were less likely to meet ASAS20 response 
criteria at all time-points. The differences reduced through follow-up and none were 
statistically significant: 3 months (36% v. 46%; -10% (-28%,8%)), 6 months (56% v. 61%; -5% (-
24%,14%)) and 12 months (60% v. 63%; -4% (-30%,23%)). Similar sized differences in response 
were observed for ASAS40: 3 months (24% v. 34%; -11% (-28%,7%)), 6 months (39% v. 44%; -
5% (-24%,14%)), and 12 months (32% v. 42%; -11% (-37%,16%)). The proportion of participants 
who were FM+ve at baseline, who continued to meet criteria at follow-up was 36.2% at 3 
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months, 40.5% at 6 months and 40% at 12 months. The decrease in the proportion of patients 
fulfilling the FM over time is due to improvements in both WPI and SSS. WPI improved by 
1.5, 1.8 and 1.4 over 3, 6 and 12 months respectively and SSS improved by 0.8, 1.2 and 0.8. 
These represent very similar improvements as a percentage of the relevant maximum scale 
score (e.g. 8% and 7% at 3 months for WPI and SSS respectively). 
 
A multivariable model predicting change in BASDAI (BASDAIbaseline – BASDAI3 months) 
demonstrated that those FM+ve at baseline had 0.58 less improvement in BASDAI than those 
FM-ve but this was not statistically significant (Table 3). Larger improvements were related 
to higher baseline BASDAI (every unit increase in BASDAI associated with an average 0.72 
greater improvement in BASDAI) and lower baseline BASFI (0.38 less improvement/unit 
increase). However, when the effect of the individual components of FM criteria were 
considered, higher scores on SSS were significantly associated with poorer response (0.32 
lower average improvement per unit increase in SSS). When CRP or BASMI was added to 
Model 2 (as a sensitivity analysis, since their inclusion restricted numbers available for 
analysis), they were not associated with improvement in BASDAI (0.00 95% CI (-0.02,0.03) 
and 0.21 (-0.06,0.48) respectively) and neither was HADS (Anxiety) (severe anxiety 0.18 95% 
CI (-1.36,1.72) per unit increase in score) or HADS (Depression) (severe depression -0.51 95% 
CI (-2.45,1.42) per unit increase in score) when put into the model together.  
 
A corresponding analysis was run with quality of life as the outcome (ASQOLbaseline – ASQOL3 
months). High scores on the SSS of the FM criteria were predictive of lower improvement in 
quality of life, as were poorer quality of life and worse disease activity on commencing 
treatment (Table 4). When CRP or BASMI was added to Model 2 (again as a sensitivity 
analysis), they were not associated with improvement in ASQoL (0.11 95% CI (-0.47,0.69) 
and -0.01 (-0.07,0.06), respectively) and neither was HADS (Anxiety) (severe anxiety -0.79 





Patients with axSpa who were FM+ve had only modestly higher disease activity and worse 
quality of life, after adjustment for disease indices, demographic and socioeconomic 
factors. Poor quality of life was more strongly determined by a high score on the SSS of FM 
criteria, indicating a high burden of somatic symptoms. Persons who were FM+ve had higher 
BASDAI scores on commencement of TNFi therapy and throughout the 12 month follow-up, 
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although the difference in magnitude reduced over the period of treatment. There was no 
significant difference in likelihood of meeting ASAS20 or ASAS40 response criteria according 
to FM status. While FM status was not significantly related to response to therapy, as 
assessed by BASDAI or ASQoL, high somatic symptom burden was associated with worse 
response. Approximately 2 in 5 of persons who met FM criteria at commencement of 
therapy, continued to do so at each follow-up over the year.  
 
The BSRBR-AS is a national register involving non-specialist and specialist centres and thus 
the patients recruited are likely to represent the spectrum encountered in routine clinical 
practice. The study protocol dictated that participants were followed-up clinically and by 
questionnaire at 3, 6 and 12 months. This schedule was chosen to fit in with routine clinical 
practice. If the routine follow-up did not occur (or sufficient time had not passed for the 
follow-up to be due) or the participant did not return their questionnaire, then they could 
not fully participate in all the analyses presented. Therefore, for the 12 month follow-up in 
particular, the numbers analysed are considerably lower than those recruited. However, it 
is of note that the patterns of response are very similar across follow-up and therefore this 
is unlikely to have impacted on the interpretation of results. Specifically we examined 
whether BASDAI or ASQoL were importantly or statistically significantly related to likelihood 
of follow-up and confirmed they were not. Similarly, we opted not to use the ASDAS as an 
outcome measure because of the necessity that the clinic visit (for the CRP) and the 
questionnaire (for self-reported measures) occur sufficiently close in time. CRP was shown 
not to be related to BASDAI (at baseline) or as a predictor of response to therapy and did 
not play an important part in the analyses. While the patient-reported measures could be 
performed without a clinic visit, the BASMI required that a clinical visit had occurred. 
However, the BASMI was shown not to be importantly related to disease activity or a 
predictor of response.  
 
In interpreting the results of this study it is important to consider that although we were 
able to determine if participants met research criteria, this is not the same as a clinical 
diagnosis of FM. Distinguishing, for example, multi-site pain of axSpa from the axial and 
widespread pain of FM is extremely challenging.  As previously noted, the criteria for FM 
have not been validated in people with inflammatory arthritis and indeed the 201022 and 
2011 research criteria8 (but not the most recent 2016 criteria23) have sought to exclude 
persons from meeting FM criteria if they have symptoms which could be explained by 
inflammatory conditions.  
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This is one of the first studies to examine these issues in relation to co-morbid FM in people 
with axSpa. We and others have previously reported that disease indices are substantially 
elevated in patients who meet FM criteria.4,24 This study provides new information that when 
the comparison of FM+ve and FM–ve patients takes account of clinical, demographic and 
lifestyle differences between the groups, the effect on disease indices is much less 
pronounced.  Using the FM rapid screening tool (FIRST) Bello et al24 found that those who 
scored highly on the tool were more likely to discontinue TNFi therapy and that this was a 
predictor of discontinuation of first therapy (together with peripheral involvement) on 
multivariable analysis. Molto et al25 found that response to therapy was lower in those who 
scored highly on FIRST, for most endpoints, but not CRP. This study confirms this but has 
looked at longer term outcome (12 months compared to 3 months) and using internationally 
accepted criteria has identified one specific FM component (SSS), rather than meeting FM 
criteria generally, which identifies persons most likely to have a poor response.   
 
The clinical implications from this study are that as meeting criteria for FM per se only had 
a modest effect on BASDAI (i.e. 1 point) or ASQoL (1.5 points), there should not be undue 
concern that FM distorts disease indices. Being FM+ve also did not predict poor or non-
response to TNFi therapy amongst axSpa patients. Indeed with TNFi therapy and reduction 
in BASDAI, 3 out of 5 people with co-morbid FM will no longer meet criteria for FM. 
Specifically, the widespread distribution of pain was not a key determinant of response, 
instead it was a high somatic symptom burden captured by the SSS of the FM criteria which 
was a strong predictor. As an example, assuming a patient had a SSS of 12 and a WPI of 2 
then their predicted improvement on BASDAI would be 4 less than a patient scoring zero on 
both scales whereas a patient with a SSS of 2 and WPI of 14 would have an improvement 
only 2 less than a patient scoring zero on both scales.  Specifically we did not find that mood 
was an independent predictor of response. For patients with high SSS, treatments employing 
a cognitive behaviour approach, which have been shown to be effective for FM26 may be 
indicated, and studies to test the feasibility of such an approach are underway.  
 
In summary, meeting criteria for FM, in this study, only had a modest impact on assessment 
of disease activity by BASDAI, and did not influence the response to TNFi therapy. A high 
score on the symptom severity scale (SSS), representing a high somatic symptom burden, 
was a bigger influence on quality of life, assessed by ASQoL, and did identify persons who 
had significantly poorer response to TNFi therapy. It may be useful for rheumatologists to 
identify patients with high SSS who are commencing TNFi therapy and to consider additional 
non-pharmacological therapies to target such symptoms and potentially improve outcome. 
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Tables and Figures 
 
Table 1: Predictors of Bath AS Disease Index (BASDAI) score at baseline 
 
 Model 1 (n=705) Model 2 (n=626) 






Constant 2.54 ( 1.97, 3.12) 1.33 (0.73, 1.93) 
BASMI -0.14 (-0.22, -0.07) -0.08 (-0.15, -0.00) 
BASFI 0.67 (0.62, 0.73) 0.51 (0.45, 0.57) 
CRP (mg/dL) -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 
Age (years) 













































































































Fibromyalgia   
1.04 
 
















Model fit: 1) R-squared 0.6454 2) R squared 0.7055 
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Table 2 Predictors of AS Quality of Life (ASQoL) score at baseline 
 
 Model 1 (n=886) Model 2 (n=796) 






Constant 0.88 (-0.17, 1.93) -0.88 (-1.94, 0.18) 
BASDAI 0.85 ( 0.72, 0.99)  0.54 ( 0.39, 0.68) 
BASFI 1.00 ( 0.87, 1.13)  0.91 ( 0.78, 1.04) 


















































( 0.16, 0.99) 
Index of Multiple 
Deprivation  (quintiles) 






























































( 0.42, 1.52) 
Fibromyalgia   
1.42 
 
















Model fit: 1) R-squared 0.7467 2) R squared 0.7821 





Table 3 Predicting response to biologic therapy:  improvements in Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) 
 
 Model 1 (n=135) Model 2 (n=121) 






Constant -0.99 (-2.72, 0.75) -0.28 (-2.03, 1.48) 
BASDAI 0.72 (0.49, 0.95) 0.84 (0.60, 1.08) 




































Index of Multiple 
Deprivation (quintiles) 


















































































Model fit: 1) R-squared 0.3261 2) R-squared 0.4079 
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Table 4 Predicting response to biologic therapy:  improvements in quality of life (Ankylosing 
Spondylitis Quality of Life Score (ASQoL) 
 
 Model 1 (n=133) Model 2 (n=119) 






Constant -0.93 (-4.72, 2.86) -0.15 (-3.96, 3.66) 
ASQOL 0.30 (0.01, 0.59) 0.52 (0.20, 0.84) 
BASDAI 0.36 (-0.17, 0.89) 0.52 (-0.03, 1.06) 
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Model fit: 1) R-squared 0.1830 2) R-squared 0.2896 
 
 









BASDAI (n) 286 138 121 73 
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Background: Around 1 in 8 patients with axial spondyloarthritis (axSpA) also meet criteria 
for fibromyalgia and such patients have considerable unmet need. Identifying effective 
therapy is important but to what extent fibromyalgia-like symptoms relate to axSpA disease 
severity has not been established. The aim of the current analysis was to determine whether 
distinct clusters of axSpA patients exist and if so to determine a) whether they differ in 
terms of prevalence of fibromyalgia and b) the features of patients in clusters with high 
prevalence. 
 
Methods: The British Society for Rheumatology Biologics Register (BSRBR-AS) recruited 
axSpA patients from 83 centres 2012-2017. Clinical data, and information from patients was 
collected (including research criteria for fibromyalgia).  Cluster analysis was undertaken 
using split samples for development and validation both in the whole population and the 
sub-group which met fibromyalgia criteria. 
 
Results: 1338 participants were included of whom 23% met research criteria for 
fibromyalgia. Four clusters were identified. Two exhibited very high disease activity, one 
which was primarily axial (n=347) and a smaller cluster (n=32) with axial and peripheral 
disease, and in both groups more than half of members met criteria for fibromyalgia. The 
remaining two clusters (n=437, n=462) had overall less severe disease however the one which 
showed greater disease activity and poorer quality of life had a higher proportion meeting 
fibromyalgia criteria (16% v. 4%). Within those meeting fibromyalgia criteria there were 
three clusters. The two main groups were defined by level of symptom severity with a 
smaller third cluster noted to have high average swollen and tender joint counts and high 
levels of comorbidity.   
 
Conclusions: The major feature defining clusters with a high proportion of persons meeting 
criteria for fibromyalgia is high axSpA disease activity although clusters with features of 
fibromyalgia in the absence of high disease activity also show moderately high prevalence. 
Management may be most successful with pharmacologic therapy to target inflammation 
but enhanced by the concurrent use of non-pharmacologic therapy in such patients.   
 





Fibromyalgia is common as a co-morbidity in inflammatory arthritis. A recent meta-analysis 
estimated the prevalence as 21% (95% CI 17, 25) in rheumatoid arthritis (RA) across twenty 
five studies, 13% (95% CI 7, 19) in axial spondyloarthritis (axSpA) across eight studies and 
18% (95% CI 13, 23) in psoriatic arthritis across six studies (1).  There has been specific 
interest in the co-occurrence of fibromyalgia and axSpA for two reasons. The first is a result 
of a United States Food and Drug Administration Arthritis Advisory Committee meeting in 
2013 which considered the case for expanding the use of Tumour Necrosis Factor inhibition 
(TNFi) therapy from ankylosing spondylitis to non-radiographic axSpA. The application was 
not approved partly because of concerns about the inappropriate use of such therapy for 
conditions such as back pain and fibromyalgia in the presence of minor magnetic resonance 
imaging (MRI) changes or positive HLA-B27 results (2).  The second reason is around 
understanding the mechanisms of development of fibromyalgia. One hypothesis is that 
peripheral nociception, if sustained such as in axSpA, could in the context of an individual 
susceptible to its development, lead to central sensitisation and the development of 
fibromyalgia .  An alternative possibility is that high levels of disease activity, and 
consequent pain, poor function and impact on quality of life including work, lead to 
emotional distress which itself has been shown to increase the risk of fibromyalgia. (3) 
 
The British Society for Rheumatology Biologics Register (BSRBR-AS) of patients with axSpA 
is by far the largest study to have examined fibromyalgia as a comorbidity in this condition. 
In analysis of 1504 patients, it reported that 20.7% met the 2011 research criteria for 
fibromyalgia (4, 5). Those with co-morbid fibromyalgia had high levels of unmet need; this 
included substantially worse disease activity scores , function, global status (all measured 
using Bath indices) and quality of life (4), findings which have been consistent across studies 
(6, 7). If persons with poorly controlled disease are more likely to fulfill criteria for 
fibromyalgia through the process of central sensitisation, then management should focus on 
reducing disease activity associated with axSpA. Alternatively if the co-morbid fibromyalgia-
like symptoms are unrelated to disease activity and arise through distinct mechanisms, then 
management should focus on the fibromyalgia (in addition to any management necessary 
for axSpA). 
 
In this analysis, using BSRBR-AS, we aimed to establish if distinct clusters of patients with 
axSpA exist, and if so to a) ascertain whether such clusters exhibit important differences in 
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the prevalence of fibromyalgia and b) determine features of the clusters which exhibit a 




BSRBR-AS is a prospective cohort study which recruited biologic-therapy naïve patients from 
across Great Britain fulfilling Assessment of SpondyloaArthritis international Society (ASAS) 
criteria for axSpA (8).  Recruitment for the study took place between December 2012 and 
December 2017 across 83 secondary care rheumatology centres.  Initially only those fulfilling 
the imaging ASAS criteria were eligible for inclusion, however from November 2014 those 
meeting the clinical arm were also eligible.  The full protocol has been published previously 
(9).  Patients were recruited to one of two sub-cohorts: those about to commence a biologic 
therapy (adalimumab, etanercept or certolizumab pegol) and those continuing on non-
biologic therapy.  The biologic cohort was followed up at 3 months and 6 months, and both 
cohorts were followed-up at 12 months and yearly thereafter up to a maximum of 5 years.  
If a patient in the non-biologic cohort commenced biologic therapy they switched sub-cohort 
and started a new follow-up schedule.     
 
Clinical data collected during recruitment and follow-up appointments included: the 
presence of extra-spinal manifestations (history of uveitis, psoriasis, inflammatory bowel 
disease (IBD), peripheral joint involvement, dactylitis and enthesitis), history of 
comorbidities and physician-assessed swollen and tender joint count (40 and 44 joints 
respectively), and Bath metrology index (BASMI).    In addition to clinical data, patient 
reported questionnaires were mailed at the same time and included validated instruments 
assessing, among others: Bath indices of disease activity (BASDAI), function (BASFI), global 
assessment (BAS-G), mental health (Hospital Anxiety and Depression Scale (HADs) (anxiety 
and depression subscales each scored 0-21) (10)), fatigue (Chalder fatigue scale, scored 0-
11 (11)) and sleep disturbance (Jenkins Sleep Evaluation Questionnaire, scored 0-20 (12)).  
From August 2015, the patient reported questionnaire included the 2011 modification of the 
2010 ACR criteria for fibromyalgia (5). As the aim of the current analysis was to identify 
discrete clusters within the axSpA population, in which the prevalence of fibromyalgia would 
be calculated; only participants who had completed a questionnaire after August 2015 were 
eligible for inclusion and amongst those who had, the first completion of the fibromyalgia 
research criteria was used as the time-point for data included in the current analysis. 
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Cluster analysis classifies individuals into groups (clusters) which optimise homogeneity 
within groups and heterogeneity between groups, based on a selection of pre-defined 
characteristics (clustering variables).  The groups formed are highly dependent on the 
variables offered for clustering, therefore, the choice of these is ideally underpinned by 
empirical evidence.  As the number of clusters is not known prior to analysis, a common 
approach is to determine the optimal clustering solution in one sample and to validate in a 
second sample.  The choice of variables for the current analysis was determined through 
simple descriptive statistics (t-tests) in which those factors associated with fibromyalgia at 
p≤0.05 were considered important.  To mitigate the effects of any differences in 
measurement scale used across clustering variables, and to adjust for non-normal 
distribution; each variable was standardised through z-score transformation.  Prior to 
analysis, the eligible BSRBR-AS population was split into two equal-sized samples in which 
the optimal clustering solution was developed (Sample A) and then validated (Sample B).  A 
three-stage approach was chosen:  
 
Stage 1 - An agglomerative hierarchical cluster analysis was applied to Sample A using the 
Euclidean distance measure and weighted-average linkage method.  The optimal number of 
cluster solutions was determined through consultation of the dendrogram and agglomeration 
schedule. 
Stage 2 - The optimal solution from stage 1 was validated in Sample B using K-means 
clustering.  The characteristics of each cluster was assessed and compared against those 
identified by the hierarchical analysis.  Where the clustering solutions appeared identical, 
or near-identical, the solution was considered validated. 
Stage 3 - Once the optimal solution was determined and validated (stages 1 & 2) the K-
means clustering was conducted once more within Samples A and B combined to identify 
the final groupings of all participants.  These clusters were examined in terms of both the 
clustering variables used (mean and standard deviations of non-transformed values) and the 
prevalence of fibromyalgia (or more specifically meeting research criteria for fibromyalgia).   
 
On completion of the clustering procedure, the final clusters were examined to explore 
differences in both clinician and patient-reported factors.  Demographic characteristics 
included: age, age at symptom onset, gender, smoking and alcohol use, while clinical factors 
included: classification criteria met, treatments prescribed and spinal mobility (BASMI: 
scored 0 (least) - 10 (most) severe (13)).  Patient reported measures of health, from 
questionnaires, included the BASDAI, BASFI and BAS-G: all scored 0 (least) - 10 (most) severe 
(14-16)) and spinal pain (scored 0 (least) - 10 (most) severe).  Quality of life was assessed 
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by the Ankylosing Spondylitis Quality of Life Index (ASQoL: scored 0 (good) to 18 (poor) (17)) 
and the short form 12 (scored 0 (poor) to 100 (best) (18)). Participants were asked to report 
co-morbidities including: myocardial infarction, unstable angina, congestive heart failure, 
stroke, hypertension, diabetes, asthma, chronic bronchitis/emphysema, peptic ulcer, liver 
disease, renal disease, tuberculosis, demyelination, depression and cancer. This allowed a 
co-morbidity “count” to be derived. Lastly, employment status was assessed by the Work 
Productivity and Activity Impairment scale (WPAI:SHP) to give an indication of work absence 
(absenteeism), impairment in work-productivity (presenteeism), overall work and non-work 
activity impairment (all scored as 0-100% (19)).  From the information collected, the 
Ankylosing Spondylitis Disease Activity Scale (ASDAS) was calculated using the measure of 
CRP (preferentially) or ESR closest to the patient completed questionnaire used, provided 
it was within 90 days (20). In addition to calculating the proportion of participants within 
each cluster meeting criteria for fibromyalgia, the sub-scales of the criteria, namely the 
Widespread Pain Index (WPI, score 0-19) and Symptom Severity Score (SSS, score 0-12) could 
be calculated. Differences were assessed using chi-square or t-tests as appropriate and 
results are given as proportions or means (with 95% Confidence Intervals). To determine if 
similar clusters exist within the subgroup of participants meeting research criteria for 
fibromyalgia, this subgroup was split into two equal-sized samples (C and D) and the entire 
clustering process described above was repeated. 
 





In total 1,338 participants were eligible for the current analysis of whom 65% were male, 
with a median age of 49 years, and median time since symptom onset of 18 years, and 36% 
had been recruited to the biologic cohort of the study. Of those tested, 79% were HLA-B27 
positive. Most participants (64.6%) met the modified New York (mNY) criteria for ankylosing 
spondylitis, a further 29.7% fulfilled the ASAS imaging criteria for axSpA but not mNY, while 
5.7% only met ASAS clinical criteria for axSpA.  At the time when first completing research 
criteria for fibromyalgia, 23% (n=307) were classified positive.  Prior to further analysis, the 
study population was randomly split in two equal sized groups.  
 
Factors significantly associated with meeting fibromyalgia research criteria were identified 
and were eligible to be used in the cluster analysis. Where an eligible variable was strongly 
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related to another eligible variable, only the factor with the strongest relationship to 
fibromyalgia was used for clustering. The final variable group used for clustering was: 
number of extra-spinal manifestation and co-morbidity count, swollen joint count, tender 
joint count, anxiety, depression, fatigue and sleep disturbance.    
 
The results of the hierarchical analysis in Sample A indicated the presence of 4 distinct 
clusters which were validated in Sample B with the K-means analyses.  Differences in the 
clustering factors across each of the 4 clusters for samples A and B combined are detailed 
in Table 1 and Figure 1. There was one small cluster (Cluster 1) with 32 subjects. It was 
characterised by high scores or levels across all clustering variables and amongst 
participants in this cluster there was a very high proportion of participants who met research 
criteria for fibromyalgia (53%). The remaining clusters were of roughly equal size (varying 
between 347 and 462 subjects). Cluster 2 was characterised by few extra-spinal 
manifestations and comorbidities, low number of tender and swollen joints but high levels 
of anxiety, depression, fatigue and sleep disturbance. This cluster also had a very high 
proportion meeting research criteria for fibromyalgia (54%). Participants classified in Cluster 
3 had few extra-spinal manifestations or comorbidities, a low number of tender and swollen 
joints low levels of anxiety, depression, fatigue and sleep disturbance. There was a low 
proportion meeting research criteria for fibromyalgia (4%). Finally Cluster 4 was 
characterised by few extra-spinal manifestations or comorbidities, a low number of tender 
and swollen joints, low levels of anxiety, depression and fatigue, but moderate sleep 
disturbance. There was a moderate proportion meeting research criteria for fibromyalgia 
(16%). 
 
Examining factors which were not used in the clustering (Table 2), it is notable that the 
members of Clusters 1 and 2, with more than half meeting criteria for fibromyalgia, had 
markedly worse axSpA disease activity, function, global status, spinal pain, poorer mental 
and physical health. Both clusters had mean ASDAS values in the “very high disease activity” 
range. (i.e. >3.5). Quality of Life and work impact were also worst in Clusters 1 and 2, with 
intermediate levels in Cluster 4 in comparison to Cluster 3. Clusters 1 and 2 were the most 
likely to be receiving biologic therapy (31% and 39% respectively) followed by Cluster 4 (24%) 
and Cluster 3 (14%).  There were approximately double the proportion of smokers in Clusters 
1 and 2 (25% and 29% respectively) compared to Clusters 3 and 4 (13% and 14%), however in 
contrast, more had given up alcohol (28% and 28% v. 10% and 14%).  Cluster 1 was 
distinguished by having a much higher proportion of female members (59%) than any other 
cluster (30-40%). 




Participants meeting research criteria for fibromyalgia were split into two samples (C and 
D).  The results of the hierarchical analysis on Sample C indicated that there were three 
distinct clusters which was validated in the K-means analysis using Sample D. The 3 cluster 
solution using both Samples C and D combined is shown in Table 3.   Cluster 1 was small  
(n=17) with  members scoring very highly on tender and swollen joints, anxiety, depression, 
fatigue and sleep problems and consequently had high pain and symptom severity scores on 
the fibromyalgia research criteria. This cluster was predominantly female (77%), in contrast 
to the other clusters which had 40-48% female members. Cluster 2 was larger (n=157), with 
average characteristics very similar to Cluster 1 except that almost all members had  no 
swollen or tender joint and had lower levels of co-morbidities and extra-spinal 
manifestations. Nevertheless the WPI and SSS were very similar between Clusters 1 and 2. 
In contrast, subjects in Cluster 3 (n=120) scored lower across all domains and consequently 
had average WPI scores lower by between 1.3-1.5 and SSS lower by between 2.0-2.2.  
 
Examining factors which were not used in the clustering of fibromyalgia patients (Table 4) 
Clusters 1 and 2 were very similar with respect to almost all the characteristics examined 
although Cluster 1 had primarily female members and members who were less likely to have 
recent use of DMARDs. Cluster 3 had better disease activity, although all three fibromyalgia 
patient clusters had ASDAS scores in the “very high disease activity” range.  Cluster 3 also 





We have found evidence of distinct groups of axSpA patients: those with high disease activity 
which is either mainly axial or (in a smaller group) both axial and peripheral and in whom 
more than half of persons meet criteria for fibromyalgia; patients with low disease activity 
(in whom the prevalence of fibromyalgia is similar to persons without axial 
spondyloarthritis); and a group of patients with intermediate disease activity but with high 
levels of sleep disturbance and a raised prevalence of fibromyalgia. Within patients who 
meet criteria for fibromyalgia, there are two groups with higher axSpA disease activity (one 
with primarily axial disease and a smaller group with axial and peripheral disease) and this 
is reflected in higher pain and symptom severity scores of the fibromyalgia research criteria, 
in comparison to a third group. 
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The strength of this study was that it used a large national register to which most patients 
with axial spondyloarthritis were eligible to be enrolled. In examining clusters it used a split 
sample approach for their development and validation. It found consistent results – there 
were similar clusters within the total axSpA participant group and the sub-group who met 
research criteria for fibromyalgia. The clusters within the population group exhibited 
proportions meeting the research criteria for fibromyalgia which varied from the norm in 
the general population (~2-5%) ((21) to two groups with a prevalence of more than 50%. 
There are some methodological issues to be considered in the interpretation. Ideally the 
cluster structure should be confirmed in an external dataset.  Not all patients with axSpA 
meeting ASAS criteria were eligible to join the register – those patients who had already 
commenced biologic therapy or had previous experience of biologic therapy were not 
eligible to be enrolled. The overall proportion of biologic therapy patients recruited was 7% 
lower than  the proportion reporting taking biologic therapy in a recent survey of 1979 
members of the National Ankylosing Spondylitis Society – the UK patient support group (36% 
v. 43%) (22). The relative size of the clusters should be considered indicative, therefore. 
This is particularly true with respect to patients who meet only the clinical arm of the ASAS 
criteria. They were only eligible for the registry in the latter 3 years of the 5-year 
recruitment period. We therefore examined the relative sizes of the clusters if only this 
latter period was considered.  For all patients the distribution (for 1000 nominal patients) 
changed from 25:274:337:364 across Clusters 1-4 to 25:296:302:377 and for FM patients from 
58:534:408 across Clusters 1-3 to 62:541:397.  Thus it can be seen that the relatively sizes 
of the clusters are changed very little when we consider only the period over which patients 
meeting the clinical criteria of ASAS were eligible. 
 
The second methodological issue is that the patient data used in this study varied with 
respect to their entry into the study. Some patients who were enrolled later in the 
recruitment period would have completed the fibromyalgia criteria at baseline or at one of 
the first follow-ups while for those recruited early it may have been up to 2.5 years before 
they completed their fibromyalgia assessment. Thus for the biologic therapy group, they 
will have completed this at various points in their history of such therapy. Finally the 2011 
research criteria for fibromyalgia have not specifically been validated in the context of 
inflammatory arthritis. Indeed the criteria as published exclude persons if their pain could 
be explained by another condition. However almost all studies which have implemented the 
2011 research criteria have dropped this question as it is considered difficult to evaluate 
and indeed it has been removed from the 2016 revision of the criteria (23). We note however 
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that in the cluster analysis of all axSpA patients, most of the axSpA patients with high 
swollen and tender joint count were in Cluster 1, and that cluster has a very high prevalence 
of fibromyalgia. It is possible that such peripheral involvement may result in high numbers 
of body regions scored as painful in the fibromyalgia criteria (although the influence 
on abdominal pain and headache aspects of the criteria is less obvious).  
 
The results of the current study show that inflammation is strongly associated with meeting 
criteria for fibromyalgia. The clusters with high disease activity all had a high prevalence of 
fibromyalgia. Basu et al (24) have shown that RA patients who have features of fibromyalgia 
(what they call “fibromyalgianess”), demonstrate similar neurobiologic features, on 
imaging, to that observed in fibromyalgia patients. A further study reported that high levels 
of inflammation in RA were associated, on MRI, with more positive connections between the 
inferior parietal lobule, medial prefrontal cortex, and multiple brain networks, as well as 
reduced inferior parietal lobule grey matter, and that these patterns of connectivity were 
associated with reported fatigue, pain and cognitive dysfunction (25). The authors postulate 
that such networks may provide a mechanism by which peripheral inflammation results in 
central changes and features typically associated with fibromyalgia, although to what extent 
this association is mediated through emotional distress remains to be established. When 
treated with TNFi therapy, axSpA patients in BSRBR-AS with co-morbid fibromyalgia showed 
a similar absolute improvement in disease activity and quality of life over 6 months 
compared to those without co-morbid fibromyalgia, and two-thirds no longer satisfied 
fibromyalgia criteria suggesting that targeting inflammation is important to reduce 
fibromyalgia symptoms in patients with active axSpA (26). 
 
An alternative explanation is that having fibromyalgia distorts the measures used to assess 
axSpA. Indeed, Alluno et al (27) demonstrated that measures thought to be disease specific 
such as the Bath indices are not axSpA specific. However it is unlikely that this can entirely 
account for the current observations. Duffield et al (1) in their meta-analysis of chronic 
inflammatory arthritis reported that across studies included, patients with axSpA and 
fibromyalgia had BASDAI scores that were around two points higher than those with axSpA 
alone (mean difference 2.2 95% CI (1.9, 2.6)). The differences observed in BASDAI between 
clusters in our study greatly exceed such levels. A previous paper from the BSRBR-AS 
demonstrated that the presence of co-morbid fibromyalgia increased BASDAI scores, on 
average only by 1.04 (after adjustment for other features of the disease) and increased the 
the ASQoL score (indicating poorer quality of life) by 1.42 (26). 
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However around one-third of patients with axSpA and fibromyalgia still have co-morbid 
fibromyalgia even after TNFi and those least likely to respond have high scores on the 
fibromyalgia symptom severity scale (26). The retention rate on TNFi at 2 years is also lower 
for axSpA patients with co-morbid fibromyalgia (28% v. 42%) (6). It seems therefore that 
even if inflammation is the primary driver of fibromyalgia symptoms, then once developed, 
therapeutic targeting of inflammatory pathways while important, is not sufficient. Further 
we have observed in the cluster results of all axSpA, a group of patients with modest disease 
activity and high levels of sleep disturbance who show a high prevalence of fibromyalgia. 
Whether additionally using non pharmacologic therapies (such as cognitive behaviour 
therapies) improves outcomes in such patient groups is not known but evidence in relation 
to pain (including fibromyalgia) and sleep disorders is promising (28, 29) and is currently 




In summary, this analysis has demonstrated distinct groups of axSpA patients with very 
different likelihood of reporting co-morbid fibromyalgia. The major feature defining clusters 
with a high prevalence of fibromyalgia is high disease activity and taken together with 
evidence from previous studies in this population, and others, managing the co-morbid 
fibromyalgia may be most successful with pharmacologic therapy to target inflammation but 
enhanced by the concurrent use of non-pharmacologic therapy.  This hypothesis awaits 
testing in formal studies. The recording of information on features of fibromyalgia is not 
routine in most clinics assessing axSpA – and it would be important, if we seek to provide 
appropriate approaches to management to firstly ensure we are collecting relevant 
information to identify such disease features.   
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Tables and Figure 
Table 1 – Clustering variables across clusters (total population) and proportion meeting research criteria for fibromyalgia 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4 
N 32 347 427 462 
Clustering Factors Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) 
Extra-spinal manifestation & comorbidity 
count 
3.3 (2.7, 3.9) 1.3 (1.1, 1.4) 0.7 (0.6, 0.8) 1.2 (1.1,1.3) 
Swollen joint count 8.1 (5.5, 10.7) 0.1 (0.03, 0.2) 0.05 (0.01, 0.1) 0.1 (0.05, 0.13) 
Tender joint count 14.3 (11.2, 17.3) 0.4 (0.2, 0.5) 0.2 (0.1, 0.3) 0.4 (0.3, 0.6) 
Anxiety score 10.5 (8.6, 12.5) 12.2 (11.8, 12.5) 3.6 (3.4, 4.0) 4.5 (4.2, 4.7) 
Depression score 9.2 (7.6, 10.8) 10.3 (10.0, 10.7) 2.2 (2.0, 0.4) 5.2 (5.0, 5.5) 
Fatigue score 7.1 (5.9, 8.3) 8.0 (7.7, 8.3) 0.9 (0.8, 1.1) 3.2 (2.9,3.4) 
Sleep disturbance score 14.4 (12.4, 16.5) 14.5 (14.0, 15.0) 3.9 (3.6, 4.2) 11.2 (10.7, 11.6) 
 
FM research criteria (and components) 
Proportion positive (%) 53% 54% 4% 16% 
Widespread pain index 7.2 (6.0, 8.5) 7.4 (7.0, 7.8) 2.9 (2.7, 3.2) 5.0 (4.7, 5.3) 
Symptom severity score  7.9 (6.9, 8.9) 8.4 (8.2, 8.7) 2.7 (2.5, 2.9) 5.4 (5.2, 5.6) 




Table 2 – Differences in clinical and patient reported characteristics (not used in clustering) across clusters (total population) 
 Cluster 1 Cluster 2 Cluster 3 Cluster 4  
 N (%)  N (%) N (%) N (%) p value 






































































































































       
  Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)  
Age  
years 49.5 (45.2, 53.8) 47.5 (46.0, 48.9) 49.4 (48.1, 50.7) 50.3 (48.9, 51.6) p=0.06
2 
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Age at symptom onset  
years 31.7 (27.7, 35.7) 30.7 (29.3, 32.0) 28.7 (27.8, 29.8) 29.7 (28.6, 30.8) p=0.07
4 
Disease Activity  
BASDAI: 0 (best) – 10 
(worst) 
6.7 (5.9, 7.4) 6.7 (6.5, 6.9) 2.5 (2.3, 2.6) 4.5 (4.3, 4.7)* p<0.00
1 
Disease Activity 
ASDAS Score 3.6 (3.2, 4.0) 3.7 (3.6, 3.8) 2.2 (2.1, 2.3) 2.9 (2.7, 3.0)* p<0.00
1 
Physical Function  
BASFI: 0 (best) – 10 
(worst) 
6.2 (5.4, 6.9) 6.5 (6.3, 6.8) 2.5 (2.3, 2.7) 4.2 (4.0, 4.5)* p<0.00
1 
Spinal Mobility  
BASMI: 0 (best) – 10 
(worst) 
4.2 (3.6, 4.8) 4.1 (3.8, 4.3) 3.4 (3.2, 3.6) 3.7 (3.4, 3.9) p<0.00
1 
Patient Global  
BASG: 0 (best) – 10 
(worst) 
6.9 (6.2, 7.5) 7.0 (6.8, 7.2) 2.6 (2.4, 2.8) 4.6 (4.3, 4.8)* p<0.00
1 
Spinal Pain  




100 (best) – 0 (worst) 37.6 (33.0, 42.1) 35.2 (34.3, 36.1) 54.0 (53.3, 54.6) 47.2 (46.3, 48.0)* p<0.00
1 
SF12 Physical 
Component   
100 (best) – 0 (worst) 32.3 (29.3, 35.3) 32.3 (31.2, 33.4) 46.2 (45.3, 47.1) 39.4 (38.4, 40.5)* p<0.00
1 
Quality of Life  
ASQoL: 0 (best) – 18 
(worst)) 
12.9 (11.3, 14.4) 13.3 (12.9, 13.7) 3.0 (2.7, 3.3) 7.9 (7.5, 8.3)* p<0.00
1 
Work absence 
absenteeism (%) 17.4 (0.1, 34.7) 11.2 (7.7, 14.6) 0.4 (0.1, 0.7) 4.4 (2.6, 6.1)* p<0.00
1 
Work impairment 








(%) 63.1 (53.8, 72.4) 65.4 (63.1, 67.6) 19.8 (17.9, 21.7) 38.4 (36.1, 40.6)* p<0.00
1 
* significant difference between cluster 3 & 4 at p<0.05 
 




Table 3 – Clustering variables across clusters and fibromyalgia criteria sub-scale scores (amongst 
participants who met criteria for fibromyalgia) 
 Cluster 1 Cluster 2 Cluster 3  
N 17 157 120 
Clustering Factors Mean (95% CI) Mean  (95% CI) Mean (95% CI) 
Extra-spinal manifestation & comorbidity count 3.7 (2.8, 4.6) 1.5 (1.2, 1.7) 1.3 (1.0, 1.5) 
Swollen joint count 7.1 (4.2, 10.0) 0.08 (0.002, 
0.16) 
0.1 (0.01, 0.13) 
Tender joint count 15.0 (11.7, 18.3) 0.5 (0.2, 0.8) 0.4 (0.1, 0.7) 
Anxiety (HADs - scored 0-21) 12.4 (9.8, 15.1) 13.2 (12.6, 13.7) 8.1 (7.5, 8.7) 
Depression (HADs - scored 0-21) 10.8 (8.7, 12.9) 11.2 (10.7, 11.7) 6.2 (5.7, 6.7) 
Fatigue (Chalder Fatigue - scored 0-11) 8.9 (7.6, 10.2) 8.5 (8.1, 8.9) 4.6 (4.0, 5.2) 
Sleep disturbance (Jenkins - scored 0-20) 18.1 (16.6, 19.6) 16.0 (15.4, 16.6) 10.1 (9.1, 11.1) 
 
FM components 
Widespread pain index 9.4 (7.7, 10.0) 9.2 (8.6, 9.8) 7.9 (7.3, 8.4) 
Symptom severity score  9.5 (8.6, 10.4) 9.7 (9.4, 10.0) 7.5 (7.2, 7.9) 
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Table 4 – Differences in clinical and patient reported characteristics (not used in clustering) across clusters 
(fibromyalgia positive participants) 
 Cluster 1 Cluster 2 Cluster 3  




























































































      
  Mean 95% CI Mean  (95% CI) Mean (95% CI)  
Age years 49.2 (43.3, 55.0) 47.8 (45.7, 50.0) 50.4 (47.8, 53.0) p=0.445 
Age at symptom onset years 29.2 (25.6, 33.0) 29.7 (27.7, 31.7) 29.7 (27.5, 31.9) p=0.873 
Disease Activity  
BASDAI: 0 (best) – 10 
(worst) 7.8 (7.2, 8.5) 7.4 (7.2, 7.6) 6.0 (5.7, 6.2) p<0.001 
Disease Activity ASDAS 3.8 (3.4, 4.2) 3.9 (3.8, 4.1) 3.3 (3.2, 3.5) p<0.001 
Physical Function  
BASFI: 0 (best) – 10 
(worst) 7.2 (6.3, 8.1) 7.2 (6.9, 7.5) 5.5 (5.1, 5.9) p<0.001 
Spinal Mobility  
BASMI: 0 (best) – 10 
(worst) 4.3 (3.4, 5.1) 4.2 (3.8, 4.6) 4.1 (3.6, 4.6) p=0.934 
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Patient Global  
BASG: 0 (best) – 10 
(worst) 7.7 (7.1, 8.3) 7.7 (7.4, 7.9) 6.1 (5.7, 6.5) p<0.001 
Spinal Pain  0 (best) – 10 (worst) 6.2 (4.7, 7.6) 7.1 (6.8, 7.4) 5.6 (5.1, 6.0) p<0.001 
SF12 Mental 
Component  
100 (best) – 0 
(worst) 31.4 (26.6, 36.3) 32.5 (31.1, 34.0) 44.2 (42.5, 45.9) p<0.001 
SF12 Physical 
Component  
100 (best) – 0 
(worst) 28.9 (25.0, 32.8) 29.9 (28.4, 31.5) 34.3 (32.4, 36.2) p<0.001 
Quality of Life  
ASQoL: 0 (best) – 18 
(worst) 15.4 (14.2, 16.7) 14.6 (14.1, 15.1) 10.9 (10.2, 11.5) p<0.001 
Work absence  absenteeism: % 7.0 (1.3, 12.7) 14.2 (8.2, 20.1) 9.3 (4.4, 14.1) p=0.737 








75.9 (66.4, 85.4) 72.0 (69.4, 74.7) 54.5 (50.2, 58.8) p<0.001 
* significant difference between cluster 1 & 2 at p<0.05 
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Chapter 3 Discussion 
 
The work in this thesis has demonstrated that: 
• there is a reasonably good evidence-base on which to make recommendation for the 
management of fibromyalgia as determined by work undertaken for the revised 
EULAR management recommendations. In terms of improving pain, sleep, fatigue 
and daily functioning in people with fibromyalgia, a non-pharmacological approach 
should be the initial strategy. Exercise is effective.  However, it is unknown whether 
the effectiveness is modified by type of exercise or frequency/duration. Of other 
therapies, a cognitive behavioural approach was effective across a large number of 
trials, although the effect sizes were relatively modest. Pharmacological therapies 
generally showed at best modest benefits and were associated with side effects.  It 
was recommended that pharmacological approaches should only be used to address 
specific aspects of the condition which weren’t sufficiently improved by a non-
pharmacological approach.  The recommendations from the review gave specific 
research recommendations which will be discussed later. 
 
• the results of an RCT testing exercise and CBT for chronic widespread pain (which 
demonstrated benefit of both approaches but no additional benefit of receiving 
both), were robust to taking account of the characteristics of persons who were 
identified as eligible but chose not to take part in the trial. The estimated “number 
needed to treat” changed by no more than 1 for either (or both) of the interventions 
at short and long-term follow-ups.  
 
• persons with chronic widespread pain are at considerable increased risk of premature 
mortality (in comparison to persons of similar age and gender without chronic 
widespread pain). In addition to all-cause mortality the excess is present also for 
cardiovascular and cancer mortality. This is unlikely to be due to the experience of 
pain itself but rather consequences of that experience.  When the statistical models 
took account of lifestyle factors (or markers of such) amongst people with chronic 
widespread pain, the major part of the excess risk was no longer evident, which is 
consistent with them being on the path between the experience of chronic 
widespread pain and mortality risk. 
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• a large part of the excess risk of death in persons with chronic widespread pain, after 
taking account of lifestyle factors, was further attenuated when adjustment was 
made for use of opioid medicines.  This work showed that there could be a 
relationship between opioid use and excess mortality although there is considerable 
uncertainty in this observation which may be explained by unmeasured confounding 
factors. If there is a risk, however, it is small in magnitude and any excess risk is 
with disease related, rather than non-disease related, deaths.  The major finding 
from this paper is, even in a study whose participants have been shown to be more 
healthy than the general population, the widespread use of opioid medication (the 
vast majority amongst persons with chronic pain). Specific groups (e.g. those living 
in areas with high levels of deprivation, with low household income and/or who left 
education at a young age,  and those no longer working due to ill-health) were 
identified who had very high levels of use. 
 
Taking together the three manuscripts on fibromyalgia and axial spondyloarthritis, the 
major findings were that: 
• around 1 in 5 of people with axial spondyloarthritis met criteria for fibromyalgia. 
They reported significantly worse disease activity, function, global severity scores, 
and quality of life, and were more likely to have moderate or severe levels of mood 
disorder and clinically important fatigue, but they did not have higher C-reactive 
protein levels or most extraspinal manifestations. They were more likely to have 
received biologic therapy. They appeared to have more severe disease but the only 
measure that was not self-reported did not differ between people with and without 
fibromyalgia. 
 
• persons who met criteria for fibromyalgia had marginally worse quality of life and 
disease activity, which could not be explained by features of their axial 
spondyloarthritis. However the absolute benefit of biologic therapy on disease 
activity was similar in people with co-morbid fibromyalgia and their likelihood of 
meeting ASAS20 response criteria was the same as persons without co-morbid 
fibromyalgia.   
 
• the defining feature of clusters of people with axial spondyloarthritis in whom a high 
proportion of people met criteria for fibromyalgia was high axSpA disease activity, 
although clusters which included people with some of the symptoms associated with 
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fibromyalgia (e.g. sleep disturbance) in the absence of high disease activity also 
showed moderately high prevalence. This emphasised the likely important role of 
management specifically targeted at features of fibromyalgia in those not responding 
to pharmacological therapy, alongside other appropriate management. 
 
The main implications of the work, taken together, is influencing how people with chronic 
widespread pain or fibromyalgia can be optimally managed. Some of the key issues will be 
discussed below. 
 
3.1 Optimising outcomes for people with chronic widespread pain/fibromyalgia with 
approaches which have been shown to be effective  
 
Exercise is effective – however the challenge is how to deliver this. We know from behaviour 
change studies that simply giving people information is not sufficient. People with chronic 
pain or fibromyalgia are more likely to be overweight than persons without, may not be used 
to regular exercise, and indeed may find it difficult to know how to start. Often exercise 
can initially cause pain to become worse and without appropriate support and knowledge, 
persons with chronic pain and fibromyalgia may believe that the exercise is causing damage 
and stop.  One of the participants in our trial of CBT and exercise (Beasley et al, 2015) who 
took part in the qualitative evaluation, made this point (as reported by Bee et al, 2016): 
“It wasn’t fair to keep going to the gym and making myself – because I was worse, so much 
worse when I’d been. So I thought, well,.. I’m not going to carry on doing it to make myself 
worse and suffer.” 
It also takes considerable commitment in terms of planning and preparation, as emphasised 
by another participant reported in the same study: 
“It wasn’t easy and a couple of times, when I had lots on, I didn’t go. It seemed to take up 
a lot more time than you expected, getting there and changing. It did take up quite a lot 
of time. It needs a lot of planning really, because for me, well, I found it changes your 
routine.” 
Nevertheless a meta-analysis of adherence to walking programmes among women with 
fibromyalgia, found that in quasi-experimental and randomised controlled trials, adherence 
ranged from 73-87% (Sanz-Baños et al, 2018). Further in long-term follow-up of participants 
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in our trial of exercise and CBT (Beasley et al, 2015) we identified that 164 out of 196 
participants maintained around 5 exercise sessions per week (which were at least moderate 
intensity) 5 years after the end of the intervention (Martin et al, 2019). Of this group 20 
were people who had always maintained very high levels of exercise (around 10 
sessions/week).  
Most support for exercise probably comes through physiotherapy in secondary care, although 
this is likely to be an expensive mode of delivery. However it does allow physiotherapists 
the opportunity to deliver exercise within an overall behavioural (or psychologically-
informed) approach to management (as discussed by Denneny et al, 2020) and as 
implemented in one of our trials of low back pain (Johnson et al, 2007). There are also 
models of linking with providers of physical activity in the community (such as sports 
centres); this necessitates the training of personnel and providing appropriate levels of 
support. The National Institute for Health and Care Excellence (NICE) reviewed exercise 
referral schemes and have supported their use for persons who are sedentary, have existing 
health conditions which put them at increased risk of ill-health, provided the schemes meet 
certain criteria (NICE Public Health Guideline PH54, 2014) – one of which is that they 
incorporate sets of techniques which aim to change the health behaviours of individuals.  
There has also been support, within specific clinical guidelines, for structured exercise 
programmes, including those for low back pain (NICE Guideline NG 59, 2016) and chronic 
fatigue syndrome (NICE Clinical Guideline 53, 2007). 
Despite this, many recommendations or guides for management simply focus on 
recommendations that exercise is effective without giving any indication of how exercise is 
best facilitated. Arnold et al (2016) in recommendations for management of fibromyalgia in 
primary care state “continuation of the exercise regimen is important, because ongoing 
exercise has been associated with maintenance of improvements in FM” and indeed this 
could be a criticism also of the revised EULAR guidelines. However O’Dwyer et al (2019) in 
a systematic review of interventions in patients with fibromyalgia, using behaviour 
techniques to increase physical activity, reported only limited success, although Meade et 
al (2019) in a systematic review showed with respect to patients with musculoskeletal pain, 
that trials which included behaviour change techniques were more like to report adherence 
to the exercise regime.  
In terms of thinking of other non-pharmacological therapies such as behavioural therapies, 
a common criticism is that although it is known that behavioural therapies are somewhat 
effective for chronic pain conditions, there is very limited access to clinical psychologist 
services. Indeed in 2019 the Migration Advisory Committee (MAC) considered that there was 
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a national shortage of psychologists and recommended adding them to the Shortage 
Occupation List (SOL). In their evidence to the committee the Department of Health and 
Social Care stated that “there is a need for clinical psychologists to go onto the SOL due to 
limited increases in supply and significant increases in demand as well as high vacancy rates” 
(MAC report, 2019). Notwithstanding the necessity for clinical psychologists to be available 
to deliver care for persons with chronic pain, it should be emphasised that it is not necessary 
to have such highly skilled persons delivering behavioural therapy to all such patients even 
where behavioural therapy is identified as appropriate. In the trial which formed the basis 
of the data in Chapter 2.2 (Beasley et al, 2015) the intervention was delivered by therapists 
accredited by the British Association for Behaviour and Cognitive Psychotherapies (BABCP). 
At a minimum this requires a Bachelor of Science degree and a two-year course leading to 
a postgraduate diploma in cognitive behaviour psychotherapies (CBP). Further there has 
been a considerable amount of research in terms of internet-based therapies. The potential 
advantage of such a self-directed approach is that it requires less input by the therapist 
(usually somewhere between 1-15 mins/week). A meta-analysis of 20 studies involving 1460 
participants showed that internet delivered CBT was effective in the treatment of insomnia 
(Zachariae et al, 2016) while a meta-analysis of 20 studies involving 1418 participants 
comparing face-to-face and internet delivered CBT for psychiatric and somatic symptoms  
found that there was no evidence to conclude that they were not equivalent (although 
encouraged further larger trials) (Carlbring et al, 2018). Further studies have examined the 
training of members of the care team to deliver behavioural therapy (usually nurses) in 
terms of making any service sustainable and these have been shown to be effective in terms 
of chronic pain (e.g. Rutledge et al, 2018) and in related areas such a fatigue (Hewlett et 
al, 2019). Thus we need to move away from thinking of behaviour therapies just being 
delivered by clinical psychologists and to reserve such specialist expertise for those patients 
with the most complex requirements, instead looking at different methods of delivery and 
delivery by members within existing clinical teams.  
A second issue with behavioural therapies is that often patients are unenthusiastic in 
engaging with them. In trials of CBT both in terms of managing chronic widespread pain and 
preventing its onset of which I was chief investigator (Beasley et al, 2015; Macfarlane et al, 
2016), around one-third of persons allocated to receive CBT did not engage with the 
treatment. This was, of course, in groups who had agreed to be randomised into a trial 
where either one of the active arms or the only active arm was CBT and thus the non-
engagement rate is likely to be much higher in an unselected sample. Indeed in the 
qualitative work undertaken alongside one of these trials Bee et al (2016) reported that 
“psychological therapy brought with it connotations of social judgement, deviance and 
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stigma” but also that the “experience of psychological therapy often exceeded 
expectation”. Higgins et al (2018) examined characteristics of people with chronic low back 
pain who did not agree to be enrolled in a non-inferiority trial of cognitive behaviour therapy 
comparing face-to-face v. technology enabled delivery at a Veterans Health Affairs (VHA) 
centre in the United States. In total 54% of 290 persons declined participation and the single 
factor predicting such was currently taking opioid therapy.  It may be that in order to 
increase engagement with such therapies introductory sessions may be useful in terms of 
discussing what the therapy is (and what it is not) and perhaps also involving people who 
have derived benefit from such approaches speaking about their experience.  If done within 
a formal evaluation, outputs of interest would be the proportion of people originally not 
willing to take part in a behavioural therapy course who did subsequently take part and also 
whether these people benefit to the same extent as others taking part in such a course.  
The perception of a therapy such as CBT is important as within the same trial, treatment 
expectations were shown to influence the likelihood of response (Beasley et al, 2017) while 
overall in musculoskeletal trials a meta-analysis demonstrated that patients who received 
their preferred treatment had better outcomes than those who did not (Preference 
Collaborative Review Group, 2008).  
In terms of the role of pharmacological therapies – there are currently no medicines licensed 
in the UK or the European Union specifically for fibromyalgia, although there are 
medications used for specific features (such as low-dose short-term amitryptiline which has 
been shown to improve sleep, pain and fatigue). In contrast there are three drugs licensed 
in the United States (duloxetine, milnacipran and pregabalin). A “consumer report” carried 
out in Germany amongst 1661 patients showed that the most common therapies used were 
self-management, pain prescription and aerobic exercise, while the therapies considered 
most effective were local and systemic heat therapies, education and rest. Pharmacological 
therapies featured strongly in approaches which were noted by patients to have had 
important side effects and included opioid therapies, tramadol, ƴ-amino butyric acid 
analogues (gabapentin and pregabalin) and tramadol (Hauser et al, 2012). In a further study 
using a research registry of patients with rheumatic diseases, it was reported that amongst 
patients with fibromyalgia taking one of the “new centrally acting drugs” (pregabalin, 
duloxetine and milnacipran) the median time to drug discontinuation was 2.5 years 95% CI 
(2, 3.5 years) (Wolfe et al, 2013). In the same study, with data collection in 2010, 13% of 
patients with fibromyalgia were using strong opioids (medications for which there was a 
“strong against” recommendation in the EULAR revised recommendations for the 
management of fibromyalgia on the basis of their lack of efficacy and side effect profile) 
while 47% were using any type of opioid.   
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In terms of whether there are new approaches to the pharmacological management of 
fibromyalgia, a subsequent Cochrane review has examined the evidence in relation to 
combined pharmacological therapy but concluded on the basis of 16 studies with 1474 
participants that “there are few, large, high-quality trials comparing combination 
pharmacotherapy with monotherapy for fibromyalgia, consequently limiting evidence to 
support or refute the use of combination pharmacotherapy for fibromyalgia” (Thorpe et 
al, 2018).  There has been some interest in the use of cannabinoids for the management of 
pain in rheumatic and musculoskeletal disorders and specifically fibromyalgia (Sarzi-Puttini 
et al, 2019). A meta-analysis (with meta-regression by pain type) examined the efficacy of 
cannabinoids for chronic pain. Thirty-three studies contributed to the meta-analysis and 
these demonstrated a mean benefit over placebo (in terms of a 0-10 scale pain score) of 
0.7. Reductions were evident across mode of delivery and there was no difference in 
effectiveness for neuropathic and non-neuropathic pain (Wong et al, 2020). These 
conclusions are similar to another meta-analysis published around the same time and using 
a broadly similar body of evidence, which in addition reported that while there was no 
difference in serious adverse events at two weeks follow-up there was an increase in non-
serious adverse events (the most common of which was dizziness reported by 31% of 
participants across studies) (Johal et al, 2020). This review also emphasised that conclusions 
were restricted at present to short-term follow up (2 weeks of treatment). There was a 
single trial included in the latter study in relation to fibromyalgia, testing the use of 
Nabilone, a synthetic cannabinoid (Skrabek et al, 2008). A subsequent Cochrane review on 
this topic included two studies, both involving nabilone (compared to placebo in one study 
and amitryptiline in the other) with a total of 72 subjects (Walitt et al, 2018).   They 
concluded that there was “no convincing, unbiased, high quality evidence suggesting that 
nabilone is of value in treating people with fibromyalgia. The tolerability of nabilone was 
low in people with fibromyalgia.” 
Considering the research priorities listed in the revised recommendations for fibromyalgia – 
how can they be best addressed and what progress has been made?  Where relevant we will 
bring in results in the current thesis in considering specific recommendations.  
 
3.2 Which type of exercise is most effective: strength and/or aerobic training? 
 
Common questions asked in terms of exercise for fibromyalgia are about “What type of 
exercise is most beneficial?” and also in relation to dose “How much exercise should people 
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with fibromyalgia undertake?”. Specifically in relation to the latter, people with 
fibromyalgia describe a cycle of “boom and bust” in that they undertake activities and if 
they do “too much” then that has a negative effect on their health subsequently. Studies 
have shown that cognitive and physically demanding tasks result in greater reporting of 
cognitive and physical fatigue in people with fibromyalgia compared to people without 
(Dailey et al, 2015). For that reason, management often focusses on pacing as described in 
Jamieson-Lega et al (2013). Therefore the questions are extremely relevant. The ways in 
which this question could be addressed include a randomised controlled trial, although the 
likelihood is that the trial would need to be very large. It is likely that both forms of exercise 
have positive effects and therefore the trial would be seeking to detect the difference in 
effect between two forms of exercise which may be quite small. Further the trials would 
need to have their sample sizes inflated because of likely issues with adherence to the type 
of exercise allocated. Alternatively, one could undertake a network meta-analysis i.e. a 
meta-analysis which not only compares treatments which have been the subject of direct 
comparisons in trials but also compares treatments indirectly. For example, if there are 
trials which have compared treatments A and B, and trials which have compared treatments 
B and C, a network meta-analysis will allow one also to make estimates of the effectiveness 
comparing A with C.  
I am not aware of any trials examining differences between type of exercise nor a network 
meta-analysis examining such. Andrade et al (2020) undertook an umbrella review of studies 
of exercise in patients with fibromyalgia. They focussed on systematic reviews but did not 
undertake a meta-analysis. They concluded that there were positive effects for aerobic 
exercise, strength training, aquatic exercises and movement therapies, although the 
greatest amount (and highest quality) of evidence was for aerobic exercise and strength 
training. In terms of outcomes they improved, the evidence was strongest in relation to 
improvement in pain and quality of life. 
At present therefore the best advice would be for patients to engage with exercise (ideally 
different types) but importantly those which they either enjoy or feel they can undertake 
in the medium term, since as discussed below, engagement with the therapy is a 
prerequisite to improvement and people are most likely to keep doing types of exercise 
which they enjoy.   
 
3.3 Is combined pharmacological and non-pharmacological approaches to management more 
effective than single modality management? 




Evaluations (through randomised controlled trials) of management have focussed on either 
pharmacological approaches (usually funded by pharmaceutical companies) or non-
pharmacological approaches (usually funded by government or charitable sources). The 
literature reviews undertaken as part of the revised EULAR recommendations did not 
identify any trials set up specifically to either compare pharmacological and non-
pharmacological approaches nor to look at the effect of their combination on outcome.  If 
there are no head to head comparisons of such approaches their relative benefit could still 
be evaluated through a network meta-analysis (as described in Section 3.2). Wang et al 
(2017) attempted to do this, looking at cognitive behaviour and pharmacological therapies 
for childhood anxiety disorders  - there was a lack of relevant data but from that which was 
available there were no differences between CBT and any specific medication for the 
outcomes considered, but there was a large degree of uncertainty.  
For fibromyalgia there is a strong rationale for directly comparing benefit. Firstly these 
therapies have a different place in the management of the conditions, non-pharmacological 
therapies being first line and long-term, whereas pharmacological approaches are for 
specific symptoms and are either not intended for use long-term or as discussed previously, 
data on their use shows they are not being used long-term by most people. The second issue 
is methodological. When undertaking pharmacological trials of a product, the standard 
design is that the trial is randomised and placebo- controlled, with both the investigator 
and the participant unaware of allocation. This is not possible with most non-
pharmacological therapies in that it is not possible to blind the participant as to whether 
they are receiving the therapy or not. Although for some such therapies (such as those 
involving talking to the patient) it has been argued that there can be attention controls i.e. 
where the person receives the same amount of person to person interaction but without any 
of the “active ingredient” of the therapy. For example, in a review of the effectiveness of 
exercise interventions for people with lower limb osteoarthritis, some of the eligible trials 
included “active” control interventions such as home visits and providing sham gel (Hurley 
et al, 2018). In a systematic review and meta-analysis of the effectiveness of cognitive 
behaviour therapy, Bernardy et al (2018) of 29 studies, just 5 used “attention controls”, 6 
used an alternative non-pharmacological therapy for comparison , while the remainder 
either used waiting list controls (n=5) or “treatment as usual” (n=13).  For example, the 
studies of Pilar Martinez et al (2014) and Miro et al (2011) both used a sleep hygiene 
education programme as a control against which to compare cognitive behaviour therapy 
for insomnia.  
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Why is the lack of a “placebo” control potentially problematic?  Hróbjartsson and Gotzsche 
(2001) undertook a meta-analysis examining trials that included both a placebo and a no 
treatment arm. Their conclusion was “Although placebos had no significant effects on 
objective or binary outcomes, they had possible small benefits in studies with continuous 
subjective outcomes and for the treatment of pain”. From the 27 trials involved with 
treatment of pain, there was a significant reduction in pain in the placebo compared to the 
no treatment arm (standardised mean difference -0.27; 95 percent confidence interval, -
0.40 to -0.15)) which corresponds to an improvement of 6.5mm on a 0-100mm scale. Even 
though the most effective non-pharmacological managements (exercise and behaviour 
therapies) have relatively modest effect sizes, it needs to be acknowledged that at least 
some of this relates to “non-specific” benefits of the therapy. 
So, is there a stronger rationale for looking at combined approaches? Certainly from a 
management point of view with education and exercise forming first line therapy, there is 
no reason one would then think of an either/or situation, and if one was later to start 
pharmacological therapy then exercise should still be continued. Similarly with cognitive 
behaviour therapy, there is no good reason that this would only be provided in the absence 
of pharmacological therapy. I am not aware of any trial in chronic pain or fibromyalgia which 
has examined the effectiveness of behavioural therapy with or without pharmacological 
therapy. In attention deficit hyperactivity disorder (ADHD), a secondary analysis of an RCT 
compared a total of 48 participants randomised to CBT and a stimulant(dextroamphetamine) 
with those randomised to CBT and placebo (Weiss et al, 2012); both groups showed a clear 
improvement in symptoms but there was no difference between them. A more recent trial 
for the same condition randomised 88 participants to receive CBT with or without 
medication (Cherkosova et al, 2020). The combination of CBT and medication was superior 
for the trial outcomes, although this superiority reduced over time.  
There have however, been trials for pain and fibromyalgia using CBT which have examined 
whether treatment reduces the use of medication. For example in a trial of fibromyalgia 
and insomnia, participants received CBT for their insomnia and pain and were compared 
with waitlist controls. While the intervention led to short-term (but not long-term) changes 
in sleep medication, there was no effect on opioid use for pain (McCrae et al, 2020). 
While randomised controlled trials provide “gold standard” evidence for the effectiveness 
or efficacy of treatments the reality is that not every comparison can feasibly be answered 
by a trial, either for scientific reasons or just the cost of each trial. Trials generally cost at 
least £1m and most address a single comparison. Thus other approaches will be required – 
and the use of disease registries may be able to play a role in evaluation. They allow a 
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greater range of comparisons to be made and reflect practice in a “real world setting”. 
However the major drawback of this approach is that allocation of treatment is not 
randomised – and therefore there is the potential for “confounding by indication” whereby 
the characteristics of patients who receive alternative treatments are different.  Patients 
who receive a specific therapy might appear to have worse outcomes if such a therapy is 
given to people with severe disease (who would be expected, all other things being equal, 
to have poorer outcomes). There are statistical techniques which are used to try to take 
account of this, the most popular of which is using propensity scores. The characteristics of 
people (which could be sociodemographic, clinical or patient reported factors) are used to 
predict the probability (propensity) that each person would have received a given 
treatment. The analysis depends on the fact that these characteristics should not perfectly 
predict treatment allocation and compares, amongst people with similar propensities, the 
outcomes for those who did and did not actually receive a given therapy (discussed in 
Suvarna, 2017).  An example, which I led, using such an approach was in determining the 
role of biologic therapies in improving work outcomes for people with axial spondyloarthritis 
(Shim et al, 2018).  
 
3.4 Are there characteristics of patients with fibromyalgia which predict response to specific 
therapies? 
 
In the context of precision medicine (also previously known as personalised medicine) there 
has recently been great interest in how one can tailor management so that patients receive 
therapy to which they are likely to respond. This can take account, for example, of genetic 
factors, lifestyle and environment. While much research activity has focussed on cancer 
therapy in relation to molecular markers in tumours, the principle applies also to 
musculoskeletal conditions such as inflammatory arthritis and chronic pain. Can we provide 
the therapy to which a person is most likely to respond?  There has been some discussion of 
this in relation to fibromyalgia; Hauser et al (2018) discuss “individualized management” 
and whether this should be based upon the predominant symptoms or based on overall 
symptom severity.  There has long been a recognition that patients with fibromyalgia as a 
group are heterogeneous. Yim et al (2017) in a cluster analysis of 313 patients from Korea 
found four sub-groups which were distinguished by different levels of pain and physical, 
social and psychological function. This seems likely to be a reflection of different levels of 
severity of the condition rather than necessarily distinct subgroups based on different 
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manifestations of the condition.  Bartley et al (2018) in a study of 256 patients, who 
completed daily patient diaries for up to 154 days in the United States, identified three 
patient clusters based on symptom variability; a high and low symptom variability cluster 
and a low symptom variability cluster but with high anxiety. There have also been studies 
which have examined patho-physiological processes which may be found in subgroups of 
patients. For example, small fibre pathology has been shown to be high in fibromyalgia with 
a meta-analysis (using 222 patients from 8 studies) suggesting a prevalence of 49% (95% CI 
38-60%) (Grayston et al  2019), although doubt has been cast on whether these observations 
are specific to this condition (Clauw, 2015).  
 In terms of factors predicting response to treatment (or specific treatments), Schmidt-
Wilcke et al (2014), found that in an imaging study of 15 patients with fibromyalgia that 
reduction in pain using Milnacipran was more common amongst patients with low levels of 
connectivity between pro-inflammatory and anti-inflammatory brain regions (specifically 
the rostral part of the anterior cingulate cortex (ACC) and Insular cortex (ICC)) while there 
were other specific patterns which predicted response to placebo. Evaluating a brief (1.5 
days) inter-disciplinary treatment programme amongst 139 patients who met ACR Criteria 
for fibromyalgia, Worrel et al (2001) found that those who were more affected by symptoms 
were most likely to benefit. In a larger (and later) study from the same centre, predictors 
were reported to be younger age, more years of education, higher depression score, lower 
tender point count, and with no history of abuse (Oh et al, 2012). In our trial of telephone-
delivered cognitive behaviour therapy and/or exercise therapy we conducted a post-hoc 
analysis to identify characteristics of people who responded to the individual therapies 
(Beasley et al, 2015). Those persons with more disabling pain, higher psychological distress 
and those who exhibited passive coping at the time of recruitment to the trial were more 
likely to meet response criteria, in comparison to persons without these characteristics. 
There were no patient characteristics which were predictive of response in the exercise 
group. Although not significant, it was noteworthy that the odds of response in males 
(compared to females) was lower in each of the telephone delivered cognitive behaviour 
therapy, exercise and combined study arms.  An analysis of the same trial follow-up data 
examined the role of treatment expectations and preferences in relation to treatment 
response. While preference did not predict response at 24 months follow-up (34.8% response 
in those matched to their preferred treatment v. 30.3% in those not) , if a subject was 
allocated a treatment which they expected to result in improvement, they were more likely 
to meet response criteria compared to those allocated a treatment which they didn’t think 
would result in improvement (32.8% v. 19.1%) (Beasley et al, 2017). Of course to benefit 
from a therapy patients have to engage with it, for medications that simply means taking 
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the medication as intended but for non-pharmacological therapies it means “engaging” in a 
wider sense. The previous trial followed participants in the exercise arm over a longer period 
(after the conclusion of the trial follow-up) and 164 out of 196 were classified as engagers. 
Predictors of non-engagement 5 years post-treatment were higher body mass index, more 
disabling chronic pain, poorer self-rated health, physical functioning, more frequent use of 
passive coping strategies and less frequent use of active coping strategies at the time of 
recruitment to the trial (Martin et al, 2019).  
In summary, currently there is no good evidence of characteristics which predict response 
to treatment in patients with fibromyalgia neither for pharmacological or non-
pharmacological therapies.  With respect to non-pharmacological therapies (recommended 
as the mainstay for management by EULAR), there are several issues which have been 
identified as important: expectations of improvement with a therapy, engagement with 
therapy as well as other physical and psychosocial characteristics of patients.  
 
3.5 How should fibromyalgia be managed when it occurs as a co-morbidity to inflammatory 
arthritis? 
 
Three of the published manuscripts on this thesis have provided results relevant to this 
question although none are randomised controlled trials. They have quantified the co-
occurrence of meeting criteria for fibromyalgia in persons with axial spondyloarthritis (1 in 
5). This was higher than the 13% pooled estimate of co-occurrence in ankylosing spondylitis 
in a meta-analysis by Duffield et al (2018), but closer to their estimates for rheumatoid 
arthritis (21%) and psoriatic arthritis (18%).  The characteristics of people with axSpA who 
also met criteria for fibromyalgia were consistent with higher disease activity although, in 
contrast, there was no difference in C-reactive protein nor in extra spinal manifestations. 
An alternative hypothesis is that meeting criteria for fibromyalgia is associated with a 
general increase in symptom reporting and this causes an elevation of self-reported axSpA 
disease markers. Indeed the manuscript of Macfarlane et al (2018) quantified this as 
approximately one point in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 
after socio-demographic, clinical and lifestyle factors were taken into account. The concern 
is that such patients with fibromyalgia and axSpA may therefore be over-treated with 
biologics if that is partly determined by BASDAI. However the work in the same study showed 
that the absolute response to biologic therapy (in terms of disease activity and quality of 
life) was similar nor was there any difference in the likelihood of meeting the ASAS20 
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response criteria twelve months after starting therapy. Of particular note in this study was 
the fact that high somatic symptom burden (as measured by the symptom severity scale of 
the fibromyalgia criteria) was a predictor of non-response. As was stated within the relevant 
manuscripts, criteria for fibromyalgia have not been validated in the context of 
inflammatory arthritis and it is very challenging to separate features of axSpA from 
fibromyalgia and therefore these aspects, specifically cognitive dysfunction, fatigue and 
unrefreshed sleep may be particularly important in this respect. In contrast, Molto et al 
(2018) did find that there was a differential response to biologic therapy in axSpA patients 
who did and did not meet criteria for fibromyalgia (45 v. 54% response according to 
BASDAI50).  
The conclusions from these papers would dictate that the decision to commence biologic 
therapy should not be influenced whether someone meets criteria for fibromyalgia – 
although it is worth noting that if persons have a high score on the fibromyalgia symptom 
severity scale then there are higher risk of non-response and may benefit from specific 
management focussed on fibromyalgia symptoms either alongside or post-biologic therapy 
(if no response). There are no studies available currently to determine which of these two 
options are best.   Further the manuscript which undertook a cluster analysis identifies an 
additional group (low axSpA disease activity but features of fibromyalgia) which could 
benefit from management specifically targeted at features of fibromyalgia.   
There is therefore a strong case for examining, in inflammatory arthritis, through a 
randomised controlled trial, the use of therapies for fibromyalgia symptoms, in order to 
improve outcomes. Issues to be determined would be whether there was a case for 
conducting such studies across inflammatory arthritis or whether there are key differences 
between them, what the timing of the intervention would be e.g. close to or soon after the 
time of diagnosis or at the time of commencing biologic therapy, and what the intervention 
would be (cognitive behaviour therapy would be one option, but whether it should be wider 
than that, for example more akin to “coaching”).  
 
3.6 What aspects of a healthcare system optimise outcome for patients with fibromyalgia? 
 
This recommendation arose out of the observation that while there was a reasonable body 
of evidence around some treatments (pharmacological and non-pharmacological) there was 
perceived to be a lack of data about how you then organise healthcare systems to deliver 
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effective treatments. Indeed we were not aware of relevant evidence to inform this part of 
the recommendations. Because of this “gap” I subsequently led a grant application (which 
was successful) to Versus Arthritis to address this lack of evidence. The PACFiND study 
(PAtient-centred Care for Fibromyalgia: New pathway Design) is a five year programme 
(2019-24), based in the United Kingdom,  which is organised around three workpackages:  
Workpackage A: Patient experiences of fibromyalgia and the healthcare they receive 
This work will undertake an in-depth analysis of the patient journey, focussing on 
experiences of care and areas of unmet need, and identify current patterns of healthcare 
use using data linkage to map the patients’ digital healthcare journey.  The outputs from 
this will include  a) creation of a new Healthtalk online resource: this will provide a web-
based set of video resources describing patient experiences of the condition which is free 
and readily accessible to patients (https://www.healthtalk.org)  b) a short film to act as a 
learning tool for the training of health professionals as well as a basis for the co-design 
process proposed later in the project (workpackage C) c) a dataset from the data linkage 
work which can be interrogated to ask specific questions about current use of health services 
by patients with fibromyalgia. This is being accomplished (the work is currently underway)  
by undertaking: a survey of a population sample of people with fibromyalgia; interviews 
with people with fibromyalgia from different healthcare and geographical settings; linking 
patient clinical records held in primary and secondary care with prescribing records and, 
where available, with patient self-report. 
Workpackage B: Organisation and delivery of care for people with fibromyalgia 
This work examines the organisation and delivery of care for people with fibromyalgia 
through a mapping exercise to identify and describe current provision of care for people 
with fibromyalgia and a series of geographically diverse case studies across the United 
Kingdom. We will employ non-participant qualitative observations of practice, analysis of 
local and national service documents, and qualitative interviews with healthcare 
professionals and service managers to understand the context and mechanisms influencing 
current healthcare interventions and outcomes for people with fibromyalgia. 
Workpackage C: Developing a new model of care for people with fibromyalgia 
This work will identify and develop new models of care for people with fibromyalgia, 
informed by results from workpackages A and B, adopting a co-design approach to work with 
patients, their families and care providers as partners alongside healthcare professionals 
and decision makers. The benefits and costs of existing and proposed models of care will be 
modelled and patient preferences for key features of a new model will be determined before 
182 | P a g e  
 
 
assessing and selecting a new model of care in collaboration with all key stakeholders. The 
project will produce a framework to support implementation and evaluation of the new care 
model in a range of different healthcare contexts. 
Some early work from this programme has already reported (Doebl et al, 2020). This involved 
systematic reviews around models of care for people with fibromyalgia and patient 
experiences, preferences and unmet need. The major finding was that there was little 
evidence to inform the first question although there was evidence of a lack of benefit of 
ongoing care in secondary care settings. In terms of the second question, there were aspects 
that may be argued to be common across many long-term conditions such as inconsistent 
and poorly co-ordinated care. However there was also some aspects likely to be specific to 
fibromyalgia: patients reported that “fibromyalgia was often not viewed as a real condition, 
resulting in difficult encounters with healthcare staff, in particular not feeling believed or 
listened to”. Unsurprisingly they also reported significant time taken to receive a diagnosis.  
I am not aware of any other major project addressing the same issues at the current time.  
 
3.7 What are the implications for management of the data around pain and mortality, as 
well as use of opioids 
 
The data are now clear that persons with chronic widespread pain have increased premature 
mortality and this is not directly related to pain itself but likely a consequence of having it. 
Thus it becomes an important, but to date neglected, issue in patient management, 
although this may be changing (Nijs et al, 2020).   Key features of the mechanism relating 
chronic pain to excess mortality are body mass index, exercise and diet. At present none of 
these feature strongly in management of chronic pain – and changing lifestyle is challenging. 
For example William et al (2019) evaluated, in a randomised controlled trial, a healthy 
lifestyle coaching intervention consisting of brief advice and a 6-month telephone delivered 
programme for people with musculoskeletal pain who were overweight or obese. The 
intervention did not reduce weight, improve diet or physical activity nor change pain beliefs. 
In a review of the role of lifestyle factors in managing chronic pain, Dean and Söderlund 
(2015) identified three important areas in relation to lifestyle interventions: firstly that 
physical therapies might complement lifestyle behaviour change; secondly that adopting a 
healthy lifestyle may reduce the need for physical therapies; and thirdly that persons with 
healthy lifestyle might respond more favourably to physical therapies for chronic pain. Of 
course the effect on mortality can be added to these benefits. We now need to work towards 
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incorporating consideration of lifestyle factors in the management of chronic pain and 
research how to enable people with chronic pain to effect change.   
 
The final paper addressed the issue of opioid use – which clinically is most commonly 
prescribed for chronic pain. UK Biobank participants are not representative of the general 
population, and an analysis has shown that they are less likely to be obese, to smoke, to 
drink alcohol daily, and they have fewer self-reported health conditions (Fry et al, 2017). 
Specifically on follow-up they have lower cancer incidence and all-cause mortality. So 
appreciating that the data will be an underestimate of opioid use, the figures are 
remarkable in that 1 in 20 of participants were regular users rising to 1 in 9 amongst those 
of low socio-economic status and to 1 in 3 of persons who had stopped work because of their 
health. The data are not new in showing high rates of use but what the study adds are that 
it allows us to characterise people with particularly high usage in terms of level of 
education, socio-economic status and geography. Further it is clear from the data presented 
in the manuscript that the health of regular users is poor and in particular they still report 
chronic pain and poor quality of life. While this does not demonstrate that opioids are 
ineffective in the medium term, the data is consistent with such an interpretation and 
accords with a meta-analysis of their effects which showed only small improvements in pain 
and function and  suggested (based only on low quality studies) that their effect was similar 
to non-opioid medications (Busse et al, 2018). The result in the manuscript demonstrating 
a relationship with excess mortality has not demonstrated that this association is causal. 
What it has done, however, is to identify that people who regularly consume opioids have 
excess mortality and this is still the case (albeit a small excess) after one controls for a 
range of health factors.  
Mathieson et al (2020) reviewed world-wide data on what proportion of patients with chronic 
non-cancer pain are prescribed opioids and found that from 42 studies, the pooled estimate 
was 31%, 95% CI (29%-33%). Strong opioids were more frequently prescribed than weak 
opioids. Prescribing did not vary by region of the world but was becoming more common 
with time. Given that opioid use is associated with serious risks (including addiction and 
overdose) this is now a global priority about how to deal with the so-called “opioid 
epidemic” firstly by reducing opioid consumption in current users and secondly reducing the 
use in new patients. Many countries have produced guidelines (e.g. Dowell et al (2016) for 
the Untied States) but the challenge is that there are not obvious alternatives providing 
effective and safe relief from chronic pain.  A systematic review examining studies focussed 
on methods to reduce opioid consumption found 67 studies (11 of which were randomised 
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controlled trials) studying 8 different types of intervention.  These included interdisciplinary 
pain programs, buprenorphine-assisted dose reduction and behavioural therapy programs. 
Most of the studies (n=51) were rated as poor quality. Among 40 studies examining patient 
outcomes after dose reduction, improvement was reported in pain severity (8 of 8 fair-
quality studies), function (5 of 5 fair-quality studies), and quality of life (3 of 3 fair-quality 
studies) (Frank et al, 2017). A Cochrane review of randomised controlled trials focussed on 
reducing (or cessation of) opioid consumption found only 5 trials with a total of 278 
participants.  The interventions included acupuncture, mindfulness and CBT. The results 
were described as “mixed” and the authors noted that while there were reductions in opioid 
consumption with the interventions, such reductions were also often seen in the control 
interventions (Eccleston et al, 2017).  
 
Further studies are underway to determine how to effectively (and safely) reduce opioid 
consumption. For example in the United Kingdom a randomised controlled trial (i-WOTCH) 
has been funded by the National Institute of Health Research (NIHR) 
(https://warwick.ac.uk/fac/sci/med/research/ctu/trials/iwotch/ ). Eligible persons are 
those with chronic (non-malignant) pain who have been regularly using opioids for at least 
three months. The intervention (which aims to reduce pain interference) is described 
(abridged) as follows: 
“The aim of the active arm intervention group is to empower people so that they are better 
able to make informed choices jointly with their healthcare provider. The active arm 
intervention includes a three day group course, relaxation CD, mindfulness CD, educational 
DVD and a copy of “My Opioid Manager” book. ….. Additionally, participants will be offered 
two one-to-one tapering support appointments with a specially trained nurse to agree a 
programme of tapering their opioid dosage, and two follow-up phone calls. The three-day 
course is delivered … by a trained lay facilitator ….. using Cognitive Behavioural Therapy 
techniques and grounded in the biopsychosocial approach to health and illness…..The 
control group participants will receive the relaxation CD and “My Opioid Manager” book 
only.” 
Thus as with the management of pain, behavioural approaches underpin methods to reduce 
reliance on opioid medication.  This will be one of the major challenges in pain management 
over the coming years – reducing the prescribing of opioids to new patients while helping 
those who have been taking them long-term to come off and to replace that with other 
forms of management for chronic pain. The main challenge is what the other forms of 
management will be. Patients can perceive negatively the attempt to reduce or stop 
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medications which some patients believe are key to reducing pain and allowing them to be 
able to function.  Emphasising the public health issue, newspaper headlines recently have 
focussed on the scale of the problem  “Thousands prescribed addictive opioids in north and 
north-east (Press and Journal , May 6th 2019)”  and Opioid crisis fears as fifth of Scots given 
powerful painkillers (The Times Scotland, 30th August 2018), the latter in response to a 
nationwide record linkage study (Torrance et al, 2018) but also the responses of patients 
“Painkillers help me get through ‘torture of daily life’, says head of chronic pain support 




The work in this thesis has summarised the evidence base for managing fibromyalgia, of 
which chronic widespread pain is a key feature. It has highlighted priority areas for research 
and how some of these are currently being tackled and how others could be tackled.  The 
discussion has emphasised that this is not always going to be possible through randomised 
controlled trials. It has provided new evidence around the co-occurrence of fibromyalgia 
and an inflammatory arthritis and presented data which can influence approaches to 
management of patients who may have both conditions, in the current absence of definitive 
management trials (or other study designs providing relevant information). Finally it has 
provided clear new data around the link between chronic pain and premature mortality 
which highlights the key role of lifestyle factors and a strong rationale for including a focus 
on such factors in management.  The data on opioid use while not the first such data, do 
emphasise that this is a public health issue affecting particular socio-economic groups and 
such descriptive data must help to inform the approach to tacking this epidemic. 
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